2013 CRS Program Book

CRS 2013 Program 40th Annual Meeting & Exposition of the Controlled Release Society

©David Cornwell

July 21–24, 2013 Hawaii Convention Center Honolulu, Hawaii, U.S.A.

©istockphoto.com

Emerging Challenges for Global Delivery

Download the CRS Annual Meeting Mobile App

President’s Welcome to the Annual Meeting Welcome. Aloha. 歓迎.

Dear Colleagues and Friends, In the Hawaiian language, aloha stands for more than just “hello” or “goodbye.” Its deeper meaning is “the joyful (oha) sharing (alo) of life energy (ha) in the present (alo).”

It is fitting that we find ourselves in Hawaii, a global crossroads with a history of graciously welcoming explorers and travelers alike. As researchers, scientists, and innovators, we too are travelers of a sort: intrepid explorers looking toward new frontiers and imagining worlds of possibility.

We are here because we share a passion for investigation and discovery—and it is passion that makes everything you are about to experience over the next several days possible. You will see it in the nearly 700 posters on display. It will be evident in the quality, diversity, and interdisciplinary nature of the scientific programs and mini-symposia you will attend, and you will feel it as you interact with your colleagues at the roundtable sessions, the networking events and exposition.

We live in a digital world, and technology has enabled us to share information and knowledge on a scale that the original inhabitants of these islands could never have imagined. But passion is something not easily shared by e-mail or on social networks. It is only when we bring passion and knowledge together that innovation and discovery can begin.

Kazunori Kataoka

“It is only when we bring passion and knowledge together that innovation and discovery can begin.”

The explorers who originally came to these islands could not have imagined how their interactions with the people they found here would profoundly change both them and the world.

We can only imagine how our interactions here will impact the future of delivery science.

Thank you for being part of CRS and for your continued commitment to our society and our science. Thank you as well for honoring me by allowing me to serve as your president.

Sincerely, Kazunori Kataoka President, Controlled Release Society

1

Table of Contents

2013 Program Team

Chair W. Mark Saltzman Yale University, U.S.A.

Deputy Chair Ick Chan Kwon KIST, Korea

Marcel B. Bally British Columbia Cancer Research Centre, Canada

Marcus E. Brewster Johnson & Johnson, Belgium

Charles R. Frey Coating Place Inc., U.S.A.

Nicole Papen-Botterhuis TNO, Netherlands

Justin S. Hanes Johns Hopkins University, U.S.A.

Joshua J. Reineke Wayne State University, U.S.A.

Sarah J. Eccleston Aptuit Ltd., United Kingdom

Hideyoshi Harashima Hokkaido University, Japan

Christian Seiler Merck Sharp & Dohme, United Kingdom

General Meeting Information .................................... 4 Hawaii Convention Center Level 3 Floor Plan ......... 7 Schedule-at-a-Glance Saturday – Sunday ................................................. 8 Monday – Tuesday .............................................. 10 Tuesday – Wednesday ......................................... 11 Daily Schedule Saturday .............................................................. 12 Sunday ................................................................ 14 Sunday Technology Forums ............................... 17 Sunday Soapbox Sessions ................................... 19 Monday .............................................................. 21 Tuesday ............................................................... 28 Wednesday .......................................................... 37 Posters ...................................................................... 40 Exposition ................................................................ 51 Sponsors ................................................................... 57 Awards & Recognition ............................................. 62 Acknowledgements .................................................. 68 2013 CRS Presenting Author Index ......................... 70

Advertisers’ Index Biopharm Solutions .................................................. 13 www.biopharmsolutions.com Catalent Pharma Solutions.......................................... 3 www.catalent.com EMD Millipore........................................................... 9 www.emdmillipore.com OctoPlus ......................................... Inside Front Cover www.octoplus.nl Patheon....................................................... Back Cover www.patheon.com Texture Technologies Corp............... Inside Back Cover www.texturetechnologies.com Controlled Release Society 41st Annual Meeting & Exposition of the ............... 31 Controlled Release Society Accessing 2013 Annual Meeting Abstracts .............. 15 CRS Foundation ...................................................... 67 CRS Headquarters Staff ........................................... 72 Educational Opportunities from CRS ..................... 23 Job Center ........................................................... 29, 30 LATTE .................................................................... 37 Membership ............................................................. 20 Mobile App ................................................................ 6 Publications .............................................................. 36

Front cover photo ©David Cornwell; front cover Illustration ©istockphoto.com

2

two new sites opening in china

rp scherer softgel & clinical trial supply

optimized therapeutic profiles. better treatments.

As a global leader in drug development and delivery, we have the expertise in innovative and proven drug delivery technologies to optimize the therapeutic profiles of your treatments.

CONTROL API BLOOD LEVELS

We can help deliver the right amount of API when it is needed to control plasma profiles and onset of action with our controlled release technologies, including enteric-coated softgel and OSDrC‰ OptiDose™.

IMPROVE TARGETED DELIVERY

From pulsatile to extended to delayed, we can tailor a delivery profile to release the right amount of drug where it is needed in the body, reducing potential side and food effects.

OPTIMIZE PATIENT DOSAGE

Reduce pill burden and dose frequency with our softgel, modified release or fixed dose combination tablets (multi-API), coatings and expert formulation.

IMPROVE ABSORPTION

˝ 2013 Catalent Pharma Solutions. All rights reserved.

Zydis is a registered trademark, and Optiform and OptiMelt are trademarks of Catalent Pharma Solutions. OSDrC is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd

Overcome solubility and permeability challenges to deliver your product with increased bioavailability with our softgel, Optiform™, OSDrC‰ OptiDose™ and OptiMelt™ hot melt extrusion technologies.

Every molecule has challenge.

We have a solution.

Call: + 1 888 SOLUTION (765 8846) Email: solutions@catalent.com Visit: www.catalent.com

DEVELOPMENT

DELIVERY

SUPPLY

General Meeting Information Registration Desk

The Registration Desk is located on Level 1 in the entrance of Exhibit Hall III Saturday through Tuesday and on Level 3 Ala Halawai Concourse on Wednesday. The desk will be open: Saturday, July 20 Sunday, July 21 Monday, July 22 Tuesday, July 23 Wednesday, July 24

07:00 – 15:00 07:30 – 18:00 07:00 – 17:30 07:00 – 17:00 07:30 – 12:00

Access the Abstracts

CRS Annual Meeting abstracts can easily be accessed using the CRS Annual Meeting mobile app, the CRS website, and the abstract printing station. The mobile app provides access via your mobile device or laptop; simply click on the Posters icon to begin viewing or view podium abstracts directly from the schedule. Sign into the CRS website to view and search the abstracts, available to all registered attendees. The abstract printing station is located in CRS Central and provides the convenience of printing abstracts as needed.

Visit CRS Central

CRS tools and resources help you stay on top of the growing global and multidisciplinary field of delivery science. Check out CRS books, journals, and other resources at CRS Central, located across from the Registration Desk.

CRS Connect

As a CRS Annual Meeting attendee, CRS Connect is your foremost opportunity to network with colleagues while in Honolulu. After accessing the CRS Annual Meeting mobile app, select the CRS Connect icon and search through the database of meeting attendees. Once you identify an individual you wish to contact, click on their name to either send them a private message or request an appointment. All of this takes place through CRS Connect while maintaining full privacy, as personal contact information is never shared. CRS has designated an area in the Exposition Hall in which CRS Connect meetings can take place.

CRS 2013 Mobile App

Sponsored by Aptalis Pharmaceutical Technologies Check the schedule, read the abstracts, create your personal schedule and to-do lists, receive announcements, connect with fellow attendees using CRS Connect, and see what companies are in the Exhibit Hall—all with your CRS meeting mobile app. Download the CRS 2013 mobile app by searching for “CRS Meeting” in the iTunes Store or Google Play. Reach the mobile app from your BlackBerry or laptop via the mobile app website mobileapp.controlledrelease.org.

Electronic Devices

As a courtesy to other meeting attendees, please turn off or silence all electronic devices during all workshops, sessions, and presentations.

4

WiFi Access

Cosponsored by BASF, Bend Research, and Lactel Absorbable Polymers CRS has contracted with the Hawaii Convention Center to provide WiFi access during the annual meeting. This access will be available to all attendees for the duration of the meeting.

WiFi coverage is available throughout the convention center.

Power up your laptop to connect to meeting abstracts on the CRS website, or use your mobile device to utilize CRS Connect and the mobile app.

Network: CRS2013 Access Code: CRS

Photography

Photography is not permitted in the session rooms, exhibit hall, or poster sessions. Contact CRS staff at the Registration Desk for further clarification.

Awards

CRS will be honoring several awardees throughout the meeting.

Awards will be given out at the Monday Opening Session/ Award Ceremony and during the three plenary sessions. See daily highlights and the Awards & Recognition information in this program book.

Exposition Hours and Location

The Exposition is located in Exposition Hall III and has dedicated hours when all exhibitors are present at their booths.

The scheduled Exposition activities are as follows: Set-Up Saturday, July 20 08:00 – 17:00

Sunday, July 21 08:00 – 14:00

Exposition Open Sunday, July 21 17:30 – 19:30 Exposition Grand Opening and Welcome Reception Monday, July 22 09:30 – 10:30 Exposition Open

Meet with Exhibitors, Prize Drawing, Refreshment Break 09:30 – 17:30 Exposition Hall Open 16:30 – 17:30 Poster Viewing and Exposition Happy Hour Meet with Exhibitors, Prize Drawing, Refreshment Break Tuesday, July 23 09:30 – 10:30 Exposition Open

Meet with Exhibitors, Prize Drawing, Refreshment Break 09:30 – 16:00 Exposition Hall Open 15:00 – 16:00 Exposition Open

Meet with Exhibitors, Prize Drawing, Refreshment Break Take-Down Tuesday, July 23 16:00 – 18:00 Exhibit Take-Down

Poster Sessions

The posters are located in Exhibit Hall III. All posters will be on display Sunday through Tuesday during the designated hours. Poster authors will be present during one of three prespecified time slots. All posters must be removed during Poster Take-Down or they will be removed and discarded. The poster viewing area will be secured overnight. Photographing posters is not permitted.

2013 Poster Schedule Sunday, July 21 08:00 – 14:00 Exhibit and Poster Set-Up 17:30 – 19:30 Poster Viewing Hours, Exposition Grand Opening and Welcome Reception Monday, July 22 09:30 – 10:30 Poster Session 1 – Authors Present 09:30 – 17:30 Poster Viewing Hours 16:30 – 17:30 Poster Viewing and Exposition Happy Hour Tuesday, July 23 09:30 – 10:30 Poster Session 2 – Authors Present 09:30 – 16:00 Poster Viewing Hours 15:00 – 16:00 Poster Session 3 – Authors Present 16:00 – 17:00 Poster Take-Down

Poster Snapshots

Poster Snapshots are three-minute audio recordings that provide a summary preview of poster content. Attendees can listen to a recording at any time, including prior to attending the poster sessions and even while standing in front of a poster.

Poster snapshots are submitted by poster presenters and are available through the CRS Annual Meeting mobile app.

Speaker Preparation Room

Room 301 A/B The Speaker Preparation Room is available for PowerPoint previewing and downloading presentation materials. Speakers are to upload presentations one day prior to their presentation date, i.e., if you speak on Monday, July 22, you will upload your presentation on Sunday, July 21. Presenters are not allowed to use their own laptops to give their presentations. The Speaker Preparation Room will not be open on Wednesday, July 24.

The Speaker Preparation Room will be staffed and open as follows: Saturday, July 20 07:00 – 17:00 Sunday speakers upload presentations Sunday, July 21 07:00 – 17:30 Monday speakers upload presentations Monday, July 22 07:00 – 17:30 Tuesday speakers upload presentations Tuesday, July 23 07:00 – 17:30 Wednesday speakers upload presentations

Committee Meetings

CRS committees (and other attendees) are invited to schedule meetings by reserving a meeting room at the Registration Desk.

A limited number of meeting rooms are available for use Sunday through Wednesday.

Meeting Schedule (as of May 31, 2013) Sunday, July 21 2014 CRS Annual Meeting Program Committee

09:00 – 10:00

317B

Monday, July 22 Young Scientist Committee/ Mentor-Protégé Subcommittee 09:30 – 10:30 Finance Committee 15:00 – 16:00

317A 317B

Tuesday, July 23 DDTR Editorial Board

Chapter Committee

Consumer & Diversified Products Division

Board of Scientific Advisors Wednesday, July 24 Books Committee

Preclinical Sciences & Animal Health Division

07:00 – 08:00 09:30 – 10:30

317A 317B

16:00 – 17:00 16:00 – 17:30

317B 317A

07:00 – 08:00

317A

08:30 – 09:30

317B

Photo Release

Many photographs will be taken throughout the CRS Annual Meeting & Exposition and are used in CRS electronic and printed promotional materials during the meeting and after it has concluded. By virtue of your attendance, you agree to the Controlled Release Society’s use of your likeness in said promotional media.

Children and the CRS Annual Meeting & Exposition

The CRS Annual Meeting & Exposition is a professional, scientific meeting. CRS does not permit children under the age of 18 to attend the scientific sessions, poster sessions, exposition, and social events. For safety reasons, only registered exhibitors and poster presenters are permitted in the exposition/ poster hall during set-up and take-down hours. Children 18+ must register and buy applicable individual tickets if not attending/registering as a student.

Message Board

For your convenience, a message board is located in CRS Central. The board may be used to post job openings/resumes, messages to colleagues, or other relevant information.

Meeting and Future Event Literature

Space for the display of promotional materials for future educational meetings is available in CRS Central. Organizers of educational meetings and events may display their materials in this reserved location. Any literature that is left in areas other than the designated location or that does not promote educational meetings will be discarded.

5

Access the meeting anytime, anywhere The 2013 CRS Annual Meeting & Exposition Mobile App

• • •

• • •

Check the schedule Read the abstracts Create your personal schedule and to-do lists Receive announcements Connect with fellow attendees See what companies are in the exhibit hall

Download Now. It’s Fast and Easy.

Search for “CRS Meeting” in the iTunes store, or the Android App Store/ Google Play. Access the mobile app from your Blackberry or laptop at the mobile app website: mobileapp.controlledrelease.org Sponsored by

WiFi for your mobile device or laptop is available in the Hawaii Convention Center for all CRS annual meeting attendees, free of charge.

Sponsored by

6

PĀ KALOKA COURTYARD

76 9

808

GRAND STAIRCASE

8 54

PORTE COCHERE

MAIN LOBBY (Level 1)

SERVICE CORRIDOR

SERVICE CORRIDOR

22

PĀ KAMALI`I COURTYARD

310

Exhibit Hall III Located on Level 1

808

Hawaii Convention Center • Level 3

7

Schedule-at-a-Glance Saturday, July 20 07:00 – 15:00 07:00 – 15:00 07:00 – 17:00 08:00 – 17:00

08:00 – 17:00 08:00 – 17:00

09:00 – 17:00

12:00 – 14:00 13:00 – 17:30

CRS Registration Open Exhibit Hall III CRS Central Open Exhibit Hall III Speaker Preparation Room Open 301A/B Educational Workshop: Controlled Release Dosage Forms and 323A Product Development Strategy for Expected New Regulatory Trends* Exhibit Set-Up Exhibit Hall III Young Scientist Workshop: Fundamentals of Controlled 323B Release Drug Delivery: Physiochemical and Biological Aspects Educational Workshop: Oral Delivery of Bioactives Using 324 Lipid-Based Drug Delivery Systems* (continued on Sunday) Leadership Forum (by invitation) 306A/B Educational Workshop: Using In Vitro–In Vivo Correlation 323C (IVIVC) to Meet Challenges in Global Delivery*

Sunday, July 21 07:00 – 17:30 Speaker Preparation Room Open 07:30 – 18:00 CRS Registration Open 07:30 – 18:00 CRS Central Open 08:00 – 12:00 Young Scientist Workshop: Professional and Self

Development for Young Scientists and Protégés: Effective Communication 08:00 – 14:00 Exhibit and Poster Set-Up 08:30 – 12:00 Educational Workshop: Oral Delivery of Bioactives Using

Lipid-Based Drug Delivery Systems* (continued from Saturday) 09:00 – 10:00 2014 CRS Annual Meeting Program Committee Meeting 09:00 – 10:00 Technology Forum: CIMA Labs 09:00 – 10:00 Technology Forum: Colorcon and Dow Food and

Pharma Alliance 09:00 – 10:00 Technology Forum: Mott Corporation 09:00 – 11:00 Technology Forum: Purac Biomaterials and OctoPlus 10:15 – 11:15 Technology Forum: Catalent Pharma Solutions, LLC 10:15 – 11:15 Technology Forum: Medimetrics Personalized Drug

Delivery, Inc. 10:15 – 11:15 Technology Forum: SOTAX Corporation 11:15 – 12:00 Technology Forum: Hovione 11:30 – 12:30 Technology Forum: Capsugel 11:30 – 12:30 Technology Forum: MedinCell 11:30 – 12:30 Technology Forum: Halozyme Therapeutics 11:30 – 12:30 First Timers’ Meeting 12:30 – 14:00 Young Scientist Roundtable: Commercializing Ideas from

Academia: Past Lessons and Current Challenges 13:00 – 15:10 Soapbox Sessions 15:30 – 17:30 Industry Roundtable: Global Perspectives on Emerging and Established

Delivery Markets 17:30 – 19:30 Exposition Grand Opening and Welcome Reception 17:30 – 19:30 Poster Viewing Hours

*Additional registration, payment, and ticket required.

8

301A/B Exhibit Hall III Exhibit Hall III 323B Exhibit Hall III 324 317B 323A 319B 319A 322A/B 319A 319B 323A 322A/B 319A 323A 319B 306A/B 323B 312 312 Exhibit Hall III Exhibit Hall III

Improve your strike rate With enhanced Bioavailability for your successful final drug Developing drugs often seems like scoring a goal that is all boarded up. While your API is innovative and safe, it still may fail. Bioavailability is one key to success. With drug targeting, increased solubility, PK/PD modifiers, and optimized formulation, we help you to bring APIs out of the pipeline and improve your life cycle management. Suddenly, that goal is wide open. Find out how to improve your strike rate at www.emdmillipore.com/bioavailability

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

7 Booth 31

Schedule-at-a-Glance Monday, July 22 07:00 – 08:00

07:00 – 17:30 07:00 – 17:30 07:00 – 17:30 08:00 – 09:30 09:30 – 10:30

09:30 – 10:30 09:30 – 10:30

09:30 – 17:30 09:30 – 17:30 10:30 – 12:00

Get Up! Get Educated! Nanomedicines for Drug Delivery Across Epithelial Barriers: Intestines, Skin, and Lungs CRS Registration Open CRS Central Open Speaker Preparation Room Open CRS Opening Session Exposition Open – Meet with Exhibitors, Prize Drawing, Refreshment Break Poster Session 1 – Authors Present Young Scientist Committee/Mentor-Protégé Subcommittee Meeting Exposition Hall Open Poster Viewing Hours Scientific Sessions

• Food, Nutraceuticals, and Personalized Diet • Mini-Symposium: Hybrid Groups: Bridging the Gap Between Industry and Academia • Parenteral Sustained Release Drug Delivery • Rising Suns in Asia • RNAi and DNA Delivery 10:45 – 12:00 2014 Exhibit Selection, Group A 11:30 – 13:30 Mentor/Protégé Meet and Greet 13:30 – 14:45 Plenary Session: Kenzo Takada 15:00 – 16:00 Finance Committee Meeting 15:00 – 16:30 Scientific Sessions • Challenges Around Brain Delivery: Sampling Site Issues and Interspecies Extrapolations • Micro- and Nanoparticle Design • Mini-Symposium: Breakthrough Technologies in Drug Delivery Systems from Asia • Smart Building and Construction Materials and Coatings • Topical/Transdermal Drug Delivery 16:30 – 17:30 Poster Viewing and Exposition Happy Hour – Meet with

Exhibitors, Prize Drawing, Refreshment Break 17:30 – 18:30 Preclinical Sciences & Animal Health Get-Together* 21:00 – 22:30 Young Scientist Networking Event*

316B Exhibit Hall III Exhibit Hall III 301A/B 315 Exhibit Hall III Exhibit Hall III 317A Exhibit Hall III Exhibit Hall III 314 316B 316A 316C 315 Exhibit Hall III 306A/B 315 317B 316A 315 316B 314 316C Exhibit Hall III 306A/B Jimmy Buffett’s at the Beachcomber Restaurant and Honolulu Surfing Museum

Tuesday, July 23 07:00 – 08:00 07:00 – 08:00

07:00 – 17:00 07:00 – 17:00 07:00 – 17:30 08:00 – 09:30 09:30 – 10:30

09:30 – 10:30 09:30 – 16:00 09:30 – 10:30 09:30 – 16:00

10

DDTR Editorial Board Meeting Get Up! Get Educated! Quality by Design: Systematic Development of Pharmaceutical Products CRS Registration Open CRS Central Open Speaker Preparation Room Open Plenary Session: Josh Wolfe Exposition Open – Meet with Exhibitors, Prize Drawing, Refreshment Break Poster Session 2 – Authors Present Exposition Hall Open Chapter Committee Meeting Poster Viewing Hours

317A 316B Exhibit Hall III Exhibit Hall III 301A/B 315 Exhibit Hall III Exhibit Hall III Exhibit Hall III 317B Exhibit Hall III

Schedule-at-a-Glance Tuesday, July 23 (continued) 10:30 – 12:00

Scientific Sessions

• Drug Delivery for Developing Countries/Global Challenges • Imaging and Characterization Techniques for Drug

Delivery: Systems and Targeted Drug Delivery • Mini-Symposium: Energy: Problems Within the Industry That Controlled Delivery Can Solve • Peptide and Protein Delivery • Solubilization Technology: A Key Enabler for the Delivery of Poorly Soluble Drugs 10:45 – 12:00 2014 Exhibit Selection, Group B 12:00 – 13:30 C&DP Division Luncheon* 13:30 – 15:00 Scientific Sessions: • Drug Targeting, Pharmacokinetics, and Biodistribution: Differences Between Species • Mini-Symposium: Drug Combination Products • Modern Agriculture and Aquaculture • Oral CR – Pharmaceutical Formulations, Technologies, and Development Strategies • Processing Technology/Manufacturability 15:00 – 16:00 Exposition Open – Meet with Exhibitors, Prize Drawing,

Refreshment Break 15:00 – 16:00 Poster Session 3 – Authors Present 16:00 – 17:00 Consumer & Diversified Products Division Business Meeting 16:00 – 17:00 Poster Take-Down 16:00 – 17:30 Board of Scientific Advisors Meeting 16:00 – 17:30 Roundtables and Focus Groups • Ocular Drug Delivery • Oral Drug Delivery 16:00 – 18:00 Exhibit Take-Down 18:30 – 22:00 CRS President’s Banquet*

316A 316C 316B 315 314 Exhibit Hall III 306A/B 316A 316B 314 316C 315 Exhibit Hall III Exhibit Hall III 317B Exhibit Hall III 317A 316B 316C Exhibit Hall III Hilton Hawaiian Village / Rainbow Tower – Rainbow Suite

Wednesday, July 24 07:00 – 08:00 07:30 – 12:00 07:30 – 12:00 08:00 – 09:30

Books Committee Meeting CRS Registration Open CRS Central Open Scientific Sessions • Emerging Technologies • Mini-Symposium: Nanoparticles and Cancer • Oral CR – Predictive Tools (In Vitro/In Vivo/In Silico) • Personal and Home Care • Regional Delivery: Challenges in Ocular Delivery and Pulmonary Delivery 08:30 – 09:30 Preclinical Sciences & Animal Health Committee Meeting 09:45 – 11:00 Plenary Session: Paula Hammond *Additional registration, payment, and ticket required.

317A Ala Halawai Concourse Ala Halawai Concourse 316A 316B 316C 314 315 317B 315

Daily Schedule Saturday, July 20

Saturday

07:00 – 15:00 CRS Registration Open Exhibit Hall III 07:00 – 15:00 CRS Central Open Exhibit Hall III 07:00 – 17:00 Speaker Preparation Room Open 301A/B 08:00 – 17:00 Educational Workshop: Controlled Release Dosage Forms and 323A

Product Development Strategy for Expected New Regulatory Trends* 08:00 – 17:00 Exhibit Set-Up Exhibit Hall III 08:00 – 17:00 Young Scientist Workshop: Fundamentals of Controlled 323B

Release Drug Delivery: Physiochemical and Biological Aspects 09:00 – 17:00 Educational Workshop: Oral Delivery of Bioactives Using 324

Lipid-Based Drug Delivery Systems* (continued on Sunday) 12:00 – 14:00 Leadership Forum (by invitation) 306A/B 13:00 – 17:30 Educational Workshop: Using In Vitro–In Vivo Correlation 323C

(IVIVC) to Meet Challenges in Global Delivery *

Saturday Program Highlights Educational Workshops*

Young Scientist Workshop

Controlled Release Dosage Forms and Product Development Strategy for Expected New Regulatory Trends

Fundamentals of Controlled Release Drug Delivery: Physiochemical and Biological Aspects

Cosponsored by Ashland Specialty Ingredients 08:00 – 17:00 • 323A

Chairs: Raid Alany, Kingston University London, United Kingdom; Kaushalkumar Dave, South Dakota State University, U.S.A.; Giorgia Pastorin, National University of Singapore, Singapore; and Zimei Wu, The University of Auckland, New Zealand

Chairs: Ubrani Venkataram and Yanning Lin, Food & Drug Administration, U.S.A. Workshop Co-Hosts: Sherry Ku, TWi Biotech and TWi Pharmaceutical Inc., Taiwan; and Ali Rajabi-Siahboomi, Colorcon Inc., U.S.A.

Oral Delivery of Bioactives Using Lipid-Based Drug Delivery System Cosponsored by Avanti Polar Lipids Inc., and Gattefossé USA 09:00 – 17:00 • 324

Chairs: Anette Müllertz, University of Copenhagen, Denmark; and Sarah Hook, University of Otago, New Zealand

Using In Vitro–In Vivo Correlation (IVIVC) to Meet Challenges in Global Delivery Cosponsored by Simulations Plus, Inc. and SOTAX Corporation 13:00 – 17:30 • 323C Chair: Vivian Gray, V. A. Gray Consulting, Inc., U.S.A.

*Additional registration, payment, and ticket required.

12

8:00 – 17:00 • 323B

Speakers: Ben Boyd, Monash University, Australia; Diane Burgess, University of Connecticut, U.S.A.; Per Gisle Djupesland, OptiNose, Norway; Pankaj Karande, Rensselaer Polytechnic Institute, U.S.A.; Anette Müllertz, University of Copenhagen, Demark; Yvonne Perrie, Aston University, United Kingdom; Michael J. Rathbone, International Medical University, Malaysia; Ian G. Tucker, University of Otago, New Zealand; Alex van Herk, Institute of Chemical and Engineering Sciences, Singapore; and Zimei Wu, The University of Auckland, New Zealand Whether you are a Ph.D. student, a postdoctoral fellow, or an established researcher, it is absolutely vital to brush up every now and then on the fundamentals of the design and performance of innovative controlled release drug delivery systems. This is exactly the focus of this workshop. The essential physicochemical and biopharmaceutical concepts that are needed for the successful design of controlled release drug delivery systems will be reviewed. Furthermore, the various routes of drug delivery will be compared and contrasted. The workshop will also shed light on some of the cutting-edge innovations in the area underpinned by the fundamental principles.

Daily Schedule Sunday, July 21

Sunday

07:00 – 17:30 Speaker Preparation Room Open 07:30 – 18:00 CRS Registration Open 07:30 – 18:00 CRS Central Open 08:00 – 12:00 Young Scientist Workshop: Professional and Self

Development for Young Scientists and Protégés:

Effective Communication 08:00 – 14:00 Exhibit and Poster Set-Up 08:30 – 12:00 Educational Workshop: Oral Delivery of Bioactives Using

Lipid-Based Drug Delivery Systems* (continued from Saturday) 09:00 – 10:00 2014 CRS Annual Meeting Program Committee Meeting 09:00 – 10:00 Technology Forum: CIMA Labs 09:00 – 10:00 Technology Forum: Colorcon and Dow Food and

Pharma Alliance 09:00 – 10:00 Technology Forum: Mott Corporation 09:00 – 11:00 Technology Forum: Purac Biomaterials and OctoPlus 10:15 – 11:15 Technology Forum: Catalent Pharma Solutions, LLC 10:15 – 11:15 Technology Forum: Medimetrics Personalized Drug Delivery, Inc. 10:15 – 11:15 Technology Forum: SOTAX Corporation 11:15 – 12:00 Technology Forum: Hovione 11:30 – 12:30 Technology Forum: Capsugel 11:30 – 12:30 Technology Forum: MedinCell 11:30 – 12:30 Technology Forum: Halozyme Therapeutics 11:30 – 12:30 First Timers’ Meeting 12:30 – 14:00 Young Scientist Roundtable: Commercializing Ideas from

Academia: Past Lessons and Current Challenges 13:00 – 15:10 Soapbox Sessions 15:30 – 17:30 Industry Roundtable: Global Perspectives on Emerging

and Established Drug Delivery Markets 17:30 – 19:30 Exposition Grand Opening and Welcome Reception 17:30 – 19:30 Poster Viewing Hours *Additional registration, payment, and ticket required.

14

301A/B Exhibit Hall III Exhibit Hall III 323B Exhibit Hall III 324 317B 323A 319B 319A 322A/B 319A 319B 323A 322A/B 319A 323A 319B 306A/B 323B 312 312 Exhibit Hall III Exhibit Hall III

Sunday Program Highlights Soapbox Sessions

Delivery Science Meets Business Opportunities!

CRS Innovation Sunday is all about the business of delivery science, taking innovative ideas and technologies into the commercial sector. Designed to connect you with people, research, companies, and novel technologies that address challenges in delivery, come to Sunday’s interactive program open to asking questions and finding answers.

Technology Forums

These complimentary workshops are open to all registered attendees, offering in-depth coverage of controlled release technologies and services, hosted by the following companies: 09:00 – 10:00 09:00 – 10:00

09:00 – 10:00 09:00 – 11:00 10:15 – 11:15 10:15 – 11:15

10:15 – 11:15 11:15 – 12:00 11:30 – 12:30 11:30 – 12:30 11:30 – 12:30

CIMA Labs Colorcon and Dow Food and Pharma Alliance Mott Corporation Purac Biomaterials and OctoPlus Catalent Pharma Solutions, LLC Medimetrics Personalized Drug Delivery, Inc. SOTAX Hovione Capsugel Halozyme Therapeutics MedinCell

323A 319B 319A 322A/B 319A 319B 323A 322A/B 319A 319B 323A

Cosponsored by Catalent Pharma Solutions Cochairs: Eyal S. Ron, MADASH LLC, U.S.A.; and Michael J. Valazza, Catalent Pharma Solutions Moderated by Michael J. Valazza, Catalent Pharma Solutions 13:00-15:10 • 312 What’s new in delivery science? Come to the program where presenters “get up on their soapbox” to give you a quick glimpse of some of the most innovative technologies and products in development today. Session breaks allow time to network with presenters at their designated tables during beverage breaks, hosted by our sponsor.

Acuitas Therapeutics Bend Research BioModics Bioneer: Farma Faculty of Health Sciences Ceridia Pty. Limited GrayBug Losan Pharma Paraytec Ltd. Particle Dynamics, International PNST LLC dba Tranzerm Solutions Polymer Therapeutics, LLC RESMAN AS Serina Therapeutics Simulations Plus, Inc. Surface Measurement Systems Theraly Pharmaceuticals TNO

Industry Roundtable

Looking for the Abstracts?

Three easy ways to access the abstracts.

1. USE THE ABSTRACT PRINTING STATION Search and print abstracts for both podium and poster presentations at the Abstract Printing Station located at CRS Central across from the registration desk.

2. USE YOUR MOBILE DEVICE

15:30 – 17:30 • 312

Global Perspectives on Emerging and Established Delivery Markets A global panel of business development and R&D executives from major companies in Asia, Europe, and North America will provide insight on the latest trends, challenges, and needs they see in delivery science. CRS welcomes your audience participation in this session that is all about the international business of delivery science, offering a mix of presentations, panels, and case studies.

Access the abstracts from your mobile device using the 2013 CRS Annual Meeting mobile app. Search for “CRS Meeting” in the iTunes store, or Google Play. Access the mobile app from your Blackberry or laptop at the mobile app website: mobileapp.controlledrelease.org.

3. VISIT THE CRS WEBSITE The abstracts are also available on the CRS

website and can be accessed using your CRS username and password.

15

Sunday

CRS Innovation Sunday

Sunday Program Highlights Educational Workshop* (continued from Saturday)

Young Scientist Roundtable

Cosponsored by Avanti Polar Lipids Inc., and Gattefossé USA 08:30 – 12:00 • 324 Chairs: Anette Müllertz, University of Copenhagen, Denmark; and Sarah Hook, University of Otago, New Zealand

12:30 – 14:00 • 323B

Oral Delivery of Bioactives Using Lipid-Based Drug Delivery System

Sunday

Young Scientist Workshop

Professional and Self Development for Young Scientists and Protégés: Effective Communication Cosponsored by Microtek Labs Inc. and Vision Processing Technologies, Inc. 08:00 – 12:00 • 323B

Chairs: Michael J. Rathbone, International Medical University, Malaysia; and Teresa Virgallito, Microtek Labs Inc., U.S.A. Speakers: Michael J. Rathbone, International Medical University, Malaysia; and Teresa Virgallito, Microtek Labs Inc., U.S.A. The workshop will provide the young scientists with a training program for improving interpersonal relationships, improving listening skills, teaching negotiation skills, resolving conflict, and strengthening assertiveness. The young scientists will be able to improve their communications skills by increasing their awareness, attentiveness, and empathizing capacity, and facilitate better communication throughout their organization.

The workshop will also focus on intercultural communication.

Global communication is essential in today’s international business community and academic community.

Commercializing Ideas from Academia: Past Lessons and Current Challenges Chairs: Adam Bohr, Veloxis Pharmaceuticals A/S, Denmark; Hardik Shah, Alkermes Pharma Ireland Ltd., Ireland; and Jorrit Water, University of Copenhagen, Denmark Speakers: Daniel Bar-Shalom, University of Copenhagen, Denmark; Debra Bingham, Valeo Partners, U.S.A.; Tamás Letoha, Pharmacoidea, Hungary; and Peter Thomsen, Biomodics, Denmark Novel idea, proof of concept, in-depth analysis… At what point are an academic researcher’s results sufficient to start a company or bring a new product to the market? This roundtable will discuss the challenges to develop a business/marketing model while competing with the pharmaceutical industry. It will provide insight into intellectual property, evaluation of business opportunities, licensing, industrial collaborations, and regulatory aspects. Successful entrepreneurs will share their experiences and discuss challenges in commercializing ideas from academia.

First Timers’ Meeting 11:30 – 12:30 • 306A/B

If this is your first CRS Annual Meeting & Exposition, or even if you have attended for many years, learn how to get the most from the annual meeting program by attending this welcome and question-and-answer session presented by the CRS Board of Directors.

Exposition Grand Opening and Welcome Reception 17:30 – 19:30 • Exhibit Hall III Innovation Sunday concludes in the Exposition Hall, where you’ll find more new and emerging products and services, along with the opportunity to connect with some of delivery science’s leading suppliers. Enjoy an array of foods and beverages as you visit with exhibitors and colleagues.

*Additional registration, payment, and ticket required.

16

Technology Forums These complimentary forums are open to all registered attendees, offering in-depth coverage of controlled release technologies and services, hosted by the following companies:

09:00 – 10:00 Forums

CIMA Labs: Oral Drug Delivery Technology Development and Partnership

Room 323A Presenter: Vickie O’Neil, Director Formulation Development Presentation Areas: Formulation, Quality & Analytical CIMA Labs specializes in the development and manufacturing of new and improved drug products utilizing our oral drug delivery technologies. Our formulation technology offerings include ODT, oral transmucosal, solubilization, and tamperresistant extended and immediate release technologies. This presentation will showcase CIMA’s OraGuard™ technology and its advantages as an extended release delivery platform.

Company website: www.cimalabs.com

Influence and Control of Performance-Related Characteristics for Hydrophilic Polymers Utilized in Controlled Release Dosage Forms Room 319B Presenters: Kurt Fegely, General Manager – Alliance Products, Colorcon; and True Rogers, Senior Research Specialist, Dow Pharma and Food Solutions Presentation Area: Formulation This forum will examine the fundamentals of particle nature and polymer chemistry on the performance of hypromellose and polyethylene oxide in oral, controlled release dosage forms.

Strategies to mitigate variability in the performance of a dosage form and methods to prevent regulatory obstacles will be discussed. Company websites: www.colorcon.com, www.dow.com

Novel Uses for Porous Metal Technology in Medical, Pharmaceutical, and Biotechnology Applications

Room 319A Presenter: Dr. Kenneth L. Rubow, Vice President for Filtration and Advanced Media Science

Presentation Area: Processing Recent advances in porous metal technology are highlighted for sterilizing filtration, drug delivery and flow control via gradual diffusion or metering, and time released coatings. Porous metal is supplied in various shapes, sizes, and biocompatible metallurgies, including proprietary nanotechnology, and provides designers unique solutions for medical and life sciences applications. Company website: mottcorp.com

09:00 – 11:00 Forum

PLGA in Ocular Controlled Release—From Biomaterials to Drug Product

Room 322A/B Presenters: Dr. Michiel van Alst, Purac Biomaterials; Dr. Ruud Verrijk, OctoPlus; Presentation Areas: Biomaterials, Controlled Release Formulation, Quality & Analytical, Process Development Ocular Controlled Release using PLGA microspheres : Michiel van Alst (Purac Biomaterials) covers quality aspects in synthesis of PLGAs suitable for ocular controlled release.

Ruud Verrijk (OctoPlus) explains the process of making GMP grade controlled release microspheres for ocular application specifically. Company Websites: www.purac.com/ purac-biomaterials + www.octoplus.nl

10:15 – 11:15 Forums

Techniques for Enabling the Delivery of Poorly Soluble Drugs

Room 319A Presenter: Michael J. Valazza, R.Ph., Vice President, Modified Release Technologies Presentation Areas: Formulation, Processing The global pharmaceutical industry has recently been challenged by the decrease of new active compounds—caused partially by low solubility. What cannot be dissolved cannot be absorbed. This presentation will focus on Zydis® nano technology, formulation and compression of hot melt extrudates, and other current techniques for enabling drug delivery. Company website: www.catalent.com 17

11:30 – 12:30 Forums

Overcoming the Impact of Physiology Factors with IntelliCap, a New Oral Electronic Drug Delivery Device

Room 319B Presenters: Prof. Werner Weitschies, Center of Drug Absorption and Transport, University Greifswald, Germany; Jeff Shimizu, CTO, Medimetrics; Dr. Dieter Becker, CEO, Vivo Drug Delivery GmbH, Switzerland Presentation Area: Formulation Physiology factors have an often underestimated impact on in vivo drug absorption. The IntelliCap system employs a swallowable electronic capsule that identifies location by gut pH profile and releases drug formulations in a flexible programmable manner. Case studies are presented using the IntelliCap system to ensure success in modified release development. Company website: www.medimetrics.com

In Vitro Drug Release—A Regulatory Perspective

Room 323A Presenter: Samir Haddouchi, Managing Director, SPS Pharma Services Presentation Areas: Formulation, Quality & Analytical New types of formulations and drug delivery technologies call for a new approach to in vitro drug release testing. Traditional dissolution methods are not tailored to these novel dosage forms. Products such as medical devices, combination products, nanoparticles, and parenterals can be challenging when it comes to drug release testing. Company website: www.sotax.com

A Novel Two-Piece Enteric Capsule

Room 319A Presenter: Maryline Clauzel, Polymer Science and Technology Specialist Presentation Areas: Formulation, Processing Capsugel has developed a capsule that is intrinsically enteric, eliminating the need for coating either a capsule shell or tablet.

Formulation and processing steps can be removed from clinical development, resulting in speed-to-clinic evaluation of new compounds. Company website: www.capsugel.com

Building A Better SubQ Product: Improved Subcutaneous Delivery With ENHANZE™ Technology

Room 319B Presentation Area: Formulation Halozyme Therapeutics’ ENHANZE™ technology is a novel drug delivery platform that improves the bioavailability of co-injected drugs by increasing SC absorption. With ENHANZE™, it is feasible to administer large volumes via a single SC injection. The platform is in late stage development with partners that include Roche, Pfizer and Baxter. Company Website: www.halozyme.com

11:15 – 12:00 Forum

Overcoming Poor Solubility Using Solid Dispersion—From Research to Commercial Reality

Room 322A/B Presenter: Dr. Filipe Gaspar, Director of Drug Product Technologies Presentation Areas: Formulation, Processing This presentation will start by showing typical platforms used to overcome poor solubility of oral drugs. A case study for development and scale-up of solid dispersions using spray drying will be shown. The development of such processes using a Quality by Design approach will be illustrated and the benefits quantified. Company website: www.hovione.com

18

MedinGel™—Custom Tailored Delivery Durations from 3 Days to 1 Year

Room 323A Presenter: Mark S. Wilson, Vice President, Business Development Presentation Area: Formulation MedinCell’s injectable technology forms an in situ depot after subcutaneous (systemic) or intra-articular (local) administration. Burst and bioresorption rates can be tailored for osteoarthritis, mental health, diabetes, fertility, pain control, and many other applications. By protecting drug molecules within the hydrogel matrix, drug cargo can be substantially reduced for cost therapies. Company website: www.medincell.com

Soapbox Sessions Cosponsored by Catalent Pharma Solutions 13:00 – 15:10 • 312

What’s new in delivery science? Come to the program where presenters “get up on their soapbox” to give you a quick glimpse of some of the most innovative technologies and products in development today. Session breaks allow time to network with presenters at their designated tables during beverage breaks, hosted by our sponsor.

13:00 – 13:10 Introduction and Welcome

Moderator, Michael J. Valazza, Catalent Pharma Solutions

14:05 – 14:10

Controlled Release of Tracer Compounds into Well Fluids in Oil Wells for Production Profiling Anne Dalager Dyrli, RESMAN AS, Norway

14:10 – 14:15

Polyoxazoline, Not Just Another Biopolymer Tacey Viegas, Ph.D., Serina Therapeutics, Inc., U.S.A.

Session I 13:10 – 13:15

Dosage Form Evaluation in the Dynamic Gastric Model Daniel Bar-Shalom, Bioneer: Farma Faculty of Health Sciences, Denmark

13:15 – 13:20

A Dispersible Bioadhesive Film for Oral Delivery of Peptides Paul Foreman, Losan Pharma (in collaboration with Henkel Corporation), Germany

13:20 – 13:25

Therapeutic Protein Expression In Vivo Using mRNA LNP Thomas Madden, Ph.D., Acuitas Therapeutics, Canada

13:25 – 13:30

Lipoceramics: A New Solution to LipidBased Formulation and Delivery Clive Prestidge, Ceridia Pty. Limited, Australia

13:30 – 13:35

Compelling Therapies One PEG at a Time Seulki Lee, Theraly Pharmaceuticals, U.S.A.

13:35 – 13:40

A New Oral Dosage Form: A Chewable Liquid Dr. Irwin C. Jacobs, Particle Dynamics International, U.S.A.

13:40 – 13:50

Networking Break

Session II 13:50 – 13:55

13:55 – 14:00

14:00 – 14:05

Enabling Pharmacokinetic Control of Solubilized Forms W. Brett Caldwell, Ph.D., Bend Research Inc., U.S.A. Physiologically-based Absorption Modeling and the Future of IVIVCs Grazyna Fraczkiewicz, Simulations Plus, Inc., U.S.A.

14:15 – 14:20

Oxygen Protection of Food and Pharma Ingredients in Humid Conditions Using New Barrier Coatings Nicole Papen-Botterhuis, TNO, The Netherlands

14:20 – 14:30

Networking Break

Session III 14:30 – 14:35

14:35 – 14:40

GrayBug: Innovation in Ocular Drug Delivery Justin Hanes, GrayBug, U.S.A. Novel Protein Nanocarriers for Skin Delivery Applications Omathanu Perumal, PNST LLC dba Tranzerm Solutions, U.S.A.

14:40 – 14:45

Biodegradable Drug-Eluting Polymers for Antimicrobial, Antibiofilm Medical Device Applications Kathryn Uhrich, Ph.D., Polymer Therapeutics, LLC, U.S.A.

14:45 – 14:50

A Hybrid Polymer Material for Controlled Long-Time Drug Release Peter Thomsen, BioModics Aps, Denmark

14:50 – 14:55

Surface Energy Analysis: A Novel Approach to Heterogeneity Mapping of the Surface Chemistry of Materials Joe Domingue, Surface Measurement Systems, U.S.A.

14:55 – 15:10

Networking Break

A Miniaturized Instrument for Rapid In Vitro Permeation Testing Alexander Chapman, Paraytec Ltd., U.K. 19

Your Membership:

Your Access to the Future of Delivery Science and Technology Your membership is your all-access pass to leading research and the delivery science community.

Innovative Research From the research presented in the journals Drug Delivery and Translational Research and the Journal of Controlled Release, to the science presented at the CRS Annual Meeting & Exposition, to books and online webcasts, CRS is your source for the best delivery science and technology research.

Targeted Networking The CRS Annual Meeting & Exposition is just the beginning of the great opportunities to connect with delivery scientists. Utilize the online community through the website, find experts through the LATTE database, join a committee, connect on LinkedIn, or join your local chapter, and access one of the most valuable resources – each other.

Test tubes and shampoo images courtesy of istock.com. Eye drops courtesy of Comstock.

Career Advancement Advance your professional skills through volunteering, participating in the mentoring program, and more. CRS offers fellowship programs and recognition through awards. The online career center is one more chance to develop your career in delivery science.

Take advantage of everything your membership has to offer now. Access it all online. controlledreleasesociety.org 20

Daily Schedule Monday, July 22

Get Up! Get Educated! Nanomedicines for Drug Delivery Across Epithelial Barriers: Intestines, Skin, and Lungs CRS Registration Open CRS Central Open Speaker Preparation Room Open CRS Opening Session Exposition Open – Meet with Exhibitors, Prize Drawing Refreshment Break Poster Session 1 – Authors Present Young Scientist Committee/Mentor-Protégé Subcommittee Meeting Exposition Hall Open Poster Viewing Hours Scientific Sessions

• Food, Nutraceuticals, and Personalized Diet • Mini-Symposium: Hybrid Groups: Bridging the Gap Between Industry and Academia • Parenteral Sustained Release Drug Delivery • Rising Suns in Asia • RNAi and DNA Delivery 10:45 – 12:00 2014 Exhibit Selection, Group A 11:30 – 13:30 Mentor/Protégé Meet and Greet 13:30 – 14:45 Plenary Session: Kenzo Takada 15:00 – 16:00 Finance Committee Meeting 15:00 – 16:30 Scientific Sessions • Challenges Around Brain Delivery: Sampling Site Issues and Interspecies Extrapolations • Micro- and Nanoparticle Design • Mini-Symposium: Breakthrough Technologies in Drug Delivery Systems from Asia • Smart Building and Construction Materials and Coatings • Topical/Transdermal Drug Delivery

16:30 – 17:30 Poster Viewing and Exposition Happy Hour – Meet with

Exhibitors, Prize Drawing, Refreshment Break 17:30 – 18:30 Preclinical Sciences & Animal Health Get-Together* 21:00 – 22:30 Young Scientist Networking Event*

316B Exhibit Hall III Exhibit Hall III 301A/B 315 Exhibit Hall III Exhibit Hall III 317A Exhibit Hall III Exhibit Hall III

Monday

07:00 – 08:00

07:00 – 17:30 07:00 – 17:30 07:00 – 17:30 08:00 – 09:30 09:30 – 10:30

09:30 – 10:30 09:30 – 10:30

09:30 – 17:30 09:30 – 17:30 10:30 – 12:00

314 316B 316A 316C 315 Exhibit Hall III 306A/B 315 317B 316A 315 316B 314 316C Exhibit Hall III 306A/B Jimmy Buffett’s at the Beachcomber Restaurant and Honolulu Surfing Museum

*Additional registration, payment, and ticket required.

21

Monday Program Highlights Get Up! Get Educated!

Mentor-Protégé Meet and Greet

Nanomedicines for Drug Delivery Across Epithelial Barriers: Intestines, Skin, and Lungs

11:30 – 13:30 • 306A/B

07:00 – 08:00 • 316B

Chair: Prajakta Dandekar Jain, Institute of Chemical Technology, Mumbai, India

Speaker: Claus-Michael Lehr, Helmholtz Institute of Pharmaceutical Research Saarland (HIPS), Germany

Monday

This session is a must-attend for young scientists and will educate them on how nanoscale drug formulations have an edge over conventional formulations for improved drug delivery across epithelial barriers. Discussion involving experimental evidence will prove the advantage of drug/antigen loaded nanoparticles for targeted therapy of inflammatory bowel diseases, as needle-free vaccines via the dermal route to avoid the need for painful injections, and for delivery across the air-blood barrier while controlling mucociliary and macrophage clearance.

Opening Session 08:00 – 09:30 • 315

The Opening Session will feature a welcome by President Kazunori Kataoka, who will provide a brief update on what your association is doing to further delivery science and technology during the annual business meeting portion of the meeting. This session will also be a time to honor the 2013 CRS Distinguished Service awardee and Fellows awardees, along with the CRS T. Nagai Postdoctoral Research Achievement Award and talks from our Founders Award winner, Richard Guy, and Young Investigator Award winner, Ali Khademhosseini. Five new members of the College of Fellows will also be inducted.

The session will conclude with our third annual College of Fellows event, a special panel discussion on “Global Collaboration in Delivery Science” moderated by College of Fellows member Clive Wilson, featuring a distinguished panel of leaders in delivery science and technology. This College of Fellows panel is considering global collaboration in delivery science and the ways in which technology or culture facilitates or interferes with progress. Learning to function together in ever bigger teams in an efficient way will be important in the future.

Panelists: Diane Burgess, University of Connecticut, U.S.A.; David Friend, CONRAD, U.S.A.; and Kazunori Kataoka, University of Tokyo, Japan

Poster Session Cosponsored by AstraZeneca All scientific posters will be on display throughout the meeting.

Poster authors have been designated into one of three sessions.

On Monday, authors will be present at posters during the time specified below. To determine which poster authors will be present during Monday’s session, please use the poster information found in the CRS program book, the mobile app, CRS website, and abstract printing station.

Poster Session 1: 09:30 – 10:30 • Exhibit Hall III 22

Organized by the Young Scientist Mentor/Protégé Subcommittee This is a must-attend session for those who preregistered for the 2013-2014 CRS Young Scientist Mentor-Protégé Program.

Mentors and protégés will be introduced during this event and be given the opportunity to discuss the protégé’s goals, exchange expectations for what is hoped to be gained from the mentoring relationship, and develop a plan of interaction for the year-long program. Do not miss this exciting occasion to meet face-to-face with your mentor or protégé.

Please note, only those who received notification of acceptance into the program may attend this event. Lunch will not be provided; however, attendees are invited to bring their own lunch.

Plenary Human B-Lymphocytes as a Source of High-Affinity, Really Fully Human Antibodies 13:30 – 14:45 • 315 Moderator: Kinam Park

Kenzo Takada, Chairman and Founder, Evec, Inc., Professor Emeritus, Hokkaido University, Japan

Producing antibody medicines through the hybridoma method in which transgenic mice are grafted with human antibody genes results in low-affinity antibodies that are not fully human.

In contrast, human blood B-lymphocytes are activated through natural immune reactions. They are stimulated repeatedly with a small amount of antigen, so only those producing highaffinity antibodies are activated. Thus, human lymphocytes are an excellent source of high-affinity, really fully human antibodies. This session covers Evec’s antibody production technology using Epstein-Barr virus and its experience in license negotiations.

Prior to the plenary, the CRS Foundation’s 2012 Sung Wan Kim Postdoctoral Fellowship recipient, Tram Dang, will present research from her fellowship year at the Ali Khademhosseini Laboratory, Brigham and Women’s Hospital and Harvard Medical School.

Poster Viewing and Exposition Happy Hour 16:30 – 17:30 • Exhibit Hall III With nearly 700 posters to see, this is time well spent, and it’s made even better with the beverage of your choice. A variety of selections will be available for purchase during the event.

Preclinical Sciences & Animal Health Get-Together* 17:30 – 18:30 • 306A/B Organizers: Marilyn Martinez, FDA Center for Vet Medicine, U.S.A.; and Michael J. Rathbone, International Medical University, Malaysia The Preclinical Sciences & Animal Health (PSAH) Division is very active in sharing with its members the most recent information on the study of therapeutics in animals, from drug development for that species to the perspective of their use to support human drug product development. The PSAH GetTogether will begin with a presentation entitled “The Beagle Dog as a Preclinical Species: History, Potential Pitfalls, and Future Directions.”

After the presentation, the event will conclude with valuable face-to-face networking time for those in attendance. To attend the event, it is not necessary to be a member of the PSAH Division but only to have an interest in this area of delivery science. Each attendee will receive one drink ticket, as well as light hors d’oeuvres.

Young Scientist Networking Event* Cosponsored by Upsher-Smith Labs and Diurnal Ltd 21:00 – 22:30 • Jimmy Buffett’s at the Beachcomber Restaurant and Honolulu Surfing Museum Spend an enjoyable evening networking with colleagues when you attend the Young Scientist Networking Event, hosted at Jimmy Buffett’s at the Beachcomber Restaurant and Honolulu Surfing Museum. Reunite with familiar faces and make new connections as you tour the surfing museum, which includes a premier collection of surfing artifacts, videos, and surf-inspired items. Then enjoy hors d’oeuvres, their famous Who’s to Blame Margarita and other beverages in a venue that truly celebrates the people, culture, and incredible natural wonders of Hawaii. *Additional registration, payment, and ticket required.

Upcoming Educational Opportunities from CRS These CRS workshops will take place at the 2013 AAPS Annual Meeting & Exposition November 10–14, 2013 San Antonio, Texas, U.S.A.

Introduction to Microencapsulation Technologies Workshop Knowledge of multiple encapsulation technologies and how they are applied is valuable information for developing new products or solving existing problems. It is important, at a minimum, to have a basic understanding of all commonly available processes and their applications.

This workshop provides an introduction to common micro- and nanoencapsulation processes and their various applications. The workshop is structured to 1) introduce common encapsulation techniques, 2) review common materials, and 3) provide an overview of the wide range of applications for controlled release products.

Workshop Organizers James Oxley, Southwest Research Institute, U.S.A. Irwin Jacobs, Particle Dynamics International, LLC, U.S.A.

Mitigating Risks for Patients When Developing Oral Controlled Release Dosage Forms Workshop The focus will be to understand the possible risks to patients and approaches to manage them when developing oral extended-release (ER) dosage forms.

The discussion will relate to the design, development and manufacture of commonly used ER systems. Industry leaders and subject matter experts will provide scientific basis to the material science, formulation, and process attributes that will help to mitigate risks, under the umbrella of quality by design (QbD). The overall goals of such approaches are to improve quality, reduce costs, but maintain patient safety and treatment.

Workshop Organizers Ali Rajabi-Siahboomi, Colorcon, U.S.A. Mansoor Khan, CDER, USFDA, U.S.A.

•••••••••

Register online at www.aaps.org.

Information about these workshops is also available on the CRS website at controlledreleasesociety.org.

23

Monday

Cosponsored by Merial

Podium • Monday Morning Monday Morning

314

316B

316A

Food, Nutraceuticals and Personalized Diet

Mini Symposia: Hybrid Groups Bridging the Gap Between Industry and Academia

Parenteral Sustained Release Drug Delivery

I Jacobs, R Perez

J Hanes, L Mayer

K Park, J Remenar

1

Invited Speaker: Systems Approaches to Personalized Nutrition and Ingredient Bioavailability M Kussmann Nestle Institute of Health Sciences, Switzerland

6

Invited Speaker: Transforming Discovery into Opportunity - The Centre for Drug Research and Development (CDRD) and New Models for Commercialization K Es Sabar The Centre for Drug Research and Development, Canada

9

11:00

2

Novel protein based microparticles for intestinal delivery of bioactive compounds Z Tian, R Wang, L Chen University of Alberta, Canada

7

Invited Speaker: Connecting Academia and Pharmaceutical Industry – A Max Planck Initiative Toward Closing the Innovation Gap in Drug Discovery B Klebl Lead Discover Center GmbH, Germany

10 Enhanced Exposure of a Chemotherapeutic Drug to the Lymphatic System with the use of PEG-Modified and Nano-Sized Drug Carriers G M Ryan Monash University, Australia

11:15

3

Tauroursodeoxycholic Acid Attenuates Lipid Accumulation and Adipogenesis of Adipose-derived Stem Cells B Cha, J Kim, J Ahn, H Park, S Park, S Lee Chung-Ang University, Korea

11:30

4

Silk-based Biomaterials for Stabilization and Sustained Release of Neutraceuticals X Wang Suzhou University, Peoples Rep of China

11:45

5

Evaluation of cellular uptake and transport of Ginkgo biloba Extract niosomes Y Jin, D Li, L Teng, W Zhang, J Jin, J Wen University of Auckland, New Zealand

10:30

Invited Speaker: Aqueous Microencapsulation of Large Molecules in PLGAs S P Schwendeman, K H Desai, J M Mazzara University of Michigan, U.S.A.

Monday

10:45

12:00

End of Session

11 In vitro release studies on parenteral sustained release dosage forms: Crystal suspensions of poorly soluble peptides desired for intra-articular application B Sterner, M Harms, M Windbergs, M Weigandt, C Lehr Merck KGaA, Germany

8

Invited Speaker: Funding Translational Research in Academia P Griffin The Scripps Research Institute, U.S.A.

12 A Drug Transport Model for Delivery Vectors Incorporating Chemical and Microstructure Properties M Kojic, M Milosevic, N Kojic, M Ferrari, A Ziemys The Methodist Hospital Research Institute, U.S.A.

13 Anastrozole loaded-PLGA microspheres as a novel therapy to overcome noncompliance issues on breast cancer patients H Kim, K H Lee, S H Hong, H Shin SK Chemicals, Korea

End of Session

End of Session Cosponsored by Alkermes

24

Podium 316C

Rising Suns in Asia

Y Matsumura, Y Takakura

315

RNAi and DNA Delivery

D Luo, D Oupicky 19 Invited Speaker: Oncolytic adenovirus coated with stimuli-responsive block copolymer for passive tumor targeting C Yun Hanyang University, South Korea

11:00

15 C225-Conjugated Polymeric Micelles for Targetable Photodynamic Therapy P Lai National Chung Hsing University, Taiwan

20 Sequence-Defined Multifunctional Carriers for Targeted siRNA Delivery E Wagner Ludwig Maximilians University, Germany

11:15

16 Development of pH Responsive Polymeric Self-Assembly System for Curcumin Delivery W Sajomsang National Nanotechnology Center, Thailand

21 Ischemic Myocardium Targeting Peptide-guided Gene Delivery System Y Won, A N McGinn, M Lee, D A Bull, S Kim University of Utah, U.S.A.

11:30

17 Multifunctional carrier for RNA delivery 22 Noncovalenly PEGylated Ternary S Duan, W Yuan, F Wu, T Jin Complex for Pulmonary Delivery of Shanghai Jiao Tong University, Peoples Therapeutic siRNA Rep of China W Kong, H Kim, S Hahn POSTECH, Korea

11:45

18 Enhanced Gene Expression, Transfection, and Reduced Cytotoxicity of Novel Hyaluronic AcidPEI-Cyclodextrin Polyplexes S Jain, S Kumar, A K Agrawal, K Thanki, U C Banerjee National Institute of Pharmaceutical Education and Research, India

23 A flexible nano carrier for siRNA delivery into tumor K Kogure, Y Shimatani, K Uno, H Chon, S Hama Kyoto Pharmaceutical University, Japan

End of Session

End of Session

Monday

14 Invited Speaker: Nanotechnology in vivo: Redox Polymer Therapeutics Y Nagasaki, Y Nagasaki University of Tsukuba, Japan

10:30

10:45

12:00

Cosponsored by Japan Society of Drug Delivery System

25

Podium • Monday Monday Afternoon

Afternoon

316A

Challenges Around Brain Delivery: Sampling Site Issues and Interspecies Extrapolations P Cheifetz, M Rathbone

315

Micro- and Nanoparticle Design

Y Bae, S Schwendeman

316B

Mini Symposia: Breakthrough Technologies in DDS from Asia

H Harashima, T Mizushima

24 Invited Speaker: Challenges in measuring active concentration in the brain and its impact for nanocarrier delivery M Hammarlund-Udenaes, I Loryan, A Lindqvist Uppsala University, Sweden

29 Invited Speaker: Precision fabrication of emulsion-templated structures for encapsulation and release using microfluidics D A Weitz Harvard University, U.S.A.

34 Invited Speaker: Structural Modified siRNAs for Systemic siRNA Delivery K Kim, S Lee, S Kim, C Ahn, I Kwon Korea Institute of Science and Technology, Korea

15:30

25 Self-assembling nanoparticles containing zoledronic acid: a new challenge for the treatment of brain tumors G Salzano UniversitĂ degli Studi di Napoli Federico II, Italy

323 Enhancing Tumor Cell Response to Chemotherapy by Simultaneous Delivery of siRNA and Anticancer Drug Using Nanoparticles X Xu Harvard Medical School, U.S.A.

35 Invited Speaker: Bioresponsive Degradable Nanocarriers for Active Intracellular Anticancer Drug Delivery Z Zhong Soochow University, Peoples Rep of China

15:45

26 Complete recovery of cognition for 31 Activation of An Immune-Regulatory senescence-accelerated-prone mice by Macrophage Response and Inhibition oral redox-polymer therapeutics of Lung Inflammation in A Mouse Y Nagasaki, P Chonpathompikunlert, T Model of COPD Using Porous Alpha BYoshitomi, N Imaizumi, Y Ozaki crystallin-Loaded PLGA Microparticles University of Tsukuba, Japan M Midi Utrecht University, Netherlands

16:00

27 Nanogels as a Platform for Targeted Delivery of Cisplatin to the Brain Tumor N Nukolova, V Baklaushev, A Kabanov, V Chekhonin Lomonosov Moscow State University, Russia

32 Heat-activated Thermosensitive Liposomal Cisplatin (HTLC) Results in Effective Growth Delay of Cervical Carcinoma in Mice Y Dou, J Zheng, R Weersink, N Chaudary, W D Foltz, D A Jaffray, C J Allen University of Toronto, Canada

16:15

28 Targeted Nano-NRTI Formulations for Suppression of HIV-1 Infection in the Brain S V Vinogradov, S Gorantla, T Senanayake, E Makarov, Y Lu University of Nebraska Medical Center, U.S.A.

33 Multistage Vector for Controlled Oral Delivery of Anti-Inflammatory Drug in Inflammatory Bowel Disease Treatment F Leonard, E Collnot, C Lehr, M Ferrari, B Godin The Methodist Hospital Research Institute, U.S.A.

15:00

Monday

15:15

16:30

End of Session

End of Session

36 Invited Speaker: Liposomal Systems for Pulmonary and Ocular Drug Delivery H Takeuchi Gifu Pharmaceutical University, Japan

End of Session Cosponsored by Japan Society of Drug Delivery System

26

Podium 314

Smart Building and Construction Materials and Coatings K Carson, C Frey

316C

Topical/Transdermal Drug Delivery

R Guy, M Prausnitz 42 Invited Speaker: Nanoparticulate Delivery to the Skin by exploiting Passive Physical Principles R H Müller, C M Keck Free University, Germany

15:30

38 Enzyme-Based Nanocomposites: Using Nature to Ward off Emerging Threats R S Kane, N Grover, K K Mehta, R C Pangule, K Solanki, M Douaisi, E E Paskaleva, C Dinu, J S Dordick Rensselaer Polytechnic Institute, U.S.A.

43 Permeability and Stability of Dispersion Systems in the Presence of Penetration Enhancers J R Falconer, J Wen, S Zargar-Shoshtari, J J Chen, M Farid, G M El Maghraby, R G Alany University of Auckland, New Zealand

15:45

39 Pelletized Phase Change Material for Energy-Efficient Buildings R Abhari, N Shukla, A Fallahi, K Biswas Syntroleum Corporation, U.S.A.

44 Controlled 90-Day In Vitro and In Vivo Delivery of Tenofovir and Levonorgestrel from a Dual-Segment Reservoir Intravaginal Ring J T Clark, M R Clark, T J Johnson, N B Shelke, J S Nebeker, G F Doncel, D R Friend, P F Kiser University of Utah, U.S.A.

16:00

40 Microencapsulation of Salts for Enhanced Thermochemical Storage Materials R Cuypers, A J De Jong, J Eversdijk, H Van 't Spijker, H P Oversloot, B L Ingenhut, R K Cremers, N E Papen-Botterhuis TNO Responsive Materials & Coatings, Netherlands

45 Needle free vaccination using nanoparticles via transfollicular route — a perspective for transcutaneous vaccination A Mittal, A S Raber, U F Schaefer, S Weissmann, T Ebensen, K Schulze, C A Guzmán, C M Lehr, S Hansen Saarland University, Germany

16:15

41 Microcapsule Delivery Systems for Textile Applications T Virgallito Microtek Labs Inc, U.S.A.

46 Rapid Skin Permeabilization by the Simultaneous Application of DualFrequency Ultrasound C M Schoellhammer, B E Polat, J Mendenhall, R Maa, B Jones, D P Hart, R Langer, D Blankschtein Massachusetts Institute of Technology, U.S.A.

Monday

37 Invited Speaker: Crack-mediated Release of Encapsulated Bacteriabased Agent Makes Concrete Selfhealing H M Jonkers Delft University of Technology, Netherlands

15:00

15:15

16:30

End of Session

End of Session

Cosponsored by Coating Place Inc.

27

Daily Schedule Tuesday, July 23

Tuesday

07:00 – 08:00 07:00 – 08:00

07:00 – 17:00 07:00 – 17:00 07:00 – 17:30 08:00 – 09:30 09:30 – 10:30

09:30 – 10:30 09:30 – 10:30 09:30 – 16:00 09:30 – 16:00 10:30 – 12:00

DDTR Editorial Board Meeting Get Up! Get Educated! Quality by Design: Systematic Development of Pharmaceutical Products CRS Registration Open CRS Central Open Speaker Preparation Room Open Plenary Session: Josh Wolfe Exposition Open – Meet with Exhibitors, Prize Drawing, Refreshment Break Poster Session 2 – Authors Present Chapter Committee Meeting Poster Viewing Hours Exposition Hall Open Scientific Sessions

• Drug Delivery for Developing Countries/Global Challenges • Imaging and Characterization Techniques for Drug Delivery:

Systems and Targeted Drug Delivery • Mini-Symposium: Energy: Problems Within the Industry That Controlled Delivery Can Solve • Peptide and Protein Delivery • Solubilization Technology: A Key Enabler for the Delivery of Poorly Soluble Drugs 10:45 – 12:00 2014 Exhibit Selection, Group B 12:00 – 13:30 C&DP Division Luncheon* 13:30 – 15:00 Scientific Sessions:

• Drug Targeting, Pharmacokinetics, and Biodistribution: Differences Between Species • Mini-Symposium: Drug Combination Products • Modern Agriculture and Aquaculture • Oral CR – Pharmaceutical Formulations, Technologies, and Development Strategies • Processing Technology/Manufacturability 15:00 – 16:00 Exposition Open – Meet with Exhibitors, Prize Drawing

Refreshment Break 15:00 – 16:00 Poster Session 3 – Authors Present 16:00 – 17:00 Consumer & Diversified Products Division Business Meeting 16:00 – 17:00 Poster Take-Down 16:00 – 17:30 Board of Scientific Advisors Meeting 16:00 – 17:30 Roundtables and Focus Groups • Ocular Drug Delivery • Oral Drug Delivery 16:00 – 18:00 Exhibit Take-Down 18:30 – 22:00 CRS President’s Banquet*

*Additional registration, payment, and ticket required.

28

317A 316B Exhibit Hall III Exhibit Hall III 301A/B 315 Exhibit Hall III Exhibit Hall III 317B Exhibit Hall III Exhibit Hall III 316A 316C 316B 315 314 Exhibit Hall III 306A/B 316A 316B 314 316C 315 Exhibit Hall III Exhibit Hall III 317B Exhibit Hall III 317A 316B 316C Exhibit Hall III Hilton Hawaiian Village / Rainbow Tower – Rainbow Suite

Tuesday Program Highlights Get Up! Get Educated!

Poster Sessions

Quality by Design: Systematic Development of Pharmaceutical Products

Cosponsored by AstraZeneca

Chairs: Joshua Reineke, Wayne State University, U.S.A.; and Pirthi Pal Singh, Panacea Biotec Ltd., India Speaker: Anette Müllertz, University of Copenhagen, Denmark Beyond development of delivery systems, formulation scientists must integrate scientific development along with regulatory requirements. Regulatory agencies monitor the path selected for initial screening, prototype development, process and composition optimization, and stability of drug product in addition to the final developed product. Quality by Design (QbD) ensures the systematic approach to development that begins with predefined objectives and emphasizes process understanding and process control, based on sound science and quality risk management.!

Plenary Hype and Hope: A View from a Venture Capitalist 08:00 – 09:30 • 315 Moderator: Justin Hanes

All scientific posters will be on display throughout the meeting in Exhibit Hall III. Poster authors have been designated into one of three sessions. On Tuesday, authors will be present at posters during one of the two times specified below. To determine which poster authors will be present during which session, please use the poster information found in the CRS program book, the mobile app, CRS website, and abstract printing station.

Poster Session 2: 09:30 – 10:30 Poster Session 3: 15:00 – 16:00

C&DP Division Luncheon*

Cosponsored by Coating Place, Fleet Laboratories, and Ronald T. Dodge Co. 12:00 – 13:30 • 306A/B Join your fellow Consumer & Diversified Products Division members for this networking buffet luncheon at the Hawaii Convention Center. All attendees interested in C&DP—which includes encapsulation and controlled release research for food, nutraceuticals, personal care, cosmetics, home care, agriculture, textiles, and coatings—are welcome to attend. continued on page 30

Josh Wolfe, Founding Partner and Managing Director, Lux Capital, U.S.A.

Josh Wolfe provides a venture capital investor perspective on commercializing scientific breakthroughs, raising capital, recruiting talent, and building a high-growth high-tech venture.

He dispels myths and shares insider views on the high-stakes, risky, and competitive world of venture investing. How can you secure non-dilutive funding? What are the key terms to seek or be wary of when negotiating a deal? What are the new and emerging trends VCs are pursuing, and where are they shunning opportunities?

Awards presented prior to the plenary will include the CRS Jorge Heller Journal of Controlled Release Outstanding Paper Award to Sungho Jin of University of California, San Diego, U.S.A., and the DDTR Outstanding Paper Award to Shirley Wu of University of Toronto, Canada, and CRS Outstanding Chapter Award to the United Kingdom-Ireland Local Chapter.

JOB SEEKERS Are you ready to take the next step in your delivery science career?

CRS Job Center • Search for jobs by keyword, location, and more • Post your resume anonymously • Get personalized job alerts Online at controlledreleasesociety.org/careers www.controlledreleasesociety.org/careers

29

Tuesday

07:00 – 08:00 • 316B

Tuesday Program Highlights (continued) Roundtables and Focus Groups

Oral Drug Delivery Roundtable and Focus Group

Ocular Drug Delivery Roundtable and Focus Group

Cosponsored by Colorcon

Novel Biomaterials for Ocular Drug Delivery

Multiparticulate Oral Drug Delivery Systems for Fixed Dose Combinations

16:00 – 17:30 • 316B Chairs: Ruiwen Shi, Allergan Inc., U.S.A.; and Clive Wilson, University of Strathclyde, United Kingdom

Tuesday

A number of eye diseases such as glaucoma, age-related macular degeneration, and diabetic retinopathy are rising at an alarming rate. They are among the most common causes of blindness in the United States. Local delivery of therapeutic agents to the target tissues is considered a key for effectively treating these diseases while minimizing systemic toxicity. Advances in materials science and engineering have created unprecedented opportunities for the development of intraocular drug delivery systems. This roundtable session will focus on the discussion of the current status of biomaterials that are being used in ocular drug delivery systems and novel materials that are emerging for such purposes. The session will feature invited presentations followed by a panel discussion.

Invited Speakers: Dan Luo, Cornell University, U.S.A. Bulk-scale, DNA-based Hydrogels for Drug Development and Delivery Andrew Urquhart, University of Strathclyde, United Kingdom Rational Design for Bio/Pharma Materials for Drug Delivery: Past, Present, and Future

EMPLOYERS Looking for qualified candidates in delivery science and technology?

CRS Job Center • Search for candidates by keywords or specialization • Post your openings for candidates to find • Track your recruitment campaigns Online at controlledreleasesociety.org/careers

16:00 – 17:30 • 316C Chairs: Sarah Eccleston, Aptuit Ltd., United Kingdom; and Ali Rajabi-Siahboomi, Colorcon Inc., U.S.A. Although there are many drug products in the market utilizing multiparticulate technologies, the full scope of this platform is not fully realized. This is a key platform technology to use for delivering multidrug therapies for general use, for special patient groups (geriatric and pediatric population), and for emerging markets. Regardless of the purpose of the multiparticulate systems, from taste masking, delayed to extended release applications, the development process may require careful consideration. During this roundtable session, an overview of the multiparticulate opportunities for fixed dose combinations, inclusive of case studies to illustrate the challenges and best practices, will be discussed. Please join us to hear from industry leaders on this hot topic and share your experiences during the discussion.

Invited Speakers: Brett Caldwell, Bend Research, U.S.A. Designing and Utilizing Multiparticulates for Fixed Dose Combination Dosage Forms Michael Valazza, Catalent, U.S.A. Multiparticulates in Developing Novel Fixed Dose Combination Products

CRS President’s Banquet*

18:30 – 22:00 • Hilton Hawaiian Village / Rainbow Tower – Rainbow Suite Join your colleagues for an enjoyable evening that will showcase the global breadth of the Controlled Release Society.

CRS Local Chapters will highlight recent ground-breaking achievements in delivery science taking place within their geographical areas, spanning the world from the United Kingdom to Taiwan and New Zealand. Delight in a sumptuous dinner while celebrating a successful CRS Annual Meeting at the crossroads of the Pacific. Outgoing CRS President Kazunori Kataoka will then close the banquet with a few words reflecting back on his CRS presidency. One drink ticket is included with your dinner. Cash bar available. *Additional registration, payment, and ticket required.

30

41st Annual Meeting & Exposition of the Controlled Release Society

July 13–16, 2014 The Hilton Chicago Chicago, IL U.S.A.

Call For Papers Opens November, 2013

of Delivery Technology: Innovation to Commercialization

Exhibit and Sponsorship Selection Available Now

controlledreleasesociety.org

A premiere luxury hotel since 1927, the Hilton Chicago (originally the Stevens Hotel) is among downtown Chicago’s most grand and iconic buildings. With one of the largest exhibit areas on a single level of any hotel in the United States plus an array of first-class amenities, it remains a destination hotel for business travelers and tourists from around the world.

Podium • Tuesday Morning Tuesday Morning 316A

Drug Delivery for Developing Countries L Ensign, T Fahmy

316C

Imaging and Characterization Techniques for Drug Delivery: Systems and Targeted Drug Delivery K Uhrich, T Vandamme

316B

Mini Symposia: Energy: Problems Within the Industry that Controlled Delivery Can Solve J McKinney, N Papen-Botterhuis

47 Invited Speaker: Multipurpose Prevention Technologies for Global Health K A Woodrow University of Washington, U.S.A.

52 Invited Speaker: Noninvasive in vitro 57 Invited Speaker: Novel Composite and in vivo Monitoring of Drug Delivery Microencapsulated Phase Change Processes by Electron Spin Tablet Resonance, Benchtop-NMR and J Darkwa Multispectral Optical Imaging University of Nottingham Ningbo, China, K Mäder Peoples Rep of China Martin Luther University, Germany

11:00

48 Vaginal Ring Configurations for the Simultaneous Delivery of Dapivirine and Levonorgestrel S M Fetherston, P Boyd, I Major, B Devlin, J Holt, K Malcolm Queen's University Belfast, United Kingdom

53 Direct Multi-nuclear Magnetic Resonance Imaging Studies of Controlled Drug Release C Chen, L F Gladden, M D Mantle University of Cambridge, United Kingdom

11:15

49 An improved claudin-targeting mucosal vaccine using a double alanine-substituted mutant of the Cterminal fragment of Clostridium perfringens enterotoxin H Suzuki, J Kunisawa, A Watari, M Yamashita, K Yagi, M Kondoh Osaka University, Japan

54 CT/Optical Liposomes for High Accuracy Tumor Resection Using Image-Guided Surgery J Zheng, R De Souza, M Li, M Dunne, C Allen, D A Jaffray Princess Margaret Hospital, Canada

11:30

50 Skin is Special: Exploiting It With 55 Tumor-Microenvironment-On-Chip: Practical Microneedle Devices For Simulation of Complex Transport Improved Vaccines, And Diagnosis of around Tumor Disease B Kwak, K Park, B Han M A Kendall Purdue University, U.S.A. Australian Institute for Bioengineering and Nanotechnology, Australia

11:45

51 Development and Characterization of Emulsomes for Macrophage Targeted Multidrug Therapy against Tuberculosis S Gupta, Y Pathak University of South Florida, U.S.A.

10:30

Tuesday

10:45

12:00

32

End of Session

58 Invited Speaker: High Temperature Phase Change Materials J D Oxley Southwest Research Institute, U.S.A.

59 Invited Speaker: Controlled Release of Tracer Compounds for Inflow Monitoring in Oil Wells A D Dyrli, L Kilaas, R Skjetne RESMAN AS, Norway

56 New Applications of UV Imaging in Stability Testing: Release of Drug from Coated Particles in Pediatric SemiSolid Dosage Forms D Bar-Shalom, S Seric, P Bjørnsholt, A J Chapman, D M Goodall University of Copenhagen, Denmark

End of Session

End of Session

Podium 315

Peptide and Protein Delivery

V Labhasetwar, E Mathiowitz 10:30

314

Solubilization Technology - A Key Enabler for the Delivery of Poorly Soluble Drugs D Lyon, Y Perrie

60 Invited Speaker: Modular 65 Invited Speaker: Solubilization nanomaterials for instructing Technology - A Key Enabler for the therapeutic immune responses against Delivery of Poorly Soluble Drugs cancer and autoimmune disease R M Shanker T Fahmy, J Park, D Kim, A Seifert, M Pfizer Inc, U.S.A. McHugh, M Look Yale University, U.S.A.

Tuesday

10:45

11:00

61 Arginine-rich cell-penetrating peptides 66 Evolution of nanostructure during — The role of heparan sulfate in uptake digestion of medium chain formulation R Wallbrecher, W P Verdurmen, P H lipids — dependence on lipid mass and Bovee-Geurts, F Bröcker, A Reinhardt, P bile salt to lipid ratio H Seeberger, R Brock S Phan, C A Prestidge, A Hawley, X Radboud University, Netherlands Mulet, L Waddington, B J Boyd Monash Institute of Pharmaceutical Sciences, Australia

11:15

62 Artificial Receptor-Mediated Endocytosis for Efficient Protein Delivery into Cells T Mori, K Tobinaga, C Lee, M Takeo, M Matsuda, T Niidome, Y Katayama Kyushu University, Japan

67 Enhanced Bioavailability of Poorly Soluble Drugs by Co-spray Drying with Mesoporous Materials S Shen, W Ng, L Chia, R Tan Institute of Chemical and Engineering Sciences, Singapore

11:30

63 Development and Phase 1 Clinical Results for BA058-coated Microneedles for the Treatment of Osteoporosis K Hansen, D Dohmeier, T Fenn, J Moseman, D Wirtanen, J Christensen, S Schaefer, G Hattersley 3M Drug Delivery, U.S.A.

68 Drug-polymer filled micro-containers for oral delivery loaded using supercritical CO2 aided-impregnation P Marizza, S Sylvest Keller, A Müllertz, T Rades, A Boisen DTU, Denmark

11:45

64 Transport of PEGylated liposomes to 69 Effect of Supercritical Carbon Dioxide follicle induced by pre-stimulation of on Hot Melt Extruded Cellulose empty liposomes: Potentiating specific Polymers antibody responses against antigen M A Repka, E A Ashour, S Shah, S encapsulated in the liposomes Majumdar, R Bosworth, M Keshtmand, V T Shimizu, T Ishida, H Kiwada Bi, T Durig University of Tokushima, Japan University of Mississippi, U.S.A.

12:00

End of Session

End of Session

33

Podium • Tuesday Afternoon Tuesday Afternoon 316A

Drug Targeting, Pharmacokinetics, and Biodistribution: Differences Between Species B Boyd, S Owen

316B

Mini Symposia: Drug Combination Products C Allen, M Bally

314

Modern Agriculture and Aquaculture

C McDaniel, R Schmid

70 Invited Speaker: Drug targeting, Pharmacokinetics and Biodistribution: Differences between species J Klostergaard University of Texas, U.S.A.

75 Invited Speaker: The Genetic Landscape of a Cell C Boone University of Toronto, Canada

14:00

71 PBPK Modeling of the Nanoparticle Biodistribution: Interspecies Extrapolation and Tumor Targeting M Li, J Reineke Wayne State University, U.S.A.

76 Invited Speaker: Engineering Nano934 Historical Perspective on Coating scale Carriers to Coordinate the In Vivo Technology in Agriculture/Aquaculture Delivery of Anticancer Drug C Frey, H Hall Combinations Coating Place, U.S.A. L D Mayer, B Liboiron, D Cabral-Lilly, T Harasym, P Tardi Celator Pharmaceuticals, U.S.A.

14:15

72 Pharmacokinetics and bioavailability of a controlled release monoclonal antibody formulation D Schweizer, T Serno, I Vostiar, K Schönhammer, M Jahn, A Göpferich Novartis Pharma AG, Switzerland

14:30

73 A Novel Design of Hyaluronic Acidbased Nanogels against CD44expressing Tumors X Wei, T H Senanayake, S V Vinogradov University of Nebraska Medical Center, U.S.A.

14:45

74 Hyaluronic Acid – Gold Nanoparticle / Interferon α Complex for Targeted Treatment of Hepatitis C Virus Infection S Hahn, M Lee, J Yang POSTECH, South Korea

13:30

78 Invited Speaker: Aquatic Animal Health Applications of Controlled-Release Technologies D B Powell, R C Palm ProFishent Inc., U.S.A.

Tuesday

13:45

15:00

34

End of Session

80 Modeling concentration-time relationships of benzylpenicillin in milk after intramuscular injection of penethamate in dairy cows R Jain, O Bork, I G Tucker University of Otago, New Zealand

77 Invited Speaker: Biomimetic LongCirculating Nanoparticles for Combinatorial Drug Delivery L Zhang, C Hu, R Fang University of California, U.S.A.

81 Novel controlled release intramammary delivery system for treating bovine mastitis during lactation period O Bork, K Petrovski, F Alawi, I Tucker University of Otago, New Zealand

82 Water activity, pre-wetting and survival of Pseudomonas sp. ADP immobilized onto zeolite S A Stelting, A Sunna, C R Bunt AgResearch, New Zealand

End of Session

End of Session

Podium 316C

Oral CR - Pharmaceutical Formulations, Technologies and Development Strategies A Rajabi-Siahboomi, C Seiler

315

Processing Technology/Manufacturability F Gaspar, T Virgallito

83 Invited Speaker: Mechanistic insights of the effects of process and formulation variables on the performance of hydrophilic matrix tablets using magnetic resonance imaging P Timmins, S Hanley, J Brown Bristol-Myers Squibb, United Kingdom

88 Invited Speaker: Integrating Delivery Device Capability into Pharmaceutical Product Development and Manufacturing B Hill Johnson & Johnson, U.S.A.

14:00

84 Development of M Cell Targeting Peptide-Coupled Porous PLGA Microparticles for Efficient Mucosal Immune Responses by Oral Vaccine Delivery T Jiang, C Cho Seoul National University, South Korea

89 The NanoAssemblr Platform: Microfluidics-based Manufacture of Limit Size Lipid Nanoparticles for Drug and Nucleic Acid Delivery C L Walsh University of British Columbia, Canada

14:15

85 Controlled Release of Dry Polymer Coated Microparticles M W Capece, R Dave New Jersey Institute of Technology, U.S.A.

90 Preparations and evaluations of a novel liposomal cyclosporin A prepared using the supercritical fluid method P R Karn, W Cho, S Hyun, J Ahn, B Sun, H Kim, S Hwang Yonsei University, Nepal

14:30

86 Controlled Release of Poorly Soluble Drugs via Hot Melt Extrusion Z Lian, A Bell, D Tewari, C Seiler, A Djemai, T Durig Ashland Specialty Ingredients, U.S.A.

91 Controlled Release from Core-Sheath Microfibers Fabricated Using a Novel High-Throughput Electrospinning System A Deleault, Q Pham, X Yan, R Mulligan, J Marini, T Freyman Arsenal Medical, U.S.A.

14:45

87 New Insights into the Effects of Polymer Molecular Weight on Release Mechanisms through Polymer Blend Coatings H Andersson, M Marucci, J Hj채rtstam, M Stading, C von Corswant, A Larsson Swedish Institute for Food and Biotechnology, Sweden

92 Influence of tableting on the conformational and thermal stability of a model protein drug M Klukkert, A Sakmann, T Rades, C S Leopold University of Hamburg, Germany

15:00

End of Session

End of Session

13:30

Tuesday

13:45

Cosponsored by Hovione

35

Two RECENT Titles

from the Controlled Release Society!

Watch for more titles coming soon

RNA Interference from Biology to Therapeutics An up-to-the-minute, highly informative and invaluable text for those actively involved or interested in this fascinating and high-impact field. Key players and shapers in the fields of RNAi and delivery science have been assembled in a single volume to produce a truly unique interdisciplinary text, making it a “must-read” for both students and experts in, and at the interface of, RNAi, pharmaceutical science and medicine. An attractive feature is the “future perspectives” section within each chapter that allows global leaders the opportunity to express their views on the direction the field is moving.

Edited by Kenneth A. Howard

2013 1st Edition, XV; hardcover; 337 pages; ISBN 978-1-4614-4744-3

Visit booth #503 for more information on these and other titles in the CRS Advances in Delivery Science and Technology series.

Long Acting Animal Health Drug Products A comprehensive guide covering everything a formulation scientist or student needs to know about this unique drug delivery field. It provides an overview of the fundamental science necessary for the rational design and development of veterinary animal health products, and provides indepth descriptions of the technologies that are currently commercially available for the prolonged delivery of drugs to animals.

2013, 1st Edition, XII, hardcover, 389 pages; ISBN 978-1-4614-4439-8 Edited by Michael J. Rathbone and Arlene McDowell

Not a member? Join today and SAVE.

controlledreleasesociety.org

36

#8679PROG-AD

CRS members save 25% on all purchases through Springer.com

Daily Schedule Wednesday, July 24 07:00 – 08:00 07:30 – 12:00 07:30 – 12:00 08:00 – 09:30

Books Committee Meeting CRS Registration Open CRS Central Open Scientific Sessions • Emerging Technologies • Mini-Symposium: Nanoparticles and Cancer • Oral CR – Predictive Tools (In Vitro/In Vivo/In Silico) • Personal and Home Care • Regional Delivery: Challenges in Ocular Delivery and Pulmonary Delivery 08:30 – 09:30 Preclinical Sciences & Animal Health Committee Meeting 09:45 – 11:00 Plenary Session: Paula Hammond

317A Ala Halawai Concourse Ala Halawai Concourse 316A 316B 316C 314 315 317B 315

Wednesday

*Additional registration, payment, and ticket required.

Wednesday Program Highlights Plenary Electrostatic Nanolayer Delivery Platforms: From Macro- to Nanopharmacies 09:45 – 11:00 • 315 Moderator: Christine Allen Paula Hammond, David H. Koch Professor of Engineering, Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, U.S.A. The electrostatic layer-by-layer process is a simple and elegant method of constructing highly tailored ultrathin polymer and organic–inorganic composite thin films to deliver proteins and biologic drugs in a highly tunable way. This approach can be adapted to achieve various goals, including releasing drugs in specific regions, increasing the half-life of the particle in the bloodstream, and preventing recognition of the particle as a foreign body. It is also possible to synthesize extremely long strands of RNA for cellular delivery, yielding active siRNA strands at significant doses.

Awards presented prior to the plenary will include the Outstanding Annual Meeting Abstract Paper Awards to Mohammad Absar of Texas Tech University, U.S.A.; Sifei Han of Monash Institute of Pharmaceutical Sciences, Australia; Christina Hofmann of Duke University, U.S.A.; and Katherine Moga of University of North Carolina, U.S.A. Outgoing CRS Board members will also be recognized.

LATTE

Find the Academic Expertise You Need with LATTE. Research Collaborations Consulting Work Expert Witnesses LATTE (Linking Academic Technologies and Techniques to Everyone) is a searchable database of CRS members in academia with expertise in CRS-related technologies.

Search the database for the expertise you need or add your academic profile online at controlledreleasesociety.org under “Community”.

37

Podium • Wednesday Morning Wednesday Morning

316A

Emerging Technologies

S Owen, J Suk

316B

Mini Symposia: Nanoparticles and Cancer T Allen, M Tracy

316C

Oral CR - Predictive Tools (in vitro / in vivo / in silico) R Shanker, W Weitschies

93 Invited Speaker: DNA-based Hydrogels 98 Invited Speaker: Development of for Drug Development and Drug Hybrid Silica Nanoparticle Platforms: Delivery Design, evaluation and translation D Luo from lab to clinic Cornell University, U.S.A. M Bradbury, O Penate-Medina, M Benezra, E Phillips, P Zanzonico, D Hambardzumyan, D Veach, K Pillarsetty, P Smith-Jones, E Holland, S Larson, U Wiesner Memorial Sloan Kettering Cancer Center, U.S.A.

101 Invited Speaker: Modern approaches to estimating in vivo drug release and robustness of oral CR formulations S Klein University of Greifswald, Germany

08:30

94 Stem Cell Derived Nano Vesicles - A New Delivery Platform for Cancer Targeted Therapy N E Toledano Furman The Technion, Israel

102 Application of Computational Tools in the Design of Controlled Drug Delivery Systems X Wu University of Toronto, Canada

08:45

95 Cationicphiphilic macromolecules (CAMs)-lipid complexes for intracellular siRNA delivery K E Uhrich, L Gu, L Nusblat, C M Roth Rutgers, the State University of New Jersey, U.S.A.

09:00

96 On-demand Drug Release Triggered by 100 Invited Speaker: Polymeric 104 Exploit In Vivo Modeling & Simulation Two-Photon-Absorption Nanoparticles for Intracellular Nucleic (IVMS) for Developing New Sustained N A Hampp, H Kim, L Hesse Acid Delivery to Glioblastoma Released Formulation University of Marburg, Germany S Y Tzeng, K L Kozielski, H GuerreroD J Liu Cazares, A Quinones-Hinojosa, J J Green GlaxoSmithKline, U.S.A. Johns Hopkins University, U.S.A.

09:15

97 Pollen Grains as “Trojan Horses” for Oral Vaccination S Atwe, Y Ma, H S Gill Texas Tech University, U.S.A.

08:00

08:15

Wednesday

09:30

38

End of Session

99 Invited Speaker: Porphyrin-based Nanocarriers for Drug Delivery, Phototherapy and Multimodal Imaging Y Li, T Lin, C Pan, K S Lam University of California, U.S.A.

103 Drug Imaging in Novel Geometric Three-layered Tablet Using Various Physical Properties and Raman Spectroscopy D Choi, K Kim, D Lim, S Jeong Pusan National University, Korea

105 Novel orally swallowable IntelliCapTM device guarantee success in MR development by quantitative determination of regional drug absorption in man D Becker, J Zhang, T Heimbach, H Zou, J Shimizu, C Wanke Novartis Pharma AG, Switzerland

End of Session

End of Session

Podium 314

Personal and Home Care

C Ortiz, J Oxley

315

Regional Delivery: Challenges in Ocular Delivery and Pulmonary Delivery M Rathbone, J Reineke

106 Invited Speaker: Optimizing the Performance of Microcapsules in Fabric & Home Care Applications J Dihora Procter & Gamble Co., U.S.A.

111 Invited Speaker: Suprachoroidal Administration of Triamcinolone Acetonide Using a Microneedle for the Treatment of Posterior Ocular Inflammation S R Patel, B C Gilger, E A Piedrafita, J H Salmon, R Carvalho, R Verhoeven Clearside Biomedical, U.S.A.

08:30

667 In-vitro Method for Quantification of Fragrance Capsules Leakage in Personal Care Products C Ortiz, M Holmgren Colgate Palmolive, U.S.A.

112 Systemic Availability and in vivo Stability of PEGylated Poly-Lysine Dendrimers Following Pulmonary Delivery is Highly Size Dependent G M Ryan Monash University, Australia

08:45

108 Liposomes as a topical carrier system 113 Multi-functional cationic dendrimers for delivery of chlorogenic acid and for connexin43 antisense Lychnophora salicifolia hydroethanolic oligodeoxynucleotide delivery in the extract: preparation, characterization treatment of wet age-related macular and in vivo penetration evaluation degeneration A S Forte, R M Martins, S Siqueira, D R I D Rupenthal, A Stikkelman, I Toth, C R Gouvea, N P Lopes, M V Fonseca Green University of Sao Paulo, Brazil University of Auckland, New Zealand

09:00

671 Smart Microcapsules containing Enzymes for Laundry Applications P Shukla, M Jackson, A Jadhav National Chemical Laboratory, India

114 Evaluation of a Novel Lipid Based Nanoparticulate System for Ocular Drug Delivery A Seyfoddin, R Al-Kassas University of Auckland, New Zealand

09:15

110 Release of Small Molecules Utilizing Enhanced Polymer Films C Baker, D Suzin, E Mathiowitz Brown University, U.S.A.

115 Efficacy Testing of Montelukast Loaded Large Porous Particles in Allergen-Induced Rat Asthma Model B Patel, F Ahsan Texas Tech University, U.S.A.

08:00

09:30

End of Session

Wednesday

08:15

End of Session

39

2013 CRS Posters Cosponsored by AstraZeneca Scientific posters are an essential element of the CRS Annual Meeting & Exposition. The display of posters allows annual meeting attendees an excellent opportunity to share with one another important scientific achievements and learn the newest technologies in delivery science on a personal basis. Each submitted poster abstract is peer reviewed and chosen based upon predetermined selection criteria.

All scientific posters will be on display in Exhibit Hall III throughout the meeting during exhibit hours. Poster authors will be present during one of three pre-specified time slots.

Poster Sessions (authors present) Poster Session 1 Poster Session 2 Poster Session 3

Monday, July 22 Tuesday, July 23 Tuesday, July 23

09:30 – 10:30 09:30 – 10:30 15:00 – 16:00

Biological Structural Materials and Coatings

117

A Model for the Controlled Release of Nano-encapsulated Tissue Plasminogen Activator Using Shear-Activation; M Jalaal. Session 1 119 Dextran acetate-based porous scaffold for biomaterial application; A Van der Vlies. Session 2 121 Nano-scale Surface Coating of Thermoresponsive Block Copolymers for Thermally Regulating Cell Adhesion/Detachment Behavior; M Nakayama. Session 3 122 Precise Structural Analysis of Polymeric Micelles and Their Relation to Biological Performance; K Sakurai. Session 1 123 Smart Hyperthermia Nanofibers with On-Off Drug Release; M Ebara. Session 2 125 Water Permeability of Composite Materials for Future Implant Materials; S Gårdebjer. Session 3

Challenges Around Brain Delivery: Sampling Site Issues and Interspecies Extrapolations

127

Enhanced Chemotherapy for Brain Glioma by Transferrin-modified Magnetic Mesoporous PLGA Nanoparticles with Core-and-Shell Loading of Doxorubicin and Paclitaxel; C Wang. Session 1 129 Neuroprotective Effect of PEGylated Liposomes Encapsulating FK506 on Cerebral Ischemia-reperfusion Injury; Y Agato. Session 2 130 p-Hydroxybenzoic Acid (p-HA) Modified Polymeric Micelles for Brain-targeting; W Lu. Session 3 131 Targeted nucleic acid delivery to neuronal cells using Tet1modified HPMA-oligolysine copolymers; D Chu. Session 1

Drug Delivery for Developing Countries/Global Challenges

133 134 135 136 137 139 140

40

A novel peptide ligand directed targeted drug delivery to Myeloidderived suppressor cells (MDSCs) in tumor bearing mouse; X Si. Session 2 A novel transcutaneous vaccine formulation using a self-dissolving microneedle patch; S Hirobe. Session 3 Biophysical characterization of hydrogel-core, lipid-shell nanolipogels for HIV-1 chemoprophylaxis; R Ramanathan. Session 1 Claudin-1-specific monoclonal antibodies and their inhibition of hepatitis C virus infection; S Nagase. Session 2 Cytotoxicity and cell uptake of Anionic Docetaxel Self Micro Emulsifying Drug Delivery System on A-549 (human alveolar carcinoma) cell line; R Joshi. Session 3 Developing a novel, Glycol-Chitin based thermo-sensitive Gel for the vaginal delivery of Progesterone: Synthesis and Sol-Gel Transition evaluation; M Janát-Amsbury. Session 1 Development of implants for sustained release of rotigotine to achieve CDS for the treatment of PD; W Liu. Session 2

141

Drug formulations intended to stop the spreading of Sexually Transmitted Diseases (STDs); C Bergström. Session 3 142 Ellagic Acid loaded pH Sensitive nanoparticles for the treatment of inflammatory bowel disease; D Gugulothu. Session 1 143 Enhancement by cyclodextrin of cell surface modification with PEGylated lipid; Y Takafuji. Session 2 144 ESA-SMEDDS: An Innovative Approach for Bioenhanced Curcumin; P Mande. Session 3 145 Evaluation of the Enhanced Oral Bioavailability for Spray-Dried Megestrol Acetate Nanoparticles; Y Nan. Session 1 146 Fabrication and Evaluation of Novel Risperidone Implanys as a Long Term Antipsychotic Therapy; F Dorkoosh. Session 2 147 Formulation of Inactivated Polio Vaccine for Thermal Stability; J Lee. Session 3 149 Intravitreal Zero-order Release Levofloxacin Implant in an Experimental Model of Endophthalmitis; H Zhang. Session 1 150 Long term stability of acrylic derivatised dextran-concanavalin A gels as part of an implantable closed loop insulin delivery device; T Sahota. Session 2 151 Manufacturing scale-up potential of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery; E Krogstad.

Session 3 152 Mass transfer and modeling release of Olanzapine from Glycerol monooleate; F Dorkoosh. Session 1 153 NanoAnnomaal: A herbal Nanoparticulate system for antimalarial chemotherapy; S Sawant. Session 2 154 Oral Mucosal (Sub-Lingual) Delivery of Vaccines using Zydis Orally Disintegrating Tablets; S Lamb. Session 3 155 Peptide ligand mediated drug delivery to TAMs; L Wu. Session 1 157 Synthesis and Evaluation of a Novel Polymeric Micelle Based on Hyaluronic Acid and Phospholipids; F Dorkoosh. Session 2 158 Taste Masking of Ondansetron Hydrochloride using Kollicoat® Smartseal 30D by Simple High Shear Granulation Technique; P Butler. Session 1

Emerging Technologies

159 160 161 164 165 166

A functionalized hybrid material for sustained drug release; P Thomsen. Session 3 A novel system for removing etiologic factors in the blood: DrugNavigated Clearance System (DNCS); T Yamaoka. Session 1 Acceptability and Usability of Hollow Microneedle Drug Delivery Devices for the Treatment of Rheumatoid Arthritis; D Dohmeier.

Session 2 Characterizing and evaluating preclinical suitability of a syngeneic mouse ovarian cancer model; M Janát-Amsbury. Session 3 Co-delivery of MDM2 Antagonist Nutlin with Proteasome Inhibitor Curcumin in Immuno-Nanoparticle for Targeted Gliobastoma Therapy; M Das. Session 1 Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies to target a model immunomodulator to the lymphatic system; S Han. Session 2

171

Ethyl Cellulose Composite Membranes with Photosensitive Microspheres for Controlled Diffusion; S Li. Session 3 172 First successful report of a humanized Endometrial Cancer mouse model following characteristics of patient tumor growth, pathology, and metastatic progression available for preclinical drug evaluation; M Janát-Amsbury. Session 1 174 Functional Polymer-coated Exosomes: Nanogel Hybrid Assembly for Drug Delivery System; K Akiyoshi. Session 2 177 Hard capsules filled with liquid crystalline phase matrix for sustained oral drug delivery; X Pan. Session 3 178 Hydrogen Peroxide Mediated Transmucosal Drug Delivery; D Johnson. Session 1 179 Investigation Into the Effect of Different Physiochemical Parameters of Drugs on Release From poly(2-Hydroxyethyl methacrylate) Using Multiple Regression Analysis; R Bell. Session 2 180 Light-Controlled Release of Reactive Oxygen Species from AntiInfective, Covalently-Bound Porphyrin Biomaterial Conjugates; D Corbett. Session 3 181 Lysosomal mediated apoptosis of Imatinib resistant leukemia cells by an herbal reactive oxygen species (ROS) nanoscavenger; S Acharya. Session 1 182 Nanofibrous hydrogels crosslinked with catecholized polymers; Y Son. Session 2 183 Nanostructures at Oppositely Charged Surfactant-Polymer Interfaces as Tailored Release Nanomaterials; K Tangso. Session 3 184 Novel Methodology for Quantifying Distribution between Free and Bound API in Biorelevant Media: Application to Naproxen in Albumin-containing Solutions; A Chapman. Session 1 185 Photoacoustic Drug Delivery: An Emerging Technology for Intracellular Delivery; A Sengupta. Session 2 186 Plasmonic Liposomes for Synergistic Photodynamic and Photothermal Therapy; J Park. Session 3 187 Probuphine®: A Sub-dermal Buprenorphine Implant for Treating Opioid Dependence; R Patel. Session 1 188 Rapamycin Drug Eluting Stent by Crystallization onto Stent Struts; S Farah. Session 2 189 Short Chain Elastin-Like Polypeptide-Incorporated Thermosensitive Liposome: In Vitro Evaluation and In Vivo Study Combined with High Intensity Focused Ultrasound (HIFU); H Kim. Session 3 190 Single-Step Grafting of Aminooxy-Peptides to Hyaluronan: A Simple Approach to Multifunctional Therapeutics for Experimental Autoimmune Encephalomyelitis; J Sestak. Session 1 193 Super cationic nanofibrous mesh for surfaces modification; H Kim. Session 2 194 Three-Dimensional Model of Breast Tumor Stroma for Drug Testing; H Jaganathan. Session 3

Food, Nutraceuticals and Personalized Diet 195

Separation and quantification of cystine and cysteine in simulated aqueous humor using capillary electrophoresis; A Al-Kinani.

Session 1

Imaging and Characterization Techniques for Drug Delivery: Systems and Targeted Drug Delivery 196 199 200 201 202 203 204 206 207

6-MethoxyethylaminoNumonafide (MEAN) Eluting Microspheres for Catheter-Directed Delivery to Liver Tumors; D Kim. Session 2 Apoptosis-Targeted Delivery of T Cells to Tumor after Chemotherapy; B Lee. Session 3 Apoptosis-targeted low molecular weight heparin derivatives for cancer therapy; J Kim. Session 1 Bifunctional Solid Lipid Nanoparticle System as a Potential Tool for Tumor Detection Using Optical and MR Imaging; X Wu. Session 2 Biomimetic Nanoarchitectures of Peptide Dendrimers for Drug/ Gene Delivery; Z Gu. Session 3 Bioreducible Nanoparticles for Intracellular Hydrogen Peroxide Generation; F Mi. Session 1 Bladder cancer targeting nanomicelle; T Lin. Session 2 Chitosan oligosaccharide-arachidic acid-based nanoprobes for magnetic resonance imaging of cancer; H Cho. Session 3 Comparing the Acoustic Release of Doxorubicin from Targeted and non-Targeted Polymeric Micelles; G Husseini. Session 1

209 210 212 213 214 215 216 217 218 219 220 222 223 226 227

228

230 231 232 233 234 235 236 237 238 239 240 241 243 245 246

DDS Evaluation Using Intravital Real-Time Laser Scanning Confocal Microscopy; Y Matsumoto. Session 2 Design of Novel Nanosized Theragnostic Niosomes for Diagnosis and Therapy of Parkinson’s Disease; A Özer. Session 3 Development of Targeted [64Cu]CuS Nanoparticles for PET/CT Imaging and Photothermal Ablation Therapy; L Cui. Session 1 Development of Three-Dimensional Lung Multicellular Spheroids for the Evaluation of Anti-Cancer Therapeutics; S Meenach.

Session 2 Differentiation of drug release from geopolymer formulations by a new bench-top method; B Cai. Session 3 Dual Temperature- and pH-Responsive Fluorescence Molecular Probe for Cellular Imaging utilizing a Functional Polymer; M Matsuura. Session 1 Dual-targeting paclitaxel-loaded nanoparticles for the treatment of glioma in mice; Z Pang. Session 2 Dynamic contrast enhanced computed tomography imaging of perfusion predicts for the heterogeneous spatial distribution of liposomes; S Stapleton. Session 3 Effect of Polymers on API Precipitation Determined by Polarized Light Microscopy; A Müllertz. Session 1 EPR effect in metastatic and autochthonous tumor and antimetastatic effect of SMA-pirarubicin (THP); H Maeda. Session 2 Facile Preparation of Calcium Phosphate Nanoparticles for Noninvasive Cancer Diagnosis; P Mi. Session 3 Fluorescence Real-time Imaging of Cell Dynamics in Tissue of a Living Mouse using Tissue Fixing Suction Device; Y Higuchi.

Session 1 Glutathione-Responsive Polymeric Micelles Composed of In-Situ Formed Gemini Surfactants for Controlled Drug Release; H Kim. Session 2 Improvement of cellular uptake efficiency with small amount of iron oxide according to the number of surface-immobilized folic acid; Y Son. Session 3 In Vitro Drug Release and In Vivo Tumor Delivery of Near-Infrared Emissive Biodegradable Polymersomes Containing Poly(ethylene glycol) and Randomized Poly(trimethylene carbonate-cocaprolactone); C Hofmann. Session 1 In vivo Evaluation of Annexin A2-Targeted Combinatorial Nanoparticles to cause Sustained Reduction of Plasminogen Activation in Highly Metastatic Breast Cancer; A Mukerjee.

Session 2 In vivo Visualization of Fluorescent siRNA Delivery by Microneedles; T Speaker. Session 3 Inhibitory effect on choroidal neovascularization using cyclic RGD tethered heparin-Pluronic nanogels carrying avastin; K Park.

Session 1 Intravital Monitoring of Intact siRNA Using Fluorescence Resonance Energy Transfer; K Toh. Session 2 Investigation of pH and temperature profiles in the GI tract of fasted human subjects by Intellicap® system; W Weitschies.

Session 3 Monitoring Controlled Release of Doxorubicin from Porous Microparticles using in vitro Models and Time Lapse Microscopy; S Shamsudeen. Session 1 Multicellular Tumor Spheroids for Performance Evaluation of Nanomedicines In Vitro; S Eetezadi. Session 2 Multifunctional Mesoporous Nanoconstructs for Contrast Enhanced Imaging; P Decuzzi. Session 3 Nanobioconjugates for Differential Imaging of Solid and Metastatic Brain Cancer; R Patil. Session 1 Nanostructures and drug distribution within Nanostructured LipidCarriers (NLC); C Keck. Session 2 Nanotheranostic approach by magnetic nanoparticles labeled stem cells for cancer therapy; S Sahoo. Session 3 Novel Nanocarrier Drug Delivery System for Imaging and Treatment of Cancer; A Patel. Session 1 Paclitaxel Loaded Magnetic Nanoparticle Labeled Mesenchymal Stem Cells as Drug Delivery Vehicle in Cancer Therapy; A Singh.

Session 2 pH-Responsive Nanogel-Coated Polymersomes for Targetable Delivery of Anticancer Agent and Magnetic Nanoparticles; H Chiu.

Session 3 Potential Use of Folate-appended Methyl-ß-cyclodextrin as a Novel Antitumor Drug Carrier; T Higashi. Session 1 Preparation and Evaluation of Solid-Self Emulsifying Drug Delivery System for Enhancing Bioavailability and Lymphatic Delivery of Cyclosporin A; H Cho. Session 2

continued

41

Imaging and Characterization Techniques continued

280

247

281

Preparation, Characterization and In Situ Absorption Studies of Lercanidipine Loaded Eudragit Nanoparticles; N Udupa.

Session 3 248 PSMA-Targeted Aptamosomes for Improving Intracellular siRNA and Drug Co-delivery; K Kim. Session 1 249 Raman mapping to identify dry and wet states of pharmaceutical components in a hydroxypropyl methylcellulose (HPMC) hydrophilic matrix tablet; Y Oni. Session 2 251 Research on the Real-time Dynamics of Releasing Process in vivo of Drug Delivery System; Z Fang. Session 3 253 Size and Count Analysis of Drug and Gene Delivery Nanoparticles in Complex Biological Media; D Griffiths. Session 1 254 Superparamagnetic Hollow Hybrid Nanogels as a Theranostic Platform with pH-Regulated MR Imaging Contrast and Drug Release; W Chiang. Session 2 255 Targetable and Inhalable Nanoerythrosomes Containing Fasudil, a Rho-kinase Inhibitor, for the Treatment of Pulmonary Arterial Hypertension; B Patel. Session 3 256 Targeted Multifunctional Lipopolymeric Hybrid Nanosystems for Metastatic Breast Cancer Imaging and Therapy; A Mukerjee.

Session 1 257 Ultrasound-Induced Cell Permeability in Endothelial Cells for Targeted Delivery; P Anastasiadis. Session 2 258 Uptake and Degradation of Protein Nanoparticles in Cerebellar Granular Cells; M Dadparvar. Session 3

Micro- and Nanoparticle Design 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 278 279

42

83-14 monoclonal antibody-grafted solid lipid nanoparticles for targeting delivery of saquinavir across the blood-brain barrier; Y Kuo. Session 1 A cisplatin-incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity; E Ju. Session 2 A mitochondrial targeted paclitaxel loaded self-assembled nanocarrier reduces the multidrug resistance of breast cancer; Z Zhang. Session 3 A novel controlled release PLGA microspheres for the antisense oligonucleotide; L Teng. Session 1 A phase 1 study of the polymeric nanoparticle containing docetaxel to patients with advanced solid tumors; J Park. Session 2 A targeted liposomal delivery system to liver endothelial cell based on a new peptide motif present in the Apo B-100 sequence; A Akhter. Session 3 A unique combination of tissue engineering and cell encapsulation for the entrapment of insulin-producing stem and liver cells; M Machluf. Session 1 Accelerated blood clearance phenomenon upon PEGylated protein; Y Mima. Session 2 Active Targeting of Perfluorocarbon Nanoemulsions for 19F MRI; C Grapentin. Session 3 Amphiphilic Poly(amino acid) Nanoparticles as Vaccine Carriers and Adjuvants; T Akagi. Session 1 An injectable nanodelivery system for prolonged, controlled release of the local anesthetic lidocaine; E Tasciotti. Session 2 Analysis of Protein Adsorption Patterns on Ultra-Small Dendritic Polyglycerol Sulfate; S Staufenbiel. Session 3 Antigen-Expressing Immunostimulatory Liposomes, as novel genetically programmable vaccines; M Amidi. Session 1 Antioxidant poly(vanillyl alcohol-oxalate) nanoparticles as novel therapeutics for acetaminophen-induced acute liver failure; D Lee. Session 2 Artificial neural networks and modeling of release of Olanzapine from Glycerol monooleate matrices; F Dorkoosh. Session 3 Backbone Degradable HPMA Copolymer Paclitaxel and Gemcitabine Conjugates for the Combination Therapy of Ovarian Cancer; R Zhang. Session 1 Biodegradable Aluminium Phthalocyanine Amphiphilic Nanoparticles for Anticancer Photodynamic Therapy; N Nafee.

Session 2 Biomimetic Coating Modulates the Biodistribution and Release Kinetic of Nanoporous Particles; M Evangelopoulos. Session 3 Bioreducible Robust Polymersomes for Anticancer Drug Delivery; T Thambi. Session 1

282 283 284 287 288 289 290 291 292 293 294 295 298 299 300 302 303 304 305

306 308 309 310

311 312 313 314 315 317 318

Bixin Liposomes as Antineoplasic drugs carrier; R Takamoto.

Session 2 Caffeine Nanocrystals — A New Concept for Improved Skin Delivery; S Staufenbiel. Session 3 CD44 receptor targeting with Hyaluronic acid-conjugated PLGA nanoparticles loaded with SN 38; S Palakurthi. Session 1 Characterization of Temperature-Responsive Liposome with Tunable Surface Property; H Kanazawa. Session 2 Chitosan nanoparticles: correlation of in situ metrology with interactions at biological interfaces; L Lim. Session 3 Co-modification of Cholesterol-anchored Cleavable PEG and Octaarginines (R8) on Liposomes to Enhance Tumor Targeting and Anti-tumor Effect; Q He. Session 1 Comparative therapeutic performances of drug loaded magnetic dendritic nanoparticles towards various cancer cell lines; S Nigam. Session 2 Competitive cellular adhesion of pseudobacterial lipid nanocarriers and bacteria on ß-1 integrin receptors; H Labouta.

Session 3 Construction of Hyaluronic Acid-Coated Cisplatin-Loaded Hydrogel Nanoparticles for Targeted Chemotherapy; T Shirakura.

Session 1 Controlled Release of Doxorubicin Using pH and Temperature Sensitive Core-shell Nanogels Containing Amphiphilic Acid Monomer; A Serrano-Medina. Session 2 Curcumin-derivative RL71 micelles for the treatment of breast cancer; K Greish. Session 3 Cyclic RGD Peptide Amphiphiles as Potential Drug Carriers for Cancer Targeting; P Saraf. Session 1 Delivery of Photoactive Ruthenium-based Prodrugs with Crosslinked Nanoassemblies for Photodynamic Therapy; M Dickerson.

Session 2 Design And Optimization of PLGA Microspheres of Donepezil Hydrochloride for Improved Alzheimer’s Therapy; D Desai.

Session 3 Development and characterization of dexamethasone-loaded microsphere formulations prepared with PLGA blends; D Burgess.

Session 1 Development of a combinational drug-loaded nanoparticle for improving of paclitaxel uptake into multidrug resistant breast cancer cells; J Baek. Session 2 Development of a novel liposomal formulation for paclitaxel; J Eloy. Session 3 Development of Calcium Phosphate Nanoparticles for Oral Delivery of Therapeutic agents; W Wild. Session 1 Development of Dequalinium Coated Poly ( D,L-lactide-coglycolide) Nanoparticles for Paclitaxel Delivery; V Yellepeddi.

Session 2 Development of Mesoporous Silica Nanoparticle (MSN)-loaded PICsomes for Delivery of Low Molecular-weight Drugs; A Goto.

Session 3 Development of novel nanovesicles consisting of an antitumor agent tocopheryl succinate for cancer combination therapy; S Hama. Session 1 Development of platinum nanoparticles, liver-targeting reactive oxygen species scavenger, for prevention of hepatic ischemia/ reperfusion injury; H Katsumi. Session 2 Development of Ursolic Acid Nanocrystals with Improved in-vitro Anticancer Activity; Y Zheng. Session 3 Discovery of peptidic agents targeting human lung cancer by in vivo phage display; K Lee. Session 1 Double selective antitumor action of pirarubicin-conjugated N-(2hydroxypropyl) methacrylamide copolymer; H Nakamura.

Session 2 Drug-specific protein polymer nanoparticles: in vivo reduction of toxicity and suppression of tumor growth; P Shi. Session 3 Dual action pro-apoptotic drug loaded immuno-nanoparticles with enhanced chemotherapeutic effect; C Scott. Session 1 Dual MMP-7-Proximity-Activated and Folate-Targeted Nanoparticles for siRNA Delivery; T Giorgio. Session 2 Dual Responsive, Stabilized Nanoparticles for Efficient in vivo Plasmid Delivery; H Wei. Session 3 Effect of a Nanoparticle-Based Multivalent Targeted Proapoptotic Peptide on Obesity; M Hossen. Session 1 Effect of terminal group of PEG on induction of ABC phenomenon to PEGylated liposome; R Fujita. Session 2 Effects of Dendrimer Phthalocyanine Incorporated Polyion Complex Micelle-Mediated Photodynamic Treatments on P-glycoprotein Activities; W Syu. Session 3

321

322 324 325 326 327 329 330 331 333 334 335 336 337 338 339 340 341 342 343 344

346 348 350 351 352 353 354

356 357 359

Enhancement of Active Targeting and Cellular Uptake of Liposomes by Bio-nanocapsule Modification; M Somiya.

Session 1 Enhancing Cellular Uptake of Poly(ethyl-cyanoacrylate) Nanoparticles Through Arginine Association; J Chiu. Session 2 Estimation of Boron-containing Rare Earth Oxides as Drugs for Boron Neutron Capture Therapy; H Yukawa. Session 1 Eudragit® nanoparticles for photodynamic therapy: Optimization of formulation design and manufacture; M Wacker. Session 2 Evaluation of Polystyrene Microsphere Uptake Utilizing invitro and in vivo Methods; E Mathiowitz. Session 3 Fabrication and characterization of Eudragit S100-coated pectin/ alginate microcapsules containing cisplatin-hyaluronan nanoparticles for colon targeted delivery; S Tsai. Session 1 Folic Acid-Conjugated Liposomal Vincristine for Multidrug Resistant Cancer Therapy; W Lu. Session 2 Formulation and Characterization of Inhalable Magnetic Nanocomposite Microparticles (MnMs) for Targeted Pulmonary Delivery; N Stocke. Session 3 Formulation and Characterization of Polypyrrole Particles for Electrically Triggered Drug Release; D Svirskis. Session 1 Fullerenol C60 for developing nanomedicine, Part 1. Assessment of anti-inflammatory effect of fullerenol C60; M Aoyama. Session 2 Fullerenol C60 for developing nanomedicine, Part 2. Assessment of therapeutic effect of fullerenol C60 for inflammatory bowel disease; T Nagano. Session 3 Functional Nanoparticles for Oral Delivery of Anti-Angiogenic Protein; Y Ho. Session 1 Gas Bubbles Stabilized by Multifunctional Nanoparticles for Ultrasound-Mediated Drug-Delivery; R Schmid. Session 2 Gold Nanorods Carry the Photosensitizers into Cancer Cells and Release them by the Irradiation of the NIR Laser; J Chen. Session 1 Graft and diblock copolymer micelles delivery the hydrophobic protoporphyrin IX for photodynamic cancer therapy; C Huang.

Session 3 Hazard Assessment of Engineered Nanocarriers using in vitro and in vivo Studies; C Webster. Session 1 Hyaluronic Acid/Doxorubicin/Gold Nanorods-Anchored Macrophage for Combined Dug Delivery and Photothermal Therapy; Y Huang. Session 2 Hybrid Polymeric Micelles Based on Polypeptides with pH Sensitivity of Secondary Structure for Targeting Delivery of Doxorubicin; Q Wang. Session 3 Impact of the Nanoparticle Protein Corona on Assessing In Vitro Cellular Uptake of Silver Nanoparticles into Human Epidermal Keratinocytes; N Monteiro-Riviere. Session 1 Importance of an interface between PEG and hydrophobic blocks, mechanistic study of PEG-related IgM response; K Shiraishi.

Session 2 Improving the Loading Efficiency and Anticancer Activity of Anthraquinone Derivative by Using Liposomal Formulations; C Chiang. Session 3 In vitro interaction between novel bixin liposomes and human hepatoma cell lines; I Kikuchi. Session 2 In Vivo Efficacy of Rosiglitazone-Loaded Hybrid Nanoparticles for the Treatment of Cardiovascular Diseases; S Aryal. Session 3 Intratracheal administered polymeric micelles translocate through the air-blood barrier into the blood and pass through the bloodbrain barrier to the brain; X Hu. Session 1 Involvement of functional groups on the surface of carboxyl group-terminated PAMAM dendrimers bearing arbutin in inhibition of SGLT1-mediated D-glucose uptake; S Sakuma. Session 2 Measuring drug release from micro- and nanoformulations by derivative spectrophotometry in combination with a fiber optic system; J Kraemer. Session 3 Metrology of a NanoCurcumin Delivery System in Biologically Relevant Media; L Lim. Session 1 Microcapsules with Composite Membrane Containing Hydroxypropyl Cellulose for Thermally-Modulated Pulsatile Drug-Release; H Ichikawa. Session 2 Microparticles built by layer by layer assembly for the encapsulation and sustained release of resveratrol; A Ribeiro.

Session 3 Molecular modeling of PAMAM dendrimers modified with peptides and polymers; H Lee. Session 1 Multi-Functional Nanoparticles for CD44 and Folate Receptors Targeting; S Yu. Session 2

360

361 363 364 366 367 368 369

371 372

374 375 376 377 378 379 380

383 384 385 386 387 388 389 390 391 392 393 394 395 396 397

Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells; I Altintas. Session 3 Nanocapsules prepared by vesicle templating using RAFT polymerization; A van Herk. Session 1 Nanoporous silicon particles for thrombolytic therapy; G Qin. Session 2 Nanoscale, Non-Drug HIV Entry Inhibitors Using a CXCR4 Selective Synthetic Peptide, DV3: Binding Affinity and Evaluation of Drug Delivery Potential; Z Szekely. Session 3 N-modification of chitosan for improved membrane permeability: Synthesis, physicochemical characterization and submicron particle formulation; A Al-Kinani. Session 1 Novel drug vehicle with MR/US imaging functionality; T Liu. Session 2 Novel Enzyme Responsive Cross-linked Polymeric Micelles for Chemotherapy; W Cheng. Session 3 Novel Method to Load High Amount of Drugs and Macromolecules into Polyion Complex Vesicles (PICsomes); A Kishimura. Session 1 Novel TPGS based paclitaxel prodrug to overcome multidrug resistance of cancer cells; S Tan. Session 2 Optimizing drug delivery platforms by matching physico-chemical and pharmacokinetic properties of drugs and drug vectors; A Ziemys. Session 3 Paclitaxel and carboplatin co-loaded nanovesicles prepared with novel multifunctional amphiphilic phosphonated calix[4]arene; J Mo. Session 1 Particles with Optimal Release Profile; F Kazazi Hyseni. Session 2 PEGylated liposomes injected sequentially distribute in different region of solid tumor; M Nishio. Session 3 Peptide conjugated liposomes for the targeted and localized delivery of fasudil for the treatment of pulmonary arterial hypertension; K Nahar. Session 1 Peptidic PEGylated solid lipid nanoparticles for oral delivery of salmon calcitonin (sCT) and the influence of mucus; Y Huang.

Session 2 Performance testing of microparticulate solid dispersions prepared using electrospraying; A Bohr. Session 3 Phage-Derived Peptides Facilitate Caco-2 Cell Translocation of Nanoparticles: Initial Studies and Implications on Oral Delivery; P Sinko. Session 1 Polymethacrylic acid-based nanoparticles for the peroral delivery of flurbiprofen — physicochemical properties and evaluation in cell culture models; S Beyer. Session 2 Potential Use of Folate-appended ß-Cyclodextrins as Tumor Targeting Carriers for Antitumor Drugs; H Arima. Session 3 Preparation and characterization of cationically modified bee venom-loaded PLGA nanoparticles; M Park. Session 1 Preparation and evaluation of chondroitin sulfate-chitosan nanoparticles for doxorubicin delivery; S Tang. Session 2 Preparation of a drug delivery system based on magnetic nanoparticles conjugated with polyethylene imine; F Dorkoosh.

Session 3 Preparation of hydrophobic carrier for medical agents using cross-linked polysaccharide; K Maeda. Session 1 Preparation of nano-particulated docetaxel using NUFS (nanoparticulation using fat and supercritical fluid) technique and its preclinical evaluation; E Ko. Session 2 Preparation of Zwitterionic Polypeptides and Biomedical Application; H Tian. Session 3 Prodrug-Loaded Mesoporous Silica Nanoparticles for StimuliResponsive Chemotherapy; E Ruiz-Hernández. Session 1 Protein-polymer conjugates as therapeutics; H Makwana. Session 2 Raloxifene micelles for the treatment of prostate cancer; S Taurin.

Session 3 Rationally Designed Discoidal PLGA/PEG Nanoconstructs for Cancer Theranostics; J Key. Session 1 Recent Developments and Preclinical Evaluation of HPMA Copolymer-Drug Conjugates as Anticancer Therapeutics; J Yang.

Session 2 Robust Cross-linked Hyaluronic Acid Nanoparticles for Efficient Intracellular Drug Delivery; H Han. Session 3 Serum anti-PEG IgM concentration is a determinant factor on hepatic accumulation of PEGylated liposome in the accelerated blood clearance phenomenon; Y Hashimoto. Session 1

continued

43

Micro- and Nanoparticle Design continued 398

Shape Matters: Effect of Polymeric Nanocarriers Shape on Epithelial and Endothelial Cell Lines; R Agarwal. Session 2 399 Shell-Detachable Polypeptide Nanogel with Reduction-Responsive Core as Intelligent Carrier for Improved Chemotherapy Efficacy;

J Ding. Session 3 400 Sialic acid-functionalized nanoparticles as a novel antiinflammatory drug delivery platform; M Greene. Session 1 401 Size- and Surface Chemistry-Dependent Exocytosis of Gold Nanoparticles in Macrophages; N Oh. Session 2 402 Size controlled of core-corona type nanospheres using thermoresponsive macromonomers with various chain lengths;

T Matsuyama. Session 3 404 Sodium Carboxymethyl Cellulose Loaded with Vildagliptin for Diabetic Delivery: In Vitro and In Vivo Evaluation of Nanoparticles;

I Alhaider. Session 1 405 Solid lipid nanoparticles as a drug delivery system for cancer

stem cell therapy; S Shi. Session 2 407 Stealth Biodegradable Nanoparticles Fabricated by Dispersion Polymerization; E Akala. Session 3 408 Stromal depletion and control of metastases with a polymeric conjugate of docetaxel; S Li. Session 1 409 Successful formulation of solid lipid nanoparticles (SLN) using polyhydroxy surfactants; C Keck. Session 2 410 Surface Engineering of Gold Nanoparticles with Poly(aminoethers) for Theranostics Applications; K Rege. Session 3 411 Synergistic Enhancement of Breast Cancer Cell Cytotoxicity via Co-Delivery of Doxorubicin and VEGF siRNA Loaded PeptideConjugated Nanoparticles; W Lin. Session 1 412 Synergistic Stimulation of Immune Cells by Combination of Adjuvant and Nanoparticles Composed of Amphiphilic Poly(γglutamic acid); F Shima. Session 2 413 Synthesis and Characterization of pH and Thermal Sensitive Copolymers of N-isopropylacrylamide and Carboxyalkyl Methacrylates; J Cornejo-Bravo. Session 3 415 Targeting of e-selectin expressing human endothelial cells using liposomes with a Sialyl Lewis X ligand; J Unga. Session 1 416 Temperature-responsive nanoparticles for temperature-controllable drug release and intracellular uptake; Y Matsukami. Session 3 417 The Effect of Polymer End-group Capping on Protein Release and Degradation of Poly(D,L-lactic-co-glycolic) Based Particles; N Samadi. Session 2 418 The glucose-lowering potential of exenatide orally delivered via a goblet cell-targeting nanoparticles; X Li. Session 3 419 The influence of drug loading on caveolin mediated intracellular internalization of Doxorubicin Nanomicelles; H Nehoff. Session 1 420 The nanoparticulation of α-galactosylceramide by octaargininemodified liposome enhances α-galactosylceramide mediated antitumor effects in an experimental lung metastasis model;

T Nakamura. Session 2 421 Therapeutic Hydrogen Sulfide Delivery System based on Polymeric Micelles; U Hasegawa. Session 3 422 Thermosensitive Liposomes for the Localized Delivery of Gemcitabine and Oxaliplatin; J May. Session 1 424 Transport of L-DOPA loaded PLGA Nanoparticles across

Blood-Brain Barrier; J Wen. Session 2 425 Triamcinalone and Raloxifene Loaded PCL Microspheres for Treatment of Rheumatoid Arthritis; D Keskin. Session 3 426 Triggered Release of CPT-11 in Multidrug Resistant Cancer Cells

by Biofunctionalized Lipid Bilayer Supported Mesoporous Silica Nanoparticles; X Zhang. Session 1 427 Tumor-Selective Anticancer Drug Delivery System Mediated by Dendritic Poly(L-Lysine)s; T Niidome. Session 2 428 Tunable Degradation and Release Profiles from Multistage Nanovectors; M Evangelopoulos. Session 3 429 Uncovering tumor-host molecular and cellular interactions involved in tumor dormancy using polymer therapeutics; R Satchi-Fainaro.

Session 1 430 Uptake of new somatostatin analogue loaded recombinant human serum albumin nanoparticles in pancreatic carcinoma cells; I Rosenberger. Session 2

Modern Agriculture 431

Zein coated sodium nitrite for brushtail possum control; C Bunt.

Session 3

44

Oral CR - Pharmaceutical Formulations, Technologies and Development Strategies 432 433 434 435 436 437

438 439 441 443 446 447 450 451 452 453 454 456 457 458 459 461 462 463 465 466 468 469 470 471 472 473 474 475

A Comparison of Spherical Core Materials Used for Controlled Release Drug Layering Processes; S Engels. Session 1 A novel biphasic drug delivery system containing taste masked diclofenac sodium; K Nielson. Session 2 A novel granulation technique to obtain zero order release from solid dosage forms; A Gokhale. Session 3 Absorption profiles of an oral paclitaxel formulation, DHP107 with variable dosing intervals in mice; Y Jang. Session 1 Anti-tumor activity and tumor distribution of paclitaxel following an oral administration of DHP109 in mice; Y Jang. Session 2 Application of Super Fine Powder, Special Low Viscosity Grade of Hydroxypropyl Cellulose(HPC-SSL-SFP) to “Tablet Hardness Enhancer” for Hydrophilic Matrix Formulation; K Sugisawa. Session 3 Aqueous ethyl cellulose coating with alcohol resistant properties: Formulation and process considerations; R Chokshi. Session 1 Barrier Membrane Coating of Hydrophilic Matrices: A Simplified Strategy to Attain Zero Order Drug Release; A Rajabi-Siahboomi.

Session 2 Characterizations of Tablets Manufactured by One-Step Dry Coating (OSDrC®) OptiDose™ Technology; S Lamb. Session 3 Consideration of Critical Material Attributes in Hypromellose-Based Hydrophilic Matrices Comprising Drugs of Various Solubility; A Rajabi-Siahboomi. Session 1 Co-Processed Excipients: A Strategy for Reducing Risk in Early Dosage Form Development; A Lambert. Session 2 Design of experiments approach for the development of coated pellets for MUPS tablets; A Novikova. Session 3 Development of a Swellable Matrix Tablet for a Novel CNS Drug Candidate; M Brewster. Session 1 Development of Extended-release Capsules loaded with Albuminbased Microspheres; D Do. Session 2 Development of Thioguanine Extended Release Tablets; Y Song.

Session 3 Ectopic protein bodies, a novel strategy for oral delivery of recombinant proteins; A Hofbauer. Session 1 Effect of Different Types of Chitosan on Its Mucoadhesive Properties; S Senel. Session 2 Effect of Polyethylene Oxide Molecular Weight and Osmogen Content on Performance of Push-Pull Osmotic Pump Tablets; A Rajabi-Siahboomi. Session 3 Enhanced Drug Delivery across the Intestinal Epithelium using Planar Bioadhesive Microdevices; H Chirra Dinakar. Session 1 Enteric coating of microcontainers for oral delivery of poorly water soluble drugs; S Keller. Session 2 Ethanol-Resistant Polymeric Film Coatings for Controlled Drug Delivery; R Chokshi. Session 3 Evaluation of Super Fine Powder, Special Low Viscosity Grade of Hydroxypropyl Cellulose (HPC-SSL-SFP) for Orally Disintegrating Tablet Application; K Sugisawa. Session 1 Evaluation of Ultra High Viscosity Hydroxypropyl Cellulose for Hydrophilic Matrix, Sustained Release Formulation; K Sugisawa.

Session 2 Experimental Design to optimize a Novel Geometric Multi-layered Matrix Tablet Formulation with various Mechanical properties and Drug Release Profiles; D Choi. Session 3 Extrusion spheronization technique for controlled release of pharmaceutical drugs; A Gokhale. Session 1 Formulation development of poorly stable and poorly permeable drugs; A Gokhale. Session 2 Gastroresistant Coating of HPC Capsules Prepared by InjectionMolding; E Macchi. Session 3 High Dose Metformin HCl Controlled-release Tablets Made via Hot-melt Extrusion; D Tewari. Session 1 Hyaluronic Acid, a new Recombinant Controlled Release Excipient for Oral Solid Dosage Forms; O Dall. Session 2 In Situ Gelling Methylcellulose/Pectin Formulation for Oral Sustained Release Delivery; K Itoh. Session 3 In vitro Evaluation of a Multiple-Unit Formulation for Oral Colonic Release of Insulin; E Macchi. Session 1 In vitro Permeation Studies of Esomeprazole through Gastric Pig Mucosa; A Rossi. Session 2 Investigating the Impact of Polymer Blends on Drug Release from Polymer Matrices; Y Perrie. Session 3 Investigation of the dissolution behavior of Eudragit® RL/L-55 blends using a response surface methodology; R Wulff. Session 1

477

Mesostructured Porous Silicon for the Controlled Delivery of Poorly Soluble Drugs; T Barnes. Session 2 478 Modified Release Strategies for Ionizable Drugs Using Ion Exchange Resins; T Rogers. Session 3 481 Non Swellable Gastroretentive Matrices: Formulation and

Response Surface Optimization; A Abdelbary. Session 1 482 Novel Co-processed Excipient for Directly Compressed Controlled Release Formulations; J Zeleznik. Session 2 484 Oral Sustained Release Formulations Based on Coating a

Nano-on-Bead Concept with a pH Sensitive Polymer; M Brewster.

Session 3 485 pH responsive raft gel forming tablet of risedronate for reducing

risk of gastroesophageal irritation of bisphosphonate; S Jang.

Session 1 486 Preliminary In Vivo Evaluation of a Gastroresistant Capsular

Device Prepared by Injection Molding; E Macchi. Session 2 487 Preparation and In Vitro Evaluation of Multifunctional Oral Drug Delivery System; C Kao. Session 3 488 Preparation and in vitro release of isoperidone gastroretentive tablets; H Xia. Session 1 489 Preparation, characterization and in vitro release studies of Enoxaparin in nanoparticle form and enterically coated tablets containing surfactants as permeation enhancers; M Goharzadeh.

Session 2 492 Production Scale of Semipermeable Coating for Push-Pull Osmotic Pump Tablets; A Rajabi-Siahboomi. Session 3 493 Reinforced alginate beads for anticancer drugs delivery; C Kim. Session 1 494 Relaxation Vs Diffusion On The Diclofenac Sodium Release From Matrix Tablets Containing Hydroxypropylmethyl Cellulose And/Or Chitosan; M Vueba. Session 2 495 Shifting the Enteric Property of Eudragit L 30D-55 to Taste-masking

by Adding Eudraigt RL 30D; C Wu. Session 3 498 Taste Masking Hydrocodone by Controlling Release in Simulated Saliva Using Ion Exchange Excipients; T Rogers. Session 1 499 The Behavior of Mixed Polymer HPMC/PEO Hydrophilic Matrices

in Ionic Environments; A Hu. Session 2 500 The Effect of Bilosomes and Vesicle Size on the Oral Biodistribution of a H3N2 Subunit Antigen; Y Perrie. Session 3 501 The Utility of Modified-Release, Osmotic Tablet Technology in

the Early Stages of Pharmaceutical Development; W Caldwell.

Session 1 502 Transit and pH in Fasted Beagle Dogs with the IntelliCap System;

J Shimizu. Session 2 503 Understanding the Response of Xanthan Gum Hydrophilic Matrices to a Dissolved Salt Environment; Y Oni. Session 3 504 Use of ion exchange resin for taste masking cetirizine HCl 10mg formulated in the Zydis® dosage form; S Lamb. Session 1 505 Use of Response Surface Methodology for the Optimization of Nevirapine Sustained Release Tablets; R Walker. Session 2 506 Zero-Order Release of Hydrocodone from a Hydrophilic Matrix Tablet Containing Naproxen Sodium; C Wertz. Session 3

Oral CR - Predictive Tools (in vitro / in vivo / in silico) 507

A Comprehensive Study of Solid Lipid Microparticles (SLMs) Behavior in Biorelevant Dissolution Media; B Albertini. Session 1 508 A Novel Mucus-Containing in Vitro Model for Assessment of Intestinal Drug Absorption; M Boegh. Session 2 509 Drug-polymer interactions significantly affect drug partition in cationic polyacrylate membranes and drug release kinetics;

K Chen. Session 3 510 Dynamic system for simulation of physiological pH gradients for hydrogen carbonate buffers (pHysio-grad); W Weitschies.

Session 1 511 Evaluation of palatability for 10 commercial famotidine orally disintegrating tablets by combination of disintegration apparatus for orally disintegrating tablet and taste sensor; M Yoshida. Session 2 513 MembranePlus™: A tool to Study in vitro/in vivo Transport, Metabolism and Protein Binding; K Szeto. Session 3 514 Optimization of parameters for scaled-down dissolution method for controlled release pellets; K Kristan. Session 1 515 Optimization of simulated gastric media based on rheological characterization of human gastric fluid; A Müllertz. Session 2 516 pHysio-stat® - an automated system for monitoring and regulating the pH value of model biorelevant media based on bicarbonate buffers; W Weitschies. Session 3

517

Predicting the Impact of Ingested Lipids on Orally Delivered Drug Absorption: Mechanistic Studies and Modeling; S Di Maio.

Session 1 518 Rapid and Non-Destructive Dissolution Measurement of Controlled Release Pellets by NIR Spectroscopy; M Horvat. Session 2 519 Simulation of midazolam pharmacokinetics after buccal administration; K Szeto. Session 3

Parenteral Sustained Release Drug Delivery 521 522

523 525 526 528 529 530 532 533 534

535

536 538

539 540 541

543 544

545 546 547 548

549

550 551

A hydrogel containing crosslinkable trilayered polymeric micelles, newly-developed macromolecular assemblies, for a sustained release of hydrophilic compounds; Y Uchida. Session 1 A Novel Drug Delivery System Based on Raloxifene Nanoparticles Composed of Biodegradable Carboxylated Polyurethane; F Dorkoosh. Session 2 A Sheet-Shaped Poly(ethylene glycol)-Modified Chitosan Hydrogel Containing Crosslinkable Polymeric Micelles for Wound Dressing and Drug Release; C Yoshida. Session 3 Andrographolide-Loaded Temperature-Responsive Hydrogels for Myocardioprotection in H9c2 Cells Hypoxia/Reoxygenation Injury Model; H Liu. Session 1 Characterization of liposomal systems designed for the remote loading of ropivacaine; C Silva. Session 2 Combination Therapy for Treating Angiogenesis by Targeting Downstream Signaling Pathways (HIF-1α & mTOR); B Dodapaneni.

Session 3 Comparative PK-PD Study On A Long Acting PLGA-based Microsphere of A Novel Antipsychotic and Oral Administration of Free Drug; L Wang. Session 1 Core-shell Nanofibers-coated Drug-eluting Stents for Suppression of Restenosis; S Yoon. Session 2 Development and Preclinical PK/PD Evaluations of Diethylstilbestrol Nanosuspensions in Rats; T Samant. Session 1 Development of an oily sustained release depot formulation in a prefilled syringe; M Chaubal. Session 2 Development of Annual Implant for the Controlled Release of Anastrozole using Polyurethane as a Rate Limiting Membrane; A Schwarz. Session 3 Development of injectable microspheres for controlled release: Rationalization of the release behavior by structure elucidation; J Meeus. Session 1 Dual Drug-loaded Block Ionomer Complex Micelles for Enhanced Combination Chemotherapy; J Kim. Session 2 Fabrication and in vitro release research on a novel antibacterial coating containing halogenated furanone compound loaded poly(L-lactic acid) nanoparticles on microarc-oxidized titanium; J Wu. Session 3 Foreign Body Response to Subcutaneous Implants: Pre-clinical Study in Gottingen Minipigs; M Kastellorizios. Session 1 Formulation and in vitro Characterization of Nanoparticles for Prenatal Cardiovascular Therapy; N Albekairi. Session 2 Hydrogels as adjuvants for PRRS modified live virus vaccine; J Shi. Session 3 Implantable Nanochannel Delivery System for the Constant and Sustained Release of Intact Liposomes; S Ferrati. Session 1 Implantable NanoGland for the Constant and Sustained Delivery of Therapeutics; A Grattoni. Session 2 Improved stability and tumor targeting of 5-fluorouracil by conjugation with hyaluronan; Z Yin. Session 3 In Situ Hydrogel for Peritoneal Delivery of Paclitaxel in Ovarian Cancer; Y Lo. Session 1 In vitro Haemocompatabiltiy of Solid Lipid Nanoparticle Delivery Systems of Diclofenac; Z Wu. Session 2 Increased in vitro and in vivo release of dexamethasone formulated with a cross-linked hyaluronic acid hydrogel; M Maltesen. Session 3 Injectable Thermosensitive Poly(Ethylene Glycol)/Polypeptide Block Copolymer Hydrogels for Localized Anti-Cancer Drug Delivery; C He. Session 1 Injectable, Sustained-Release of BMP-2 by IonicThermosensitive Poly(organophosphazene) Hydrogel for Local Bone Regeneration; B Seo. Session 2 Insights into the local inflammatory reaction induced by intramuscular injection of sustained-release drug microsuspensions; N Darville. Session 3

continued

45

Parenteral Sustained Release Drug Delivery continued 552

Intracellular Uptake Mechanism of Biodegradable and Injectable Poly(organophosphazene)-Docetaxel Conjugate Hydrogels;

J Cho. Session 1 553 LinkeRx™: A Versatile Platform for Designing Prodrugs for Extended Release after Intramuscular Administration; J Remenar.

Session 2 555 Liposomes and Polymers in Folate-Targeted Cancer Therapeutics: a Comparative Study; A Scomparin. Session 3 556 Local Interstitial Delivery of Estradiol by Micellar Drug Release for Cardioprotection in vitro; H Liu. Session 1 557 Multiscale Drug Delivery System: Micelles Encapsulated in Hydrogels; M Tang. Session 2 558 Pathogen mimicking particles in an injectable synthetic-immunepriming center (sIPC) provide efficient immune cell activation and protection in murine tumor models; J Leleux. Session 3 559 Pharmacokinetics (PK) and Safety of a 120-day Implantable Risperidone Device in Rats; F Martin. Session 1 560 Polymer therapeutics: A combinational drug delivery approach for effective cancer treatment; M Vandana. Session 2 561 Polyoxazoline is a suitable biopolymer for the extended release of irinotecan in rats and dogs; T Viegas. Session 3 562 Polysaccharide conjugates of Amphotericin B for improved efficacy and reduced toxicity; D Ickowicz. Session 1 563 Precision Particle Fabrication Microsphere Depot Sustains Tramadol Blood Levels with Minimal ‘Burst’; D Dumbauld.

Session 2 564 Preparation and Evaluation of Self-assembled Nanoparticles Based on Low-Molecular-Weight Heparin and Stearylamine for Controlled Delivery of Docetaxel; D Kim. Session 3 567 Redox Injectable Gel for Local Inflammation; Y Nagasaki.

Session 1 568 Self-Regenerative Nano Hybrid Materials for Long Term Controlled Drug Delivery Applications; M Alm. Session 2 569 SER-201, a novel polyoxazoline conjugate of irinotecan with improved efficacy in five mouse xenograft models; T Viegas.

Session 3 570 Short PEGylated Peptide-based Hydrogels as New Matrices for Slow Release; L Jeannin. Session 1 572 Surgical Suture Enabled with Controlled Drug Delivery for AntiScarring Functionality; S Choi. Session 2 573 Sustained Released Anti-angiogenic Thrombospondin Mimetic Peptide Induces an Angiogenesis-Dependent Dormant-Like Phenotype of Fast-Growing Glioblastomas; S Ferber. Session 3 574 The angiogenesis effect of a novel long-acting prostacyclin agonist loaded-PLGA microspheres prepared using different molecular weight in murine sponge model; M Hazekawa.

Session 1 575 Twice and Once Monthly Risperidone Loaded Microparticle Formulations; D Love. Session 2 576 Use of Porosity to Impact the Erosional Release of a Drug from PLG Microparticles; K Miller. Session 3

Peptide and Protein Delivery 579 580 582 583 584 585 586 587

588 589

46

A novel chemistry for the protein PEGylation; Y Ikeda. Session 1 A novel NGF loaded electrospun fibrous membranes used for nerve conduit on peripheral nerve regeneration; F Wu. Session 2 A Stealth and Biodegradable Polymeric Drug Carrier Composed of Amino Acid Modified Hyaluronic Acid; T Kanei. Session 3 A Titania Nanotube Membrane for Extended Zero-Order Macromolecule Delivery; K Fischer. Session 1 Affinity-driven Self-assembled Nanoparticles for the Controlled Delivery of Multiple Growth Factors; E Ruvinov. Session 2 Assessment of Acceptable Subcutaneous Injection Volumes and Flow Rates; W Lambert. Session 3 Biomimetic hydrogels with dual function peptides for modulating angiogenesis and neurogenesis; J Lee. Session 1 Camouflaged and Thrombin-triggered delivery of tissue plasminogen activator for targeted thrombolysis; S Absar.

Session 2 Cell-Penetrating Peptide-Linked Polymers as Carriers for Mucosal Vaccine Delivery; K Nishida. Session 3 Cell-Penetrating Peptides in Oral Delivery Systems for Insulin; E Nielsen. Session 1

590

591 592 594 596 597 598 599

600 601 602 603 604 605 606 609 610 611 612 613 614

615 616 617 619 620

621 623 625 626 627 628 630

631

Cell-penetrating Peptides Targeting Intracellular Infections; J Bahnsen. Session 2 Controlled Release Mucoadhesive Films Containing Nanoparticles of Lysozyme; J McConville. Session 3 Controlled-release of GDF-5 from fibrous scaffold for enhanced hASCs-based bone regeneration; J Shin. Session 1 Delivery of the latent tuberculosis antigen Hybrid56 in a liposome delivery system: does liposome surface charge have an effect on immune response; Y Perrie. Session 2 Development of A Novel Cell-penetrating Peptide for Intracellular Delivery of Proteins and Loposomes; T Sato. Session 3 Development of Dendritic Cell-Targeted Peptide Vaccine Against Melanoma by Ligand-Modified Nanoparticles; J Silva. Session 1 Development of enzyme-loaded PICsomes for enzyme/prodrug therapy; Y Anraku. Session 2 Development of multivalent pro-apoptotic peptide-based polymers for treatment of glioblastoma multiforme; D Chu. Session 3 Development of photosensitive liposomes for controlled drug release; P Bhujbal. Session 1 Effect of Sec61ß gene on the tight junction barrier function in MDCK cells; M Washiyama. Session 2 Efficacy and pharmacokinetics of insulin delivered to pigs by phase transition micro needle transdermal patch; T Jin. Session 3 Efficient intracellular delivery of various proteins using silica nanoparticles possessing large pores; H Na. Session 1 Electrostatic and Hydrophobic Dual-binding Interaction Inclusion Nano-complex for Controlled Release of Insulin from Poly(lactideco-glycolide) Microsphere; K Na. Session 2 Enhanced Antitumor Activity of Proteasome Inhibitor MG132loaded Polymeric Micelle Drug Carriers; Y Matsumoto. Session 3 Evaluation of a novel breast cancer-related protein, Eph receptor A10 for targeting therapy; K Nagano. Session 1 Formulation and Evaluation of Hybrid Onconase Nanoparticles for treatment of Mesothelioma; R Tekade. Session 2 Formulation and in vitro release characteristics of poly(D,L-lactideco-glycolide) micro- and nanoparticles for intravitreal delivery of connexin43 mimetic peptide; Y Chen. Session 3 Gelatin-Based Controlled Release System for Long-Term Delivery of Proteins; L Ahrens. Session 1 Improvement of Transdermal Delivery of Insulin Using Novel Microneedle Arrays Fabricated from Hyaluronic acid; A Yamamoto. Session 2 In Vitro Studies on the Release of Lysozyme from Solid Lipid Microparticles in a Biorelevant Medium; H Mu. Session 3 In vivo assessment of Melanoma Peptide Vaccine Formulations; S Hook. Session 1 Interaction of recombinant Human Growth Hormone with Albumincoated Nanoparticles; S Atwe. Session 2 Intracellular delivery of native proteins using polymeric nanoparticulate carriers formed by phase-guided assembly; T Jin. Session 3 Investigation of Vaccine Adjuvant Activity of Liposomes containing Phophatidylinositol Dimannosides and Analogues; S Hook.

Session 1 Liver cell specific targeting by PreS1 peptide-carrying nanocages; M Murata. Session 3 Loading of an antimicrobial peptide into PLGA nanoparticles increases its efficacy against intracellular Staphylococcus aureus infection in the Calu-3 bronchial epithelial cell line; J Water.

Session 1 Local antitumor effects of intratumoral delivery of rIL-2 by sustained-release PLGA/PLA microspheres; W Yuan. Session 2 Low Molecular Weight Methylcellulose-Based Injectable Hydrogel for Protein Drug Delivery; Y Kim. Session 3 Migration of dendritic cells and induction of antigen-specific immunity by γ-PGA nanoparticles; T Akagi. Session 1 MK2 Inhibitory Peptide Delivery with Endosomolytic NanoPolyplexes Prevents Vasoconstriction and Intimal Hyperplasia in Human Saphenous Vein Bypass Grafts; C Duvall. Session 2 Modification of Macrophage Function through Pioglitazone Release with Biodegradable Hydrogels; Y Tabata. Session 3 Molecular Dynamics Study of 20 kDa PEG Reagents with Different Arquitectures; S Carmali. Session 1 Neovascularization and Control of Foreign Body Response via Programmed Delivery from A Microsphere/Hydrogel Composite; J Shen. Session 2 Neurotrophic Factor Gradient Delivery for Migration Guidance of Schwann Cells and Regenerating Axons; K Krick. Session 3

632 633

634

635 636

638 639 640 641

644

645 646 647 648 649 651

652 653 654

655

656 657 658

659 661

662 663 664

Novel Silicone Composite for Prolonged Release of Antimicrobial Peptides; S Steffensen. Session 1 Oligoarginine-modified Biodegradable Nanoparticles: A Novel Delivery Carrier for Oral Administration of Insulin; G Wei. Session 2 One-pot Multiple Enzyme Reaction for the Glycosylation of Leu-Enkephalins; CNS Drug Delivery; P Simerska. Session 3 Optimization of a Glucose-Responsive Implant Microdevice for ‘Smart’ Insulin Therapy; M Chu. Session 1 Optimization of Sustained-release Delivery of protein-dextran particle composite PLGA fibers by different electrospinning methods; F Wu. Session 2 PLGA microspheres for sustained-release delivery of erythropoietin of native form to rhesus monkey, efficacy, pharmacokinetics, and immunogenicity; Z Hu. Session 3 Polymeric micelle functionality assessment using mPEG (2K)DSPE for poorly soluble peptides; F Qureshi. Session 1 Potential of Site-specific PEGylated Exendin-4 Modified with a High-molecular Weight Trimeric Polyethylene Glycol for Effective Type 2 Anti-diabetic Therapy; S Lim. Session 2 Potential Pharmaceutical Applications of Uniform-sized Chitosan Micro/Nanoparticles with Autofluorescent Property; W Wei. Session 3 Preparation of PEGylated Exendin-4-loaded PLGA Microspheres for Enhanced Stability and Anti-diabetic Activity; H Eom. Session 1 Preparation, characterization and in vitro studies of chitosan nanoparticles containing Androctonus Crassicauda scorpion venom; A M.M.Sadeghi. Session 2 Protein-excipient interaction hotspots - Fab case study; T Barata.

Session 3 Recombinant Human Hyaluronidase PH20 (rHuPH20) Facilitates Subcutaneous Dispersion and Systemic Absorption of Therapeutic Proteins in Non-Clinical Models; D Kang. Session 1 Safe and Efficacious Therapeutic Peptide Delivery Using Nano Emulsion; Y Pathak. Session 2 Screening of an injectable formulation of stapled peptide RO6836101 for oncology preclinical study; F Qureshi. Session 3 Strategies for Protein Drug Encapsulation in Biodegradable Polymer: Size Control and Prevention of Protein Denaturation; G Ma. Session 2 Sustained Release of Protein Loaded in a Biodegradable Polymeric Scaffolds for Growth Plate Regeneration; A Clark. Session 3 Synergistic Anti-tumor Effects of PEGylated TRAIL and Docetaxel Combination Therapy; Y Jang. Session 1 Synthesis and Biological Activity of Self-adjuvanting Peptidebased Therapeutic Vaccin Against Cervical Cancer; T Liu. Session 2 Synthesis of Lipid LHRH Peptides for Targeted Drug Delivery; R Stephenson. Session 3 Synthetic nanofibrils mimicking proteoglycan; H Kim. Session 1 The cell penetrating ability of the proapoptotic peptide, KLA fused to the N-terminal protein transduction domain of translationally controlled tumor protein (TCTP); H Kim. Session 2 The Global Gene-Expression Profiles of U-937 Human Macrophages Treated with Tat Peptide and Tat-FITC Conjugate; J Kuo. Session 3 The preparation of Multivesicular liposome formulation of decapeptide(TKII-10) with sustained rellease characteristics; X Liu. Session 1 Thermoresponsive Self-Assembled Tropoelastin Nano/MicroParticles for Protein Delivery; Y Choi. Session 2 Tissue Engineering Fibers with Bead-like Junctions for Sustained Release of Proteins in Native Form; F Wu. Session 3 Tunable hydrogels for differentiation of tissue progenitors using nanoparticles; E Carvalho. Session 1 VEGF-Fc delivery scaffold for promoting angiogenesis in biomaterials; J Yang. Session 2

Personal and Home Care 665 666 669 672

Bioactive-based Polymers: Applications for Skin Care; K Uhrich.

Session 3 Development of Novel Formulation Excipients for Oral Hygienic Products; H Yuan. Session 1 Preserved Argan oil-loaded NLC Concentrates for Industrial Production of NLC Cosmetics; C Keck. Session 2 The Effects of Treatment Conditions on Hair Wettability and Energetic Heterogeneity; D Burnett. Session 3

Processing Technology/Manufacturability 673

A Design of Experiment Study Applied to a New Nano Spray Drying Technic and Nanoprecipitation for Producing PLGA Drug Delivery Systems with Defined Sizes and Size Distributions; C Draheim. Session 1 674 A novel, scalable, isothermal method for nano-emulsion formation; S Kakumanu. Session 2 675 ARTcrystals® - Nanocrystal Production & Physical Long-Term Stability; R Müller. Session 3 676 Contact-free encapsulation of proteins in PLGA nanoparticles by focused ultrasound; C Lehr. Session 1 677 Controlled Synthesis of Limit Size cationic Lipid Nanoparticles by Microfluidic Mixing; Y Perrie. Session 2 678 Design, Development and Optimization of a Pilot Scale MultiSource Clobetasol 17-Propionate (CP) Cream; R Walker. Session 3 679 Effect of Drug Concentration and Processing Temperature on Extrudability and Miscibility of Solid Dispersions by Hot Melt Extrusion; S Gupta. Session 1 681 Impact of PLGA Conformational Behavior in the Feed Solution on the Drug Release Kinetics of Spray-dried Microparticles; F Wan. Session 2 682 Optimization of Platelet-Rich Plasma and Its Effects for the Recovery of Erectile Function after Bilateral Cavernous Nerve Injury in Rat Model; M Sheu. Session 3 683 Preparation of Taste Mask MUPS (multiple unit particles system) ODT; N Yoshida. Session 1 684 Process Optimization of A Level Sensor Controlled Vibratory Feeder to Manufacture below 1% Weight Variation Mini-Tabs; F Cai. Session 2 687 Recrystallization of amorphous glibenclamide in tablets — a multifactorial approach; M Klukkert. Session 3 688 Simulation based coaxial electrohydrodynamic atomization process for production of polymeric double-walled microspheres; C Wang. Session 1 689 Use of Surface Energy and Powder Flow Measurements to Investigate the Cohesive Nature of Surface Modified Mannitol;

D Burnett. Session 2

Regional Delivery: Challenges in Ocular Delivery and Pulmonary Delivery 690 691 694 695 696 697 698 699 701 702 704 705 707 708

Aquasomes as Pulmonary Drug Delivery Systems; D Lowry.

Session 3 Characterization of Complexes of Two Fluorphores with Polymeric Micelles on Cornea Transport by Fluorescence Resonance Energy Transfer; J Liaw. Session 1 Intratracheal Gene Delivery into the Mouse Model of Cystic Fibrosis Using B-H Polyplex; M Harada-Shiba. Session 2 Micron-sized Spherical Agglomerates of Pure Drug Nanoparticles for Improved Pulmonary Delivery; J Hu. Session 3 Mucosal-Penetrating Particles Enable Topical Delivery to Posterior Segment of the Eye; E Enlow. Session 1 Nanocarriers for Ocular Drug Delivery - the importance of drug loading; S Venkatraman. Session 2 NanoCluster Budesonide Combined with Novel Devices Optimize Drug Delivery in Mechanical Ventilation; W Pornputtapitak.

Session 3 New HPLC method for quantification of 2-oxothiazolidine-4carboxylic acid permeated through excised bovine sclera; A AlKinani. Session 1 Novel PEG-PLA/PLGA microparticles having porous surfaces for pulmonary drug delivery; T Takami. Session 2 Optimized Solid Lipid Nanoparticles for Pulmonary Application; N Nafee. Session 3 Prolonged drug release from in situ formulated inverted hexagonal type liquid chrystalline systems of selachyl alcohol: designing injectable drug carriers; M Burmester. Session 1 Quo vadis dissolution testing for inhalation powders?; S May. Session 2 Shifting Paradigms in Pulmonary Drug Delivery: From Aerosols to Biological Barriers; C Lehr. Session 3 Solid lipid nanoparticles improved the targeted delivery of phosphodiesterase 5 inhibitor for the treatment of pulmonary hypertension; N Nafee. Session 1

47

Rising Suns in Asia 710

Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles;

Y Kim. Session 2 711 Preparation of a water soluble carbon monoxide donor, SMACORM2 micelles, and therapeutic potential for inflammatory bowel diseases; J Fang. Session 3

RNAi and DNA Delivery 712 713

714 715 716 717 718 719 721 722 723 724

725 726 727 728 729 730 732 733 735

736 737 738

739 740 741 742

48

743 744 745 746 747

A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like materials as a carrier for plasmid DNA; H Akita. Session 1 A new approach for innovative nanomedicine of type 2 diabetes in combination with DNA microarray and in vivo siRNA delivery; E Suemitsu. Session 2 A Novel Targeted siRNA-Nanomedicine for Liver Fibrosis; F Khaja.

Session 3 Acid-Degradable Cationic Poly(ketal amidoamine) for Enhanced RNA Interference In Vitro and In Vivo; D Lee. Session 1 An Aircraft Carrier Model for Long-term Gene Therapy; Y Kim. Session 2 An approach to mitochondrial genesilencing by the mitochondrial delivery of anti-sense RNA; Y Yamada. Session 3 Analysis of antitumor effect of human papillomavirus E6 siRNAloaded polymeric micelles on human cervical cancer; H Nishida.

Session 1 Analysis of PEI transfection by subcellular fractionation and radiolabeling reveals surprising differences between the intracellular trafficking of DNA and PEI; J Shi. Session 2 Arginine-rich Cell Penetrating Peptide-microRNA Inhibitor Complexes Decrease Glioblastoma Migration Potential; Y Zhang.

Session 3 Biodegradable Polymer-SPION Nanocomplex for Gene Delivery and Magnetic Resonance Imaging; C Chang. Session 1 Biodegradable Starch Derivatives as Carriers for pDNA; C Thiele.

Session 2 Bioreducible Poly (ß-amino esters)/RNA Complex Nanoparticles Sensitize Drug Resistant Cells; Q Yin. Session 3 Brain Specific Gene Delivery by Bubble Liposomes and Ultrasound; Y Oda. Session 1 Branched siRNA nanostructures for enhanced gene silencing; C Hong. Session 2 Cationic Liposomes-Mediated Co-delivery of Plasmid DNA and siRNA for a Synergistic Gene Therapy; J Park. Session 3 Cationic Polymethacrylate Nanoparticles downregulate Bfl-1/A1 Gene: A new approach for intracellular infection; R Jain. Session 1 Cell Penetrable Nano-Polyplex Assembled Hydrogel for Effective Localized siRNA Delivery; Y Kim. Session 2 Controlled and sustained release of adeno-associated viral vectors from electrospun scaffolds; S Lee. Session 3 CpG delivery using antigen-presenting cell specific carrier polysaccharide for immunotherapy; N Miyamoto. Session 1 Cytoplasmic delivery of microRNA by using polycation liposomes; H Ando. Session 2 Design and Evaluation of PEG-appended Lactosylated Dendrimer/Cyclodextrin Conjugate as a Novel Hepatocyteselective siRNA Carrier for Familial Amyloidotic Polyneuropathy Therapy; Y Hayashi. Session 3 Development of a pH-sensitive multifunctional envelope-type nano device (MEND) as an efficient nucleic acids delivery system; H Hatakeyama. Session 1 Development of antigen presenting cell specific nucleic acid carrier using ß-1,3-glucan; S Mochizuki. Session 2 Development of biocompatible ultrasound-responsive gene delivery carrier, bubble lipopolyplex, for liver gene transfection; T Kurosaki. Session 3 Development of Cancer Gene Therapy with Nano-bubble Assisted Sonoporation; R Suzuki. Session 1

748

Development of cyanovinylcarbazole mediated photocrosslinking reaction toward for regulation of RNA functions in cell; A Shigeno.

Session 2 Development of gelatin nanocarriers for the targeted delivery of STAT-6 siRNA; S Youngren. Session 3 Development of novel multifunctional pH-sensitive carrier for efficient siRNA delivery; M Gujrati. Session 1

777

749

750 752 753 754 755 756 757 758 760 761 762 763 764 765 767 768 769 770 771 772 773 775 776

779 780

Development of systemic anti-miRNA oligonucleotide (AMO) delivery system to liver; M MURATA. Session 2 Dexamethasone-Loaded Polymeric (PLGA)n-b-bPEI Micelles for Effective Gene Delivery; H Cho. Session 3 Differentiation of human dermal fibroblast cells transfected with genes coated onto PLGA nanoparticles; J Park. Session 1 Discovery of Polymers for Plasmid DNA Delivery using Combinatorial Synthesis and Cheminformatics Modeling; K Rege.

Session 2 DNA Nanotechnology for Molecularly Self-assembled Nanoparticles and Their Drug Delivery Applications; H Lee. Session 3 Dual Specific Suicide Gene Expression Plasmid Delivery Using Bio-Reducible Polymer for Gene Therapy of Liver Cancer; H Kim. Session 1 Dual therapy of anti-apoptotic siRNA and angiogenesis-inducible plasmid in a single carrier incorporating facially amphipathic cationic polymer for treatment of ischemic heart disease; D Kim. Session 2 Dual-function Polymeric CXCR4 Antagonist to Simultaneously Inhibit Cell Invasion and Deliver Gene Therapy; J Li. Session 3 Effect of Supramolecular Structure of Cytocleavable Cationic Polyrotaxanes in Intracellular Uptake and Gene Silencing of siRNA; A Tamura. Session 1 Efficient cytoplasmic delivery of siRNA by tumoral pH sensitive nanoparticles via membrane fusion under tumor microenvironment; S Itakura. Session 2 Enhanced Adenoviral Transduction and Ablation of Resistant Bladder Cancer Cells using novel Poly(aminoethers); K Rege.

Session 3 Enhanced blood circulation of siRNA complexed with PEG-blockpoly(L-lysine) for cancer treatment; S Watanabe. Session 1 Enhanced local delivery of siRNA to the vaginal tract of mice using elongate microparticles; A Raphael. Session 2 Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery; H Shen. Session 3 Evaluation of generations 0 and 1 dendrimer conjugated bioreducible polymer (PAM-ABP) for efficient gene delivery; K Nam. Session 1 Gene Delivery Using Lipid-like Material Composed of Fat Soluble Vitamin; H TANAKA. Session 2 Graphene Oxide Mediated Delivery of DNAzyme for Simultaneous Detection and Knockdown of Viral Gene; S Kim. Session 3 Histidine enhances transfection efficiency in vitro and ex vivo of poly(amidoamine)s polyplexes for intradermal DNA tattoo vaccination; I van der Heijden. Session 1 Hybrid hydrogel/silica platform for intracellular delivery of small interfering RNA; E Tasciotti. Session 2 Hydrodynamic IGF-1 Gene Introduction Using Polyplex Nanomicelle for Treatment of Peripheral Nerve Injury; K Nagata.

Session 3 Hydrophobic grafting enhances low molecular polyethylenimine’s delivery of plasmid DNA into mammalian cells; S Liu. Session 1 Improvement of mitochondrial targeting activity of MITO-Porter using functional peptides; E Kawamura. Session 2 In situ gelling formulation for localized and sustained delivery of siRNA; L Borgheti-Cardoso. Session 3 In vitro Characterization of a Lipidic Delivery System for Antiangiogenic siRNA; A Yousefi. Session 1 Intracellularly triggered gene delivery system based on decationized polyplexes; L Novo. Session 2 Intranasal siRNA delivery into the brain combined with the cellpenetrating peptide-modified MPEG-PCL nanomicelles; T Kanazawa. Session 3 Loading Viral Vectors within Porous Microparticles for Improved Gene Delivery; R Serda. Session 1 Mechanistic Insight into Statistical HPMA-oligolysine Copolymers for Gene Delivery; J Shi. Session 2 Methylated Poly(L-histidine) to Control the Stability of its siRNA Polyion Complexes for RNAi; S Asayama. Session 3 Multi-functional Dendrimer Based Nano-therapeutic System for Prostate Cancer; U Gupta. Session 1 Multifunctional Drug Delivery System for Combinatorial Treatment of Prostate Cancer; O Taratula. Session 2 Neutralized lipid envelope-type nanoparticle encapsulating pDNA as a liver-specific and long-lasting gene expression; M Ukawa.

Session 3 Nylon-3 based poly-beta-peptides for siRNA delivery; V Nadithe.

Session 1

781 782 783 784 786 787 789 790 791 793 794 795 796

797 799 800 801

802 803 804 805 806 807

808 809 810 811 812 813 814 815

PEG Length and Linkage Dramatically Influence Polyacridine Peptide DNA Polyplex Gene Transfer Activity In Vivo; K Rice.

Session 2 Peptide Polymer Nanoparticle Composites for Ocular Gene Delivery; A Jain. Session 3 pH-sensitive Nano-crystals of Carbonate Apatite for Smart and Efficent Drug/transgene Delivery; S Hossain. Session 1 pH-Sensitive PEG-modification onto cell signal-responsive polyplex for improved colloidal stability and cell specificity in gene delivery; Y Katayama. Session 2 Polyion complex vesicles formed by a pair of PEG-catiomers and siRNAs for novel oligonucleotide delivery carriers; S Chuanoi.

Session 3 Polymeric Micelles Co-Loaded with Survivin siRNA and Paclitaxel: A Strategy to Overcome the Multidrug Resistance in Tumors; G Salzano. Session 1 Potential use of NF-kB Decoy Complex with Fucose-appended Dendrimer/α-cyclodextrin Conjugate for Treatment of Fulminant Hepatitis; C Akao. Session 2 Preparation and Evaluation of Folate-PEG-appended Dendrimer (G4) Conjugate with α-cyclodextrin as a Cancer Cell-selective siRNA Carrier; A Ohyama. Session 3 Preparation of DNA hydrogel for radio-sensitive drug release; J Jo. Session 1 RAFT Block Copolymers for siRNA Delivery to Inhibit Influenza Virus Replication; P Gunatillake. Session 2 Reduction-Triggered siRNA Release Nanoconstruct for Targeted siRNA Delivery; W Kim. Session 3 Regulation of mRNA immunogenicity by nanomicelle encapsulation for in vivo mRNA delivery; S Uchida. Session 1 Remarkable Enhancements of Cellular Membrane Uptake Ability and RNase H Activities of Arg Introduced Peptide Ribonucleic Acids (PRNA) and PRNA–DNA Chimera for Cancer Cell Specific Oligonucleotide Therapeutics; T Wada. Session 2 Reversible permeability enhancement of DNA-loaded chitosan oligosaccharide nanoparticle across Calu-3 epithelial cell model for airway gene delivery; Y Xu. Session 3 Self-immolative linker based BENSpm prodrug as dual drug/gene delivery system; Y Zhu. Session 1 siRNA Delivery by a Combination of Arginine-grafted Bioreducible Polymer, Ultrasound, and Microbubbles in an Ovarian Cancer Cell Line; S Florinas. Session 2 Specific Targeting to Brain with Osmotic Polymannitol Gene Transporter Modified with Rabies Virus Glycoprotein for Alzheimer’s Disease RNAi Interference Therapeutics; C Cho. Session 3 Stabilization of Complex with PKCα-Specific LPEI-Peptide Conjugate via Hydrophobic Interaction; C Kim. Session 1 Stem cell-derived vesicles as a gene delivery vehicle for cancer therapy; M Machluf. Session 2 Sticky Adeno-associated viral Vectors for Patterned Gene Delivery; E Kim. Session 3 Structure and Function Study of Nucleic Acid Nanoparticles For the Delivery of Peptide-siRNA Conjugates; J Hye. Session 1 Structure Modification of CpG oligounucleotides and their antitumor activities by stimulating Innate Immunity; X Xiang.

Session 2 Study of morphology and the surface topography of the complexes formed between cationic emulsions and an antimalarial oligonucleotide by atomic force microscopy; H Teixeira. Session 3 Surface Membrane of Rationally Designed Block Copolymer Assembled around Polyplex Core for Intercellular Delivery of Nucleic Acids; X Ge. Session 1 Synthesis and characterizations of cationic lipid molecules for siRNA delivery; J Zhang. Session 2 Targeted delivery of siRNA to tumors using antibody-modified lipid nanoparticle; A Okamoto. Session 3 Targeted Gene Delivery in Liver by Bubble Liposomes and Ultrasound; D Omata. Session 1 Targeting Glioblastoma with an Anticancer MicroRNA; P Ofek.

Session 2 Tethering PEG density on polyplex micelles and stealthiness in blood circulation; K Osada. Session 3 The effect of plasmid DNA sequence on gene expression and polycation complex formation; R Togashi. Session 1 The Role of Caveolin-1 and Syndecan-4 in the Internalization of PEGylated PAMAM Dendrimer Polyplexes into Myoblast and Hepatic Cells; R Qi. Session 2

816 817 818 820 821

The synthesis and activities of fatty acid-conjugated CpG oligodeoxynucleotide; C Wu. Session 3 Treatment of sensory nerve disorder by in vivo mRNA introduction using polyplex nanomicelle; K Itaka. Session 1 Tumor regression following intravenous administration of tumortargeted dendriplexes; C Dufes. Session 2 Tunable and Sustained Scaffold-based Gene Silencing In Vivo; C Duvall. Session 3 Unraveling the Role of Serum on siRNA Delivery in Vitro; J Liu. Session 1

Solubilization Technology - A Key Enabler for the Delivery of Poorly Soluble Drugs 822 823 824 826 827 829 830 831

833 835 836 837

838 839 840 841 842 844 845 846 847 848 850 852

853 854

A Combination of a Coaxial Electrospray Deposition and a PostHeating Process as a Technique That Improves Oral Bioavailability of Poorly Water-Soluble Drugs; N Ishizuka. Session 2 A High Drug-load, Solid Dispersion Formulation for A Poorly Soluble Drug Molecule; V Bi. Session 3 A Miniaturized Method to Study Dissolution, Supersaturation and Precipitation of Amorphous Compounds; C Bergström. Session 1 Amino acids as amorphous stabilizers and dissolution enhancers for poorly water soluble drugs; K Loebmann. Session 2 Antioxidant Capacity of Tailor-made Quercetin Nanocrystals with KRLTest; C Keck. Session 3 Application of a Novel Boron Carrier: Kojic Acid Appended Carborane/Hydroxypropyl-ß-Cyclodextrin Complex for Boron Neutron Capture Thearapy; R Kawasaki. Session 1 Approaches for Solubility Enhancement of Poorly Water Soluble API, P Butler. Session 3 Assessing the phase behavior of digestible and non-digestible lipid based liquid crystalline oral drug delivery systems; T Nguyen. Session 2 CapsMorph: >4 Years Long-Term Stability of Industrially Feasible Amorphous Drug Formulations; R Müller. Session 3 Comparative study of Pluronic® F174-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats; D Xia. Session 1 Controlled Digestion; Enhancing the Utility of Lipid Based Drug Delivery Systems; O Feeney. Session 2 Dispersity and bioavailability of highly drug-loaded PEG400 formulation is improved with micellar technology; K Sakai.

Session 3 Dissolution Rate Enhancement of Felodipine by Solid Dispersions using Novel Amphiphilic Polymer Soluplus®; M Pandey. Session 1 Drug solubility in excipients of lipid based formulations; L Persson.

Session 2 Esterase-Activatable ß-Lapachone Prodrug Micelles for NQO1Targeted Lung Cancer Therapy; X Ma. Session 3 Formulation and Pharmacokinetic Study of Oral Liposomal Docetaxel; D Shin. Session 1 Formulation of Solid Self-Microemulsifying Drug Delivery Systems using Inorganic Porous Adsorbents; K Bolko. Session 2 Gastric Processing is a Critical Determinant of the Ability of LipidBased Formulations to Enhance the Oral Bioavailability of a Model Poorly Water-Soluble Drug; B Boyd. Session 3 Incorporation of Curcumin into polyvinylpyrrolidone fibers by electrospinning: Improving Curcumin water-solubility; P Luz. Session 1 Investigating the Surface Wettability of Poloxamers used for Solid Dispersions; D Burnett. Session 2 Mechanism of Phospholipid complex and its SNEDDS enhancing the oral bioavailability of sylibin; J Wang. Session 3 Metaxalone Nanoformulation Utilizing SoluMatrix Technology; J Coleman. Session 1 Micronized Benzodiazepines for Sublingual Applications Produced by Using Advanced Focused Ultrasound; S Kakumanu.

Session 2 Molecular interactions between drugs and amino acids in co-amorphous formulations; K Loebmann. Session 3 Nanoemulsified antioxidant formulations mitigates oxidative stress in chronic sleep fragmented Human apolipoprotein E4 targeted replacement mice; Y Pathak. Session 1 Novel Thermosensitive Polymeric Micelles for Hydrophobic Chemotherapeutic Drugs: Enhanced Stability and Loading Capacity by Pi-Pi Stacking; Y Shi. Session 2

continued

49

Solubilization Technology continued 855

Polymeric Micellar Carriers for a Hydrophobic Anti-cancer Drug; D Svirskis. Session 3 856 Preparation and Characterization of Ternary Inclusion Complexes for solubility enhancement of paliperidone; A Sherje. Session 1 857 Preparation and evaluation of fenofibrate loaded mesoporous silica; I Song. Session 2 858 Preparation and Evaluation of Self-Microemulsifying Drug Delivery System (SMEDDS) containing Atorvastatin and Ezetimibe; S Kim. Session 3 859 Preparation and Evaluation of Solid-Self Emulsifying Drug Delivery System for Enhancing Bioavailability and Lymphatic Delivery of Paclitaxel; Y Lee. Session 1 860 Self- microemulsifying drug delivery system for oral delivery of T1-11; L Chang. Session 2 861 Small volume dissolution of poorly soluble drugs prepared as a solid dispersion; J Mole. Session 3 862 Solid Dispersion Formation of Poorly Soluble Compounds using OptiMelt Hot Melt Extrusion Technology; S Lamb. Session 1 863 Solid state characterization of drug precipitation during digestion of super-SNEDDS lipid based drug delivery system using synchrotron SAXS/WAXS; S Phan. Session 2 864 Solid State Characterization of Felodipine-Soluplus® Solid Dispersions; M Repka. Session 3 866 Solubility enhancement of mefenamic acid with eudragit® epo using melt extrusion techniques; M Repka. Session 1 867 Solubility of drug compounds in the presence of an excipient used in lipid based formulations; J Mole. Session 2 868 Structural determinants of polymeric precipitation inhibitors for use with poorly water soluble drugs; D Warren. Session 3 869 Study on the nanoemulsion of poorly soluble drugs stabilized by Organic-Inorganic Nanocomposite; X Ma. Session 1 870 Supersaturation and precipitation behavior of ionizable drugs in the presence of cellulose polymers; J Mole. Session 2 871 Using Hybrid Nanostructure to Improve the Performance of Oral Lipid Based Drug Delivery Systems; C Prestidge. Session 3

Topical/Transdermal Drug Delivery 872

873 874 875

876 878

880 882 883 884 885 886 888 889 890 891

50

A High Throughput Method for Determination of Hydrophobic Drugs in Surfacant-Containing Dissolution Media Used to Evaluate In-Vitro Release of Drug Eluting Stents (DES); M Kamberi.

Session 1 A hyaluronic acid chip within a transdermal maltose microneedle; Y Tobinaga. Session 2 An investigation of cutaneous delivery of lipoic acid loaded in liquid crystalline nanodispersion; P Campos. Session 3 Assessment of Drug-Vehicle Interactions seen in Topical Drug Delivery using three PAMPA Artificial Membrane Systems; J Riviere. Session 1 Catechol-Chitosan/Genipin Hydrogel as Mucoadhesive Buccal Drug Delivery System; J Xu. Session 2 Characteristics of the Stability in Local Anesthetic Liphspheres; A Wang. Session 3 Delivery of Ibuprofen Through Carbosil Membranes Using Finite Dose Technology; M Gerber. Session 1 Development and Evaluation of Estradiol-Loaded MicroemulsionBased Gel; L Fu. Session 2 Development of a novel drug in adhesive transdermal analgesic patch: Formulation optimization and characterization; R Ravula.

Session 3 Development of matrix based transdermal delivery system for ketotifen; E Lee. Session 1 Development of Novel Arrayed Microjet Devices for Transdermal Drug Administration; H Hsieh. Session 2 Development of Novel Microneedle-based Systems for the Minimally Invasive Monitoring of Neonates; B Torrisi. Session 3 Effect of morphology and application modes of microneedles on permeability of ibuprofen against skin; J Baek. Session 1 Effect of Reverse Iontophoresis on Theophylline Uptake by Hydrogel-forming Microneedle Arrays; E Caffarel-Salvador.

Session 2 Effect of Thickeners on Rheological and Sensorial Characteristics of Hydrophobic Ointment Formulations; K Miller. Session 3 Effects of hydroxypropyl-cellose (HPC) on the nasal drug absorption from powder formulations; A Tanaka. Session 1

892 893 894 895 899 900

901 902 903 904

905 906 907

908

910 911 912 913

914 915 916 917 918 919 920 922

923 924 925 926 927 928

929 933

Elongate Microparticles Enhance Topical Drug Delivery in Pigs and Volunteers; T Prow. Session 2 Enhancement of nasal vaccination with adenoviral vectors by mucosal adhering and DC-targeting adjuvants; X Sun. Session 3 Enhancing Permeability of Sodium Lauryl Sulfate and Dodecyl Maltoside Across The Dermal Tissue of L.Terrestris; J Lee. Session 1 Evaluation of alternative membrane models as a surrogate for buccal membrane permeation of nicotine; G Bhatia. Session 2 High tolerance transdermal patches loaded with caffeine; C Keck.

Session 3 Human In Vivo Study: Dermal Application of Rutin SmartCrystals® & Peptide-Loaded Liposomes to Decrease Skin Roughness; C Keck. Session 1 Immobilization of mEGF by Azidophenyl Chitosan for Medical Applications; T SON. Session 2 Intravenous Rutin Nanocrystals with Potential Use for Alzheimer Treatment; R Müller. Session 3 Lidocaine-Ibuprofen Ionic Liquid for Dermal Anesthesia; H Park.

Session 1 Light-activated antibacterial activity of nanoencapsulated hypericin against biofilm and planktonic cells of Methicillinresistant Staphyllococcus aureus (MRSA) clinical isolates; N Nafee. Session 2 Local delivery of phenylephrine using hollow microneedle as a treatment of fecal incontinence; M Han. Session 3 Low frequency sonophoresis: influence of solid lipid nanoparticles in skin LTRs distribution; T Pereira. Session 1 Mechanical Properties of “Super Swelling” Hydrogels; E Caffarel-Salvador. Session 2 Microneedle-mediated Nanoparticle Vaccination; C Scott.

Session 3 Nanostructured Lipid-Water Cubic Formulations for Dermal Drug Delivery; H Evenbratt. Session 1 Novel Core-Shell Zein Nanoparticles for Topical Delivery of Methotrexate; O Perumal. Session 2 Optimization of dissolving microneedle delivery system through simplifying fabrication and investigating drug release; C Wu. Session 3 Pharmacokinetic evaluation of tolterodine hydrogels in rabbits; F Sun. Session 1 Porcine Mammary Papilla is a Suitable In-vitro Model to Study Transmammary Drug Delivery through Human Mammary Papilla; K Dave. Session 2 Prediction of Percutaneous Absorption in Human of Nicotine from Marketed TTS using Three-dimensional Human Cultured Epidermis; T Hikima. Session 3 Preparation and characterization of polymeric micelles for topical delivery of itraconazole; J Choi. Session 1 Preparation and Evaluation of Triamcinolone Acetonide-loaded Hydrogel using an Electron Beam; J Park. Session 2 Quantification of nanoparticle uptake into hair follicles - in vitro in vivo correlation; A Mittal. Session 3 Rapidly-Dissolvable Microneedles for Transdermal Delivery via a Highly Reproducible Soft Lithography Approach; K Moga. Session 1 Smart Transdermal Vaccine Delivery Systems Using Hyaluronic Acid Derivatives; H Kim. Session 2 Strategies for electrospinning carrageenan-based nanofibers; D Hathi. Session 3 Synthesis and Topical Delivery of Ester and Carbonate Co-Drugs Derived from Tocopherol and Lipoic Acid; M Hass. Session 1 The effect of nanoemulsions on the transdermal delivery of citalopram; P Wu. Session 2 The finest concentration and preparing condition of new Nanostructured Lipid Carriers (NLC); C Keck. Session 3 The Penetration Enhancement Effect of Single and Binary Phase Combinations of Hydrophilic and Lipophilic Vehicles, Using Ibuprofen as a Model Drug; J Du Plessis. Session 1 Transcutaneous Immunization using Iontophoresis - In vivo Preliminary Studies; D Bernardi. Session 2 Transdermal Administration of Serotonin-Dopamine Antagonist; H Maeda. Session 3 Transdermal delivery of fluoxetine; E Jung. Session 1 UV Imaging Studies on Pluronic F127-based Hydrogel Formulations of Ibuprofen; A Chapman. Session 2

Experience the CRS Exposition!

Come to the Exposition Hall for discovery, solutions, and opportunities. Located right by the CRS Registration Desk in Exhibit Hall III, this is the place for the business of delivery science and profitable collaboration.

When is the Exposition open?

On Sunday evening (17:30 – 19:30), the Exposition kicks off with a welcome reception designed for networking among colleagues. Booths are again open for visitors during dedicated exhibit hours on Monday and Tuesday, see page 4.

What else is in the Exposition Hall?

This is the central hub for poster viewing, program breaks, prizes, networking, refreshments (thank you, Café Sponsors), and a CRS Connect seating area for meeting up with colleagues. You will also find CRS Central nearby.

Did you say prizes?

That is correct. Thanks to sponsors, there will be prize drawings at every exhibit session. You must be present in the exhibit hall to win. For details, see the handout of the exhibit floor and exhibiting company list given with your registration materials and signs in the exhibit hall.

Who will I find at the Exposition?

Knowledgeable representatives from leading companies that provide products, services, and technologies for the delivery science market.

Exhibitors of the 40th Annual Meeting & Exposition of CRS The following descriptions, supplied by the exhibiting companies as of May 23, 2013, provide product, service, and contact information. Please see the Program Addendum for additional exhibitor information.

S 100

S

108

S

400

– Sponsor

CS

– Café Sponsor

3M Drug Delivery Systems, U.S.A., Tel: 1.800.643.8086, www.3M.com/DDS. 3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceuticals using 3M’s transdermal, microneedle, and inhalation drug delivery technology. In addition, 3M offers a full range of transdermal components as well as medical and specialty packaging films. Visit Booth 100 for more information.

Advanced Polymer Materials Inc., Canada, Tel: +1.514.683.8488, www.apmpolymers.com.

Advanced Polymer Materials Inc. are a Canadabased manufacturer with R&D capability, producing innovative, unique biodegradable and biocompatible polymers and block copolymers (mPEGs, functional PEGs, multi-arm PEGs, and functional PEG/ PLA, PLGA, and PCL) to fill the need for scientific advancement in pharmacy, biomaterials, and functional nanoparticles. We do custom syntheses and contract research.

Agilent Technologies, U.S.A., Tel: +1.408.345.8886, www.agilent.com. Agilent manufactures and distributes a complete line of instrumentation serving the clinical, analytical, biotech, environmental, pharmaceutical, forensic science, food and flavor, academia, and all other laboratory markets that have needs for the best in quality, performance, and serviceability in the instruments they purchase.

219

S

Akina, Inc.: PolySciTech Division, U.S.A., Tel: +1.765.464.0501, www.polyscitech.com. Research products available include biodegradable block and specialty copolymers (polyvivo), fluorescent dyes (FlammaFluor), specialty chitosan variations (Kitopure), and release media (polyvitro). Custom synthesis to match your specification and contract analysis services are also available. Also available is scale-up, template-based microparticle manufacturing device (spinswiper) for quick generation of uniform microparticles.

204

Asahi Kasei America, Inc., U.S.A., Tel: +1.212.371.9900, ext. 222, www.ceolus.com/en/. Asahi Kasei, a leading global excipient supplier, specializes in established and highly compactible grades of microcrystalline cellulose such as the Ceolus™ KG and UF series and MCC spheres, known as Celpheres.

Our Swelstar™ pregelatinized starch products include a unique gel matrix controlled-release excipient, wet binder, and super disintegrant.

408

Avanti Polar Lipids, Inc., U.S.A., Tel: +1.205.663.2494, www.avantilipids.com. Avanti Polar Lipids, Inc., a world leader for lipids of unparalleled purity—phospholipids, sphingolipids, detergents, and sterols—manufactures exciting new products for the research chemist and cGMP lipids for pharmaceutical production. Avanti’s extensive analytical department handles cGLP services, identity testing, and bioanalytical lipid assay for the pharmaceutical and nutraceutical industries.

S CS

51

201 & BASF, U.S.A., Tel: +1.800.469.7541, 203 www.pharma-ingredients.basf.com. BASF offers a range of innovative excipients, meeting market needs S with ingredient solutions in the areas of solubilization, modified release, skin delivery, taste masking, and soft gels. BASF also supplies active ingredients and provides exclusive customer synthesis services. (S) 303

S

102

Bend Research, U.S.A., Tel: +1.800.706.8655, www.bendresearch.com/. Bend Research is a leading independent scientific development and manufacturing company. It has numerous capabilities to advance promising drug candidates from conception through commercialization. These include formulation and dosage-form support, process development and optimization, and cGMP manufacturing. It is a leader in novel drug-delivery technologies including spray-drying, hot-melt extrusion, and controlled release.

BioPharm Solutions, Inc., U.S.A., Tel: +1.848.448.8481, www.biopharmsolutions.com.

BioPharm Solutions, Inc. (BPS) is a dynamic biotech company dedicated to developing industrially feasible delivery systems for biologic medicines. By collaborating with university partners, BPS R&D team has achieved sustained-release delivery of native proteins, efficient and accurate transdermal delivery of insulin, as well as easy-operating and environmentally friendly manufacturing processes.

101 & Catalent Pharma Solutions, U.S.A., Tel: 200 +1.732.537.6200, www.catalent.com. From drug development services to delivery technologies and S supply solutions, we are the catalyst for your success.

Catalent has the deepest expertise and the most innovative drug delivery technologies to enhance your product performance, including OSDrC® OptiDose™ optimized dosing, Zydis® fast-dissolve formulations, and OptiMelt™ hot melt extrusion.

104

CIMA Labs, U.S.A., Tel: +1.763.488.4700, www.cimalabs.com. CIMA, a world leader in the drug delivery partnering business, specializes in formulating, taste-masking, and manufacturing of pharmaceuticals utilizing its orally disintegrating tablet technologies: OraSolv®, DuraSolv®, Lyoc™, OraVescent®, OraSorb™, MicroSolv™, and OraGuard™. CIMA provides its partners with formulation and global regulatory expertise, as well as clinical and commercial manufacturing.

300 & Colorcon, Inc., U.S.A., Tel: +1.215.699.7733, 302 www.colorcon.com. Colorcon is a world leader in the development, supply, and technical support of S formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our valueadded services, which support all phases of solid oral dose design and development.

52

401

CordenPharma Switzerland, Switzerland, Tel: +41 61 906 5959, www.cordenpharma.com.

CordenPharma Switzerland, one of CordenPharma’s multiple cGMP facilities across Europe and the United States, is linking together a legacy of specialized technologies and expertise to supply custom synthesized materials such as lipids, peptides, lipo-peptide conjugates, and carbohydrates, as well as proprietary APIs and building blocks including pseudoproline dipeptides, lipids, and AADs.

316

CoSci Med-Tech Co., Ltd., China, +86.10.8267.4088, www.cosci-med.com/en/index. aspx. CoSci Med-Tech Co., Ltd.: 10 years R&D for oral modified-release formulations. 25 marketed products; 30 clinical trial approvals. 130 patent applications. 13 technology platforms: multi-porous osmotic pump, double layer osmotic pump, entericcoated pellet, water-based tablet matrix, double-layer wax-based matrix, sustained-release pellet, solid dispersions, microencapsulation of cellulose acetate dispersions, extended-release drug delivery system, oral dispersible pellets, micro-tablet, colon-release formulations, and multi-unit pellet system (MUPS).

306

Covaris Inc., U.S.A., Tel: +1.781.932.3959, www. covarisinc.com. Covaris provides advanced sample preparation systems for life and analytical science.

Covaris supports formulation applications including nanosuspensions, nanoemulsions, crystallization, and liposome creation. AFA technology brings unsurpassed speed and efficiency to sample preparation. AFA is based on shock wave physics, delivering controlled, precise, and accurate acoustic energy to biological and chemical samples. (CS)

CS

507

Dissolution Technologies, U.S.A., Tel: +1.302.235.0621, www.dissolutiontech.com.

Dissolution Technologies is a peer-reviewed, indexed quarterly journal reporting current information and scientific articles on dissolution testing. Books related to dissolution topics are available for sale on the searchable website, www.dissolutiontech.com. The website contains all back and current issues, and these articles are available for free as a PDF download.

505

Drug Delivery Partnerships Conference, U.S.A., +212.661.3500, www.drugdeliverypartnerships.com.

The Drug Delivery Partnerships conference is where the drug delivery community comes to learn where pharma companies are taking risks, strategize the best methods to close the gap between R&D and commercial, integrate drug delivery combination products into the over-arching drug delivery strategy and maximize the potential for payer reimbursement.

S

S

505

S

301

S

Drug Development & Delivery, U.S.A., Tel: +1.973.299.1200, www.drug-dev.com. Drug Development & Delivery is a print and digital publication exclusively committed to advancing the applied science, technology, and related business practices of pharmaceutical and biological drug development, including: • Drug Delivery Technologies • Controlled Release • Formulation Development • Bioavailability • Medical Devices/Combination products • Contract Services • Solubility Enhancement • Life-cycle management • Regulatory issues.

DURECT Corp./LACTEL® Absorbable Polymers, U.S.A., Tel: +1.877.705.8072, www.absorbables.com.

DURECT Corporation is a specialty pharmaceutical company developing therapeutics based on its proprietary delivery technologies, including injectable depot, oral sustained-release, transdermal and biodegradable implant. In addition, DURECT produces the LACTEL Absorbable Polymers line of biodegradable polyesters for use in the pharmaceutical and medical device industries. www.absorbables.com/ crs13

CRS Elsevier, United Kingdom, +1.212.989.5800, Central www.elsevier.com. Elsevier publishes the Journal of Controlled Release, the official journal of the S Controlled Release Society and the Japanese Society of Drug Delivery System. Elsevier is the leading publisher dedicated to providing authors the latest articles, tools, and resources within pharmaceutical sciences.

317

S

107

110

EMD Millipore, U.S.A., Tel: +1.800.225.3384, www. emdmillipore.com. EMD Millipore is the life science division of Merck KGaA. We provide excipients, ODT technology, drug delivery compounds, and chemicals to support all stages of drug manufacturing from research to industrial-scale production and quality control. Our products meet the highest purity standards, with extensive documentation and services assuring regulatory.

Evonik Corporation, U.S.A., Tel: +1.732.981.5269, www.pharma-polymers.com. Evonik Industries, a global leader in specialty chemicals, provides drug delivery technologies, API manufacturing, intermediates, and amino acids. Delivery technologies include development services, solubility enhancement, functional excipients, and GMP manufacturing for oral and parenteral formulations. Advanced delivery technologies provided for small molecules, peptides, proteins, antibodies, and nucleic acids used in extended-release parenterals.

Freund-Vector Corporation, U.S.A., Tel: +1.319.377.8263, www.freund-vector.com. FreundVector Corporation is a world leader in the design, manufacturing, and marketing of solid dosage processing equipment for the coating, granulating, and drying of powders, granules, beads, and tablets for the pharmaceutical and healthcare industries. Product lines include tablet pan coaters, roll compactors,

fluid bed granulators/coaters/dryers, and high shear granulators and automated process control systems.

403

Glatt Air Techniques, Inc., U.S.A., Tel: +1.

201.825.8700, www.glatt.com. Glatt is a CDMO offering services for “hard to craft” oral solids. We offer large-scale solvent processing, the elegant spheronization of APIs through our CPS™ process, highly efficient Wurster HS™ coating, and we handle controlled substances at large scale. We also manufacture and sell “Cellets” and tartaric acid microspheres.

319

Halozyme Thereapeutics, U.S.A., Tel: +1.858.794.8889, www.halozyme.com. Halozyme Therapeutics’ ENHANZE™ technology is a novel drug delivery platform that improves the bioavailability of coinjected drugs by increasing SC absorption. With ENHANZE™, it is feasible to administer many milliliters via a single SC injection.

The platform is in late-stage development with partners that include Roche, Pfizer, and Baxter.

212 Hovione, Portugal, Tel: +351 21 982 9000,

www.hovione.com. Hovione is a global company S with over 50 years’ experience in API and drug product intermediate development and compliant CS manufacture. Hovione offers integrated API, innovative particle engineering technologies to solve problems such as poor bioavailability, patient acceptability or enabling optimal delivery by non-oral routes of administration, formulation development, and manufacturing.

210

CS

Lipoid LLC, U.S.A., Tel: +1.973.735-2692, www.lipoid.com. Lipoid is a manufacturer of pharmaceutical grade phospholipids from three cGMP facilities based in Germany. In addition to synthetic phospholipids used in controlled release, Lipoid produces parenteral, topical, and oral grade egg, soy, and rapeseed lecithin. Lipoid has over 40 Drug Master Files for excipients on file with the FDA.

103 Medimetrics, U.S.A., Tel: +1.617.840.8564,

www.medimetrics.com. Medimetrics offers IntelliCap, S the world’s first intelligent electronic capsule for oral drug product development and therapy. Using this technology, drug product can be delivered to any desired location and rate into the GI tract. Clinical studies can be run almost anywhere with IntelliCap. 116 MedinCell, France, Tel: +33 467 419 974, www.medincell.com. MedinCell’s delivery technology enables rapid formulation design. Based upon the formation of an in situ depot after subcutaneous (systemic) or intra-articular (local) administration, MedinGel enables control over burst and bioresorption and is ideal for osteoarthritis, mental health, diabetes, fertility, pain control, and many other applications. By protecting drug molecules within this hydrogel matrix, drug cargo can be substantially reduced for more cost-effective treatments.

53

205

105

The Methodist Hospital Research Institute/ Methodist Academy, U.S.A., Tel: +1.713.441.7267, www.MethodistHealth.com/Academy. The Methodist Hospital Research Institute for Medical Science and Technology’s (Methodist Academy’s) purpose is to develop educational and research partnerships that foster medical innovation. In conjunction with partner institutions, the Academy facilitates training for all trainees to be leaders of medicine by identifying clinically relevant challenges and developing research programs that translate into technological advances in the clinic.

Michelson Prize & Grants, U.S.A., Tel: +1.310.574.5780, http://michelson.foundanimals. org. The Michelson Prize & Grants provides grants of up to $750,000 to researchers to develop the first nonsurgical spay/neuter method for male and female cats and dogs. The $25 million Michelson Prize will be awarded to the first entity to develop the successful product. For more information, visit http://michelson. foundanimals.org.

502 NanoSight, U.S.A., Tel: +1.614.888.0023,

www.nanosight.com. NanoSight manufactures instruments for counting, sizing, and visualizing nanoparticles from 10 nm to 2.0 µm. Measuring protein aggregates and virus particles and fluorescently labeled nanoparticles. Size and concentration measurements are made, along with ability to visualize the nanoparticles in real time and a video of the sample being analyzed.

407

S

402

119

54

Nisso America Inc./Nippon Soda Co., Ltd., U.S.A./ Japan, Tel: +1.212.490.0350, www.nissoexcipients. com. Nisso America Inc. is a wholly owned subsidiary of Nippon Soda Co., Ltd. (Tokyo, Japan), manufacturers of Nisso HPC (hydroxypropyl cellulose). Nisso HPC is available in a wide range of viscosities, including special low-viscosity grades. For wet/dry binding, sustained release matrix tablet, film coating, and dissolution enhancement applications.

NOF Corporation, Japan, Tel: +81.3.5424.6741, www.dds-drug.com. NOF Corporation DDS Development Division specializes in supplying GMP activated PEG, phospholipids, and polysorbate 80 based upon NOF’s proprietary technologies in production. Such NOF products have been used for many years and are currently used for multiple commercial drug products. NOF also offers customized PEGs and lipids for research and GMP products.

Northern Lipids Inc., Canada, Tel: +1.604.222.2548, www.northernlipids.com. A CRO modeled around the CMC needs of pharmaceutical and biotech firms engaged in the development of complex lipid-based delivery systems. Services are adapted to meet the client’s needs and include prototype identification, formulation development and scale-up, analytical method development and validation, and sterile

product manufacturing under cGMP for clinical trial supplies only.

512

Novozymes Biopharma, U.S.A., Tel: +1.617.401.2500, www.biopharma.novozymes. com. Our customer-focused partnering approach packages our award-winning technologies such as half-life extension with over 25 years of scientific, technical, and regulatory support to customers for the delivery of improved and better-performing products. Recombinant albumin and hyaluronic acid are produced in large-scale manufacturing facilities worldwide, which are operated to Q7 cGMP quality standards to ensure the highest level of product quality, consistency, and security of long-term supply.

413

OctoPlus, a subsidiary of Dr. Reddy’s Laboratories Ltd., The Netherlands, Tel: +31 715244044, www. octoplus.nl. Companies approach OctoPlus for our expertise in injectable drug delivery. We are a CDMO for formulation development, scale-up, and GMP manufacturing of any type of injectable drug product, microspheres (proprietary technology for proteins and PLGA), liposomes, high-concentration proteins, peptides, nucleic acid derived compounds, etc., both liquid and freeze dried.

S CS

507

S

114

S

ONdrug Delivery, United Kingdom, Tel: +44 (0) 1273 78 24 24, www.ondrugdelivery.com. Established now for eight years, ONdrugDelivery is the highly regarded, leading series of sponsored themed drug delivery publications. With content from world experts at leading companies—large and small—in the global drug delivery business, ONdrugDelivery is a must for those in the industry who need to know drug delivery.

Partnership Opportunities in Drug Delivery, U.S.A., Tel +1.646.350.2580, www.theconferenceforum. org. PODD: Partnership Opportunities in Drug Delivery is an annual Boston conference, keynoted by Dr. Robert Langer and Dr. George Whitesides and chaired by Dr. Barbara Leukuel. The October 10–11 conference offers strategic-level topics, senior-level networking, and access to the widest range of drug delivery technologies. For more information: www. theconferenceforum.org.

207 Patheon, U.S.A., Tel: +1.919.226.3200, www.patheon. com. Patheon is a leading provider of contract S development and commercial manufacturing services to the global pharmaceutical industry for solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps—a market leader in soft gelatin capsule technology—Patheon now also includes a proprietary products and technology business.

505

S

Pharmaceutical Technology, U.S.A., Tel: +1.732.596.0276, www.pharmtech.com.

Pharmaceutical Technology offers news, analysis, and peer-reviewed research in formulation development (including excipients) and drug manufacturing to more than 38,000 decision-makers in the top pharmaceutical, specialty pharmaceutical, and biotechnology companies via the Pharmaceutical Technology print magazine, PharmTech.com, and three newsletters: ePT, Sourcing and Management, and the Equipment and Processing Report.

112 PharmaCircle, U.S.A.; Tel: +1.760.436.1199, Website: www.pharmacircle.com. PharmaCircle is S an innovative knowledge management company providing detailed and comprehensive pharmaceutical information and analysis for research, development and regulatory professionals. Custom databases and search engines provide online interactive access to company pipelines, products, detailed drug delivery analyses, patents, clinical trials and much, much more.

106

Polymun Scientific GmbH, Austria, Tel: +43 2243 25060 300, www.polymun.com. Polymun Scientific GmbH is a private Austrian company offering contract development and production of liposomes and lipid nanoparticle formulations using its patented formulation technology, as well as development and manufacturing of biopharmaceuticals. Polymun is EMEA certified and provides customized formulation development, scale-up, and analytical services from R&D to commercialization.

217

PolyPeptide Group, U.S.A., Tel: +1.310.782.3569, www.polypeptide.com. The PolyPeptide Group is a global leader in contract manufacturing of therapeutic peptides, with six facilities and 450 employees worldwide. The privately held organization manufactures over one-third of all proprietary and generic approved peptide drug substances. It is actively involved in alternative/advanced drug delivery and bioconjugation of peptides.

307

Precision NanoSystems Inc., Canada, Tel: +1.604.818.3061, www.precisionnanosystems.com.

Precision NanoSystems Inc. proprietary microfluidicbased nanoparticle manufacturing platform (the NanoAssemblr™) enables rapid prototyping and seamless scale-up of novel nanoparticles, including “limit-size” lipid nanoparticles defined as the smallest energetically stable structures possible.

The NanoAssemblr™ automated platform ensures reproducible manufacture of nucleic acid-lipid nanoparticles, liposomes, nanoemulsions and polymer nanoparticles.

117

Purac Biomaterials, U.S.A., Tel: +1.847.634.6330 ext. 2227, www.puracbiomaterials.com. Purac Biomaterials has more than 35 years of experience as a leading global supplier of lactide/glycolide resorbable homopolymers and copolymers. We offer a broad range of standard PURASORB® polymers

and monomers as well as provide custom synthesis capabilities for specific formulation requirements.

304

QPharma AB, Sweden, Tel: +46 40361800, www.qpharma.com. QPharma is a Swedish CDMO specializing in polymeric controlled release systems, e.g., intravaginal rings (IVRs) and intrauterine systems. We have been producing IVRs commercially (U.S.A., EU, and RoW) for over 20 years. IVR is a unique delivery system: zero-order release for weeks to many months, specifically targeting women’s reproductive regions and also systemic delivery.

415

Saint-Gobain Performance Plastics, U.S.A., +1.508.595.3043, http://www.norton-films.com.

For over 60 years, Saint-Gobain Performance Plastics and its family of companies have collectively supplied the world with high-performance polymer products for the most demanding applications, with a global manufacturing footprint. We are a leading producer of release liners, providing DMF-listed standard products and custom-designed liners to best suit your transdermal needs.

216

Scintipharma Inc., U.S.A., +1.859.276.3320, scintipharma.com. Scintipharma, Inc. provides services for evaluation and optimization of drug delivery systems using gamma scintigraphy. Human and animal studies are performed to evaluate dosage forms of marketed and potential therapeutic agents developed for all routes of administration. Human regional gastrointestinal drug absorption studies are performed using the InteliSite® companion capsule.

202

Sekisui Medical Co., Ltd., Japan, Tel: +81 3 3272 0691, www.sekisuimedical.jp/english. Sekisui Medical, based in Japan and the United States, supplies three kinds of service for worldwide pharmaceutical markets: 1) API synthesis (especially amino acids, peptides, and other low-molecular-weight small molecules), 2) ADME/Tox contract services (including in vitro ADME and transporter services through our U.S.-based subsidiary XenoTech LLC), and 3) transdermal drug delivery system design and development (TDDS). In this conference, our research and development efforts in TDDS design for peptides will be showcased.

418

Simulations Plus, Inc., U.S.A., Tel: +1.661.723.7723, www.simulations-plus.com. Simulations Plus’s GastroPlus™ sets the standard for PBPK/PD modeling for oral (immediate and controlled release formulations), intravenous, ocular, pulmonary, and inhalation delivery in human and animals, plus powerful IVIVC, virtual population simulations, and DDI capabilities. DDDPlus™ offers the mechanistic simulation of in vitro dissolution experiments for different dosage forms and media.

S

55

406

Sirius Analytical Inc., U.S.A., Tel: +1.978.338.5790, www.sirius-analytical.com. Sirius Analytical offers instrumentation and CRO services for pKa, logP/ logD, solubility, dissolution, supersaturation and particle size/shape measurement and new instrumentation for surface dissolution imaging for monitoring real-time drug release—revealing data at early stages of pre-formulation and development— allowing informed decisions to be made earlier in the drug development process.

118

Surface Measurement Systems, U.S.A., Tel: +1.610.798.8299, www.thesorptionsolution.com.

SMS, innovator of dynamic vapor sorption (DVS), offers a family of water/organic vapor instruments with high-throughput, video and Raman hyphenation options, plus a novel second-generation surface energy analyzer (SEA) compatible with a wide range of materials and morphologies (including powders/ fibers/films) and featuring a unique heterogeneity mapping capability.

419 SkyePharma, Switzerland, Tel: +41 61 467 5555; www.skyepharma.com. SkyePharma combines S proven scientific expertise with validated proprietary technologies developing innovative oral and inhalation products. Customizable Geomatrix™ technology enables a variety of modified release profiles and is incorporated into eight oral products available in over 80 markets. Geoclock™ allows timedelayed release or colonic delivery independent of pH or food.

309

Technology Catalysts International Corporation, U.S.A., Tel: +1.703.237.9600, www.technologycatalysts.com. TCI, a global technology and business consulting firm, serves the pharmaceutical, drug delivery, and OTC industries. TCI offers analysisdriven consulting in technology assessments, in- and out-licensing, business intelligence, market research, mergers and acquisitions, and other strategic business needs. Reports on drug-device combinations, medical foods, probiotics, and ODTs and OTFs are available.

111

318

Texture Technologies Corp., U.S.A., Tel: +1.914.472.0531, www.texturetechnologies.com.

TA.XTPlus and TA.HDPlus texture analyzers are used for measuring the physical properties of materials and products important to the pharmaceutical industry. They provide extremely repeatable results for quantifying firmness, adhesiveness, disintegration, cohesiveness, swelling, and other physical properties of tablets, gels, microspheres, mucoadhesives, patches, creams, lotions, gel caps, syringability, and so on.

417

Vision Processing Technologies, Inc., U.S.A., +1.507-444-3957, www.vision-processing.com.

VPT is a US-based particle processing company with unmatched flexibility and scalability to meet the needs of our customers (large and small). We utilize a proprietary-designed fluid bed microencapsulation technology which offers cost-effective and materialefficient coating solutions. Our solutions are customized and defined through collaboration and partnership with our customers.

S

S

SOTAX Corporation, U.S.A., Tel: +1.508.417.1112, www.sotax.com. SOTAX is a leader in dissolution and drug release testing systems, content uniformity and assay workstations, and tablet testing instruments for the pharmaceutical industry. Specialists in USP Apparatus 4 flow through dissolution for in vitro drug release testing of novel dosage forms. SPS Pharma Services offers contract method development services.

503 Springer, U.S.A., Tel: +1.212.460.1600, www. springer.com. Springer is the proud publisher of Drug S Delivery and Translational Research, an official journal of CRS, as well as the book series Advances in Delivery Science and Technology, published in partnership with CRS. Please stop by our booth to say aloha to our friendly publisher, Carolyn Honour.

218

56

Southwest Research Institute, U.S.A., Tel: +1.210.522.2913, www.swri.org. SwRI® provides extensive contract R&D capabilities, including the development of custom encapsulation and controlled release formulations for applications ranging from pharmaceuticals to consumer and diversified products.

Capsules and particles can be prepared in sizes from nanometers to several millimeters. Biomaterials, materials development, synthesis, and modeling capabilities are also available.

CS

206

Wyatt Technology Corporation, U.S.A., Tel: +1.805.681.9009, www.wyatt.com. Wyatt Technology is the recognized leader in instrumentation for determining the absolute molar mass, size, charge, and interactions of macromolecules and nanoparticles in solution. These tools include in-line multiangle static light scattering, high-throughput dynamic light scattering, differential refractometry, electrophoretic mobility, differential viscosity, field flow fractionation, and automated composition gradient.

Sponsors of the 40th Annual Meeting & Exposition of CRS Sponsors Make It Happen

Many of the meeting events are possible only through the generosity of sponsors. Please join CRS in thanking our 2013 sponsors* who support delivery science and add substantial value to the CRS Annual Meeting & Exposition. *Sponsors as of June 7, 2013. Please see Program Addendum for additional sponsors.

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceuticals using 3M’s transdermal, microneedle, and inhalation drug delivery technology. In addition, 3M offers a full range of transdermal components as well as medical and specialty packaging films. Visit Booth 100 for more information. www.3M.com/DDS

Advanced Polymer Materials, Inc., is a Canada-based manufacturer with R&D capability, producing innovative, unique biodegradable and biocompatible polymers and block copolymers (mPEGs, functional PEGs, multi-arm PEGs, and functional PEG/PLA, PLGA, and PCL) to fill the need for scientific advancement in pharmacy, biomaterials, and functional nanoparticles. We do custom syntheses and contract research. www.apmpolymers.com

Research products available include biodegradable block and specialty copolymers (polyvivo), fluorescent dyes (FlammaFluor), specialty chitosan variations (Kitopure), and release media (polyvitro). Custom synthesis to match your specification and contract analysis services are also available.

Also available is scale-up, template-based microparticle manufacturing device (spinswiper) for quick generation of uniform microparticles. www.polyscitech.com

Science with a Purpose. Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease. www.alkermes.com

Aptalis Pharmaceutical Technologies is your trusted oral drug delivery partner for overcoming even the most demanding delivery challenges, using proprietary technologies and development expertise for bioavailability enhancement, custom release profiles, and taste-masking for a variety of dosage forms including orally disintegrating tablets, resulting in patientoptimized products. www.AptalisPharmaTech.com

Delivering pharmaceutical and nutraceutical performance since the 1950s, Ashland Specialty Ingredients, a commercial unit of Ashland Inc., provides solutions for applications in controlled release, solubilization, binders, film coatings, and disintegrants.

Ashland creates value for its customers through applications knowledge, market insight, regulatory support, and a powerful product portfolio. www.ashland.com

AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture, and market prescription medicines for six important areas of healthcare, including some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. We apply our scientific insight and expertise to finding breakthrough medicines. www.astrazeneca.com

Avanti Polar Lipids, Inc., world leader in pure lipid products for the research chemist since 1969. Now offering cGMP manufacturing of standard and proprietary lipid products and state-of-the-art lipid analysis. Our specialties include phospholipids, sphingolipids, sterols, detergents, acyl coenzyme A, lipid probes, fluorescent and bioactive lipids, antibodies, and Snoopers™. www.avantilipids.com 57

Sponsors BASF offers a range of innovative excipients, meeting market needs with ingredient solutions in the areas of solubilization, modified release, skin delivery, taste masking, and soft gels. BASF also supplies active ingredients and provides exclusive customer synthesis services. www.pharmaingredients.basf.com

Covaris provides advanced sample preparation systems for life and analytical science. Covaris supports formulation applications including nanosuspensions, nanoemulsions, crystallization, and liposome creation. AFA technology brings unsurpassed speed and efficiency to sample preparation. AFA is based on shock wave physics, delivering controlled, precise, and accurate acoustic energy to biological and chemical samples. www.covarisinc.com

Bend Research is a leading independent scientific development and manufacturing company. It has numerous capabilities to advance promising drug candidates from conception through commercialization. These include formulation and dosage-form support, process development and optimization, and cGMP manufacturing. It is a leader in novel drug-delivery technologies including spray-drying, hot-melt extrusion, and controlled release. www.bendresearch.com

Dissolution Technologies is a peer-reviewed, indexed quarterly journal reporting current information and scientific articles on dissolution testing. Books related to dissolution topics are available for sale on the searchable website, www. dissolutiontech.com. The website contains all back and current issues, and these articles are available for free as a PDF download.

From drug development services to delivery technologies and supply solutions, we are the catalyst for your success.

Catalent has the deepest expertise and the most innovative drug delivery technologies to enhance your product performance, including OSDrC® OptiDose™ optimized dosing, Zydis® fast-dissolve formulations, and OptiMelt™ hot melt extrusion. www.catalent.com

Diurnal applies advanced drug delivery solutions to approved drugs to address unmet patient needs. Diurnal’s lead product is Chronocort®—modified release hydrocortisone—a first-in-class circadian therapy to treat the orphan diseases congenital adrenal hyperplasia and adrenal insufficiency. Chronocort® is currently in Phase 2 clinical trials at the NIH (United States). www.diurnal.co.uk

Coating Place develops and manufactures modified release oral products. We are the leading provider of Wurster microencapsulation. Services include formulation development, technology transfer, scale-up, and commercial manufacturing.

We process solvent and aqueous formulations. We offer capsule filling, tablet compression, pan coating, extrusion spheronization, and nanomilling. Controlled substances schedule II–V. www.coatingplace.com

The Drug Delivery Partnerships conference is where the drug delivery community comes to learn where pharma companies are taking risks, strategize the best methods to close the gap between R&D and commercial, integrate drug delivery combination products into the over-arching drug delivery strategy and maximize the potential for payer reimbursement. www.drugdeliverypartnerships.com

Colorcon is a world leader in the development, supply, and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our value-added services, which support all phases of solid oral dose design and development. www.colorcon.com 58

Drug Development & Delivery is a print and digital publication exclusively committed to advancing the applied science, technology, and related business practices of pharmaceutical and biological drug development, including: • Drug Delivery Technologies • Controlled Release • Formulation Development • Bioavailability • Medical Devices/Combination products • Contract Services • Solubility Enhancement • Life-cycle management • Regulatory issues. www.drug-dev.com

Sponsors Elsevier publishes the Journal of Controlled Release, the official journal of the Controlled Release Society and the Japanese Society of Drug Delivery System. Elsevier is the leading publisher dedicated to providing authors the latest articles, tools, and resources within pharmaceutical sciences. www.elsevier.com.

EMD Millipore is the life science division of Merck KGaA. We provide excipients, ODT technology, drug delivery compounds, and chemicals to support all stages of drug manufacturing from research to industrial-scale production and quality control. Our products meet the highest purity standards, with extensive documentation and services assuring regulatory compliance. www.emdmillipore. com Fleet Laboratories, a familyowned company since its founding in 1869, develops, manufactures, and sells OTD, personal care, and dietary supplement products in over 80 countries around the world with emphasis on gastrointestinal health and feminine hygiene and health. Fleet also has offices in Singapore and Madrid, Spain, with R&D and manufacturing in Zaragoza, Spain. www.fleetlabs.com Gattefossé is a global provider of excipients and innovative formulation technologies for enhancing drug delivery. We offer unique solutions for solubilisation, permeation enhancement, sustained release, taste masking, and more. Our products are referenced as key components of many currently marketed oral, topical, vaginal, and rectal dosage forms. www.gattefosse.com

Hovione is a global company with over 50 years’ experience in API and drug product intermediate development and compliant manufacture. Hovione offers integrated API, innovative particle engineering technologies to solve problems such as poor bioavailability, patient acceptability, or enabling optimal delivery by non-oral routes of administration, formulation development, and manufacturing. www.hovione.com

Founded in 1984, JSDDS is composed of more than 1,000 clinical researchers, pharmacologists, and other scientists focused on drug delivery systems. The society’s goal is to share research and advance delivery science through annual meetings, The Journal of Drug Delivery System (DDS), and awards to recognize excellence. http:// square.umin.ac.jp/js-dds/

At the forefront of polymer production is LACTEL® Absorbable Polymers by DURECT Corporation, the first commercial, biodegradable polyesters in the U.S. For decades we have supplied GMP excipients world-wide for controlled release applications. At our new, state-of-the-art facility in Birmingham, Alabama we continue to pioneer commercialscale production of medical-grade polymers. www.absorbables. com/crs13

Lipoid is a manufacturer of pharmaceutical-grade phospholipids from three cGMP facilities based in Germany.

In addition to synthetic phospholipids used in controlled release, Lipoid produces parenteral, topical, and oral grade egg, soy, and rapeseed lecithin. Lipoid has over 40 Drug Master Files for excipients on file with the FDA. www.lipoid.com

Medimetrics offers IntelliCap, the world’s first intelligent electronic capsule for oral drug product development and therapy. Using this technology, drug product can be delivered to any desired location and rate into the GI tract. Clinical studies can be run almost anywhere with IntelliCap. www.medimetrics.com Merial is a world-leading, innovationdriven animal health company, providing a comprehensive range of products to enhance the health, well-being, and performance of a wide range of animals.

Merial employs approximately 6,000 people and operates in more than 150 countries worldwide. Its 2012 sales were €2.2 billion ($2.8 billion). Merial is a Sanofi company. For more information, please see www.merial.com.

59

Sponsors

Microtek leads the way in microencapsulation technologies. As a privately held company founded in 1985, we specialize in custom microencapsulation and product development services. From product conception, to process development, to full production, we strive to leverage our more than 100 years combined microencapsulation experience for the benefit of our clients. www.microteklabs.com Mylan Technologies Inc. (MTI) is a leading producer of transdermal drug delivery systems.

From design to commercial production, our manufacturing capabilities include formulation, coating, laminating, film extrusion, die cutting, and packaging. These capabilities allow production of transdermal drug delivery systems and precision components for medical device applications. www.mylantech.com The Nagai Foundation Tokyo was founded in 1986 in commemoration of Prof. Tsuneji Nagai receiving the 1986 Hoest-Madsen Medal from FIP as the first for the Japanese. Then the foundation was officially approved as government-licensed in 1994 for the purpose of promoting international exchange in pharmacy and pharmaceutical sciences. www.nagai-found.or.jp

Nisso America Inc. is a wholly owned subsidiary of Nippon Soda Co., Ltd. (Tokyo, Japan), manufacturers of Nisso HPC (hydroxypropyl cellulose). Nisso HPC is available in a wide range of viscosities including special low viscosity grades.

For wet/dry binding, sustained release matrix tablet, film coating, and dissolution enhancement applications. www.nissoexcipients.com.

Companies approach OctoPlus for our expertise in injectable drug delivery. We are a CDMO for formulation development, scale-up, and GMP manufacturing of any type of injectable drug product, microspheres (proprietary technology for proteins and PLGA), liposomes, high concentration proteins, peptides, nucleic acid derived compounds, etc., both liquid and freeze dried. www.octoplus.nl 60

Established now for eight years, ONdrugDelivery is the highly regarded, leading series of sponsored themed drug delivery publications. With content from world experts at leading companies—large and small—in the global drug delivery business, ONdrugDelivery is a must for those in the industry who need to know drug delivery. www.ondrugdelivery.com

Patheon is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for solid and sterile dosage forms.

Through the company’s recent acquisition of Banner Pharmacaps—a market leader in soft gelatin capsule technology—Patheon now also includes a proprietary products and technology business. www.patheon.com

Advancing Development & Manufacturing

PharmTech.com

Pharmaceutical Technology offers news, analysis, and peerreviewed research in formulation development (including excipients) and drug manufacturing to more than 38,000 decision-makers in the top pharmaceutical, specialty pharmaceutical, and biotechnology companies via the Pharmaceutical Technology print magazine, PharmTech.com, and three newsletters: ePT, Sourcing and Management, and the Equipment and Processing Report. www.pharmtech.com

PharmaCircle is an innovative knowledge management company providing detailed and comprehensive pharmaceutical information and analysis for research, development, and regulatory professionals. Custom databases and search engines provide online interactive access to company pipelines, products, detailed drug delivery analyses, patents, clinical trials, and much, much more. www.pharmacircle.com

Sponsors

The Ronald T. Dodge Company is a leader in the “innovative art & science of microencapsulation and controlled release.” We are a trusted quality source of encapsulated products for the diverse customer base we serve. Using creative encapsulation techniques, we provide microcapsule services for a wide variety of customer needs. www.rtdodge.com Simulations Plus’ GastroPlus™ sets the standard for PBPK/PD modeling for oral (immediate & controlled release formulations), intravenous, ocular, pulmonary, and inhalation delivery in human and animals, plus powerful IVIVC, virtual population simulations, and DDI capabilities.

DDDPlus™ offers the mechanistic simulation of in vitro dissolution experiments for different dosage forms and media. www.simulations-plus.com Sirius Analytical offers instrumentation and CRO services for pKa, logP/logD, Solubility, Dissolution, supersaturation & particle size/shape measurement and new instrumentation for Surface Dissolution Imaging for monitoring real-time drug release - revealing data at early stages of pre-formulation and development - allowing informed decisions to be made earlier in the drug development process. www.sirius-analytical.com

Skyepharma combines proven scientific expertise with validated proprietary technologies developing innovative oral and inhalation products. Customizable GeomatrixTM technology enables a variety of modified release profiles and is incorporated into 8 oral products available in over 80 markets. GeoclockTM allows time-delayed release or colonic delivery independent of pH or food. www.skyepharma.com

Springer is the proud publisher of Drug Delivery and Translational Research, an official journal of CRS, as well as the book series Advances in Delivery Science and Technology, published in partnership with CRS. Please stop by our booth to say aloha to our friendly publisher, Carolyn Honour. www.springer.com

TCI, a global technology and business consulting firm, serves the pharmaceutical, drug delivery, and OTC industries. TCI offers analysis-driven consulting in technology assessments, in- and out-licensing, business intelligence, market research, mergers and acquisitions, and other strategic business needs.

Reports on drug-device combinations, medical foods, probiotics, and ODTs and OTFs are available. www.technology-catalysts.com Upsher-Smith pursues drug therapies to improve lives.

Our company is driven by the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Focused on market expansion in women’s health, dermatology, cardiology, and in developing products for neurology, our perspective is not “more products” but the “right products” to improve lives. www.upsher-smith.com

VPT is a US-based particle processing company with unmatched flexibility and scalability to meet the needs of our customers (large and small). We utilize a proprietarydesigned fluid bed microencapsulation technology which offers cost-effective and material-efficient coating solutions. Our solutions are customized and defined through collaboration and partnership with our customers. www.vision-processing.com

SOTAX is a leader in dissolution and drug release testing systems, content uniformity and assay workstations, and tablet testing instruments for the pharmaceutical industry. Specialists in USP Apparatus 4 flow through dissolution for in vitro drug release testing of novel dosage forms. SPS Pharma Services offers contract method development services. www.sotax.com 61

Awards & Recognition Join Us in Celebrating Our Esteemed Colleagues The Controlled Release Society is proud to honor this year’s awardees for their dedication and contributions to delivery science and the CRS. Join us in honoring all stages of what it means to be a delivery scientist, from recognizing tomorrow’s leaders with the Postdoctoral Achievement Award or the CRS Foundation’s prestigious fellowship to celebrating the lifelong dedication of our newest inductees into the College of Fellows. Awards will be given at the opening session and the three plenary sessions.

See individual award times on the following pages.

Congratulations, 2013 CRS awardees!

Annual Meeting Program Committee

Thank you to the 2013 Annual Meeting Program Committee for their time and talents in planning this scientifically outstanding meeting.

With immense appreciation and sincere gratitude, we honor the following members of the Board of Directors for their leadership and service to CRS over the past years:

Chair Mark Saltzman, Yale University, U.S.A. Deputy Chair Ick Chan Kwon, KIST, Korea Members Marcel Bally, British Columbia Cancer Research Centre, Canada Marcus Brewster, Johnson & Johnson, Belgium Sarah Eccleston, Aptuit Ltd., United Kingdom Charles Frey, Coating Place Inc., U.S.A. Justin Hanes, Johns Hopkins University, U.S.A. Hideyoshi Harashima, Hokkaido University, Japan Nicole Papen-Botterhuis, TNO, The Netherlands Joshua Reineke, Wayne State University, U.S.A. Christian Seiler, Merck Sharp & Dohme, United Kingdom Special thanks and appreciation to the following members of the Board of Scientific Advisors who will be rotating off the committee for their service to CRS over the past three years:

Kenneth Howard Chair Aarhus University, Denmark

Aron Anderson U.S.A.

Padma Devarajan Institute of Chemical Technology, India

Dennis Discher University of Pennsylvania, U.S.A.

Christopher Porter Monash University, Australia

Roderick Walker Rhodes University, South Africa

62

Martyn C. Davies Immediate Past President University of Nottingham, United Kingdom

Tom Redelmeier Treasurer Northern Lipids Inc., Canada

Michael Rathbone Director-at-Large International Medical University, Malaysia

Distinguished Service Award Established in 1994, the Distinguished Service Award is presented to a CRS member who has exhibited exceptional commitment and service to the society and is selected by the Board of Directors.

Presentation: Opening Session, Monday, July 22 08:00 – 09:30 • 315 Mark A. Tracy is president of Tracy BioConsulting, LLC, a specialized biopharmaceutical consulting firm dedicated to helping clients transform research into new medicines. Dr. Tracy has played a key role in successfully bringing nine new medicines to the clinic, utilizing the latest advances in drug delivery technology, including several that were commercialized. He has played important roles in the development of technology platforms and product pipelines for Alkermes, Inc., and Alnylam, Inc., two leading biotechnology companies. He is a past president of the Controlled Release Society and a fellow of the American Institute for Medical and Biological Engineering (AIMBE).

College of Fellows The College of Fellows recognizes those members who have made outstanding contributions to the field of delivery science and technology over a minimum of 10 years. Contributions may have been technical, scientific, and/or managerial in one or more fields of research, commercial development, education, and/or leadership within the areas of interest to CRS. Fellowship is the most prestigious level of membership in CRS. Presentation: Opening Session, Monday, July 22 08:00 – 09:30 • 315 Ashutosh Chilkoti is the Theo Pilkington Chair in Biomedical Engineering and the director of the Center for Biologically Inspired Materials and Materials Systems at Duke University. His areas of research include biomolecular engineering, focusing on stimulus-responsive biopolymers for applications in protein purification and drug delivery, and biointerface science, focusing on the development of clinical diagnostics and plasmonic biosensors. He has coauthored over 200 publications, been cited around 11,000 times, has an H-index of 62, has 17 patents awarded and 31 in process, founded a start-up company, received numerous awards, and serves on the editorial boards of five journals.

Justin Hanes is the Lewis J. Ort Endowed Professor and director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine. He holds faculty appointments in biomedical engineering, chemical and biomolecular engineering, environmental health sciences, neurosurgery, oncology, and ophthalmology. He directs a research program at the interface of nanotechnology, biomaterials, bioengineering, drug delivery, and translational medicine at Johns Hopkins. Justin received a B.S. in chemical engineering from UCLA in 1991 and a Ph.D. in chemical engineering from MIT in 1996. He did postdoctoral training in oncology and neurosurgery at Johns Hopkins in 1996–1998.

Hideyoshi Harashima is a professor of pharmaceutics and the chair of the Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Japan (since 1999). He received his Ph.D. from the University of Tokyo in 1987. After postdoctoral training at Stanford University, U.S.A., he became an associate professor at the Faculty of Pharmaceutical Sciences, University of Tokushima. He serves as an associate editor of the Journal of Controlled Release and as an executive editor of Advanced Drug Delivery Reviews. He is president of the Academy of Pharmaceutical Science and Technology of Japan (APSTJ, 2012–present).

Claus-Michael Lehr, a professor at Saarland University, is cofounder and head of the Drug Delivery department at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). HIPS is Germany’s first permanent public research institute for pharmaceutical research. Prof.

Lehr also cofounded Across Barriers and PharmBioTec, providing R&D services to the pharmaceutical industry.

For the past 15 years, Prof. Lehr’s team has focused on exploring the biological barriers of the gastrointestinal tract, skin, and lungs, in particular through cell- and tissue-based in vitro models and novel carrier technologies capable of crossing these epithelial barriers and delivering the active molecule to the target.

Ijeoma F. Uchegbu is cofounder and chief scientific officer of Nanomerics, a spin-off company from University College London (UCL), United Kingdom. Nanomerics (www.nanomerics.com) is a specialty pharmaceutical company with a nanoenabled pain therapeutic in development. Ijeoma is also a professor of pharmaceutical nanoscience at UCL, and her research has provided insights into nanoparticle design for peptide brain delivery, gene delivery to tumors, and hydropbobic drug delivery.

Ijeoma has been awarded the 2007 U.K. Department for Business Innovation Skills’s Women of Outstanding Achievement in Science Engineering and Technology award and the Royal Pharmaceutical Society’s Pharmaceutical Scientist of the Year 2012 award.

The College of Fellows panel discussion will take place during the Opening Session. The panel will discuss “Global Collaboration in Delivery Science” moderated by College of Fellows member Clive Wilson, featuring a distinguished panel of leaders in delivery science and technology. This College of Fellows panel is considering global collaboration in delivery science and the ways in which technology or culture facilitates or interferes with progress. Learning to function together in ever bigger teams in an efficient way will be important in the future.

College of Fellows Panel Discussion: Global Collaboration in Delivery Science Moderator: Clive Wilson, University of Strathclyde, United Kingdom Panelists: Diane Burgess, University of Connecticut, U.S.A. David Friend, CONRAD, U.S.A. Kazunori Kataoka, University of Tokyo, Japan

63

Founders Award The society grants this honor to a current CRS member who is internationally recognized for outstanding contributions in the science and technology of controlled release.

Presentation: Opening Session, Monday, July 22 08:00 – 09:30 • 315 Award Lecture: Skin—The Finest Clothing Made Richard Guy received an M.A. in chemistry from Oxford University and his Ph.D. in pharmaceutical chemistry from the University of London. He is currently a professor of pharmaceutical sciences at the University of Bath, having previously held academic posts at the Universities of California (UCSF) and Geneva.

Dr. Guy’s research has focused on skin barrier function characterization, transdermal drug delivery, enhancement of percutaneous absorption, iontophoresis, noninvasive biosensing, and the prediction and assessment of skin penetration and topical bioavailability. Dr. Guy has published 300+ peerreviewed articles and is coinventor of several issued patents.

Young Investigator Award Cosponsored by Aptalis Pharmaceutical Technologies This award recognizes a CRS member, age 40 years or younger on December 31 of the current year, who has made outstanding contributions in the science of controlled release.

Presentation: Opening Session, Monday, July 22 08:00 – 09:30 • 315 Award Lecture: Microfabricated Hydrogels and Controlled Release Technology for Tissue Engineering Ali Khademhosseini is an associate professor of medicine and health sciences and technology at HarvardMIT’s Division of Health Sciences and Technology and Harvard Medical School and associate faculty at the Wyss Institute.

He is developing micro- and nanoscale technologies to control cellular behavior for tissue engineering and drug delivery applications. He has published over 220 peer-reviewed papers and 160 abstracts.

He has received numerous awards, including the NSF Career, PECASE, ONR Young Investigator, Colburn, Y. C. Fung, IEEE EMBS, and IEEE Nanotechnology awards. He received his Ph.D. in bioengineering from MIT and his master’s and bachelor’s degrees from University of Toronto, both in chemical engineering.

64

CRS/T. Nagai Postdoctoral Research Achievement Award Cosponsored by The Nagai Foundation Tokyo This award recognizes an individual postdoc who has recently completed postdoctoral research in controlled release science and technology and the postdoc’s advisor, who played an integral role in the achievements.

Presentation: Opening Session, Monday, July 22 08:00 – 09:30 • 315 Shawn C. Owen is currently a postdoctoral fellow at the University of Toronto in Prof.

Molly S. Shoichet’s laboratory. He received a B.S. in biochemistry, B.A. in Chinese, and Ph.D. in pharmaceutics and pharmaceutical chemistry at the University of Utah, where he was a Novartis fellow and recipient of the Wolf Prize for Excellence in Teaching.

His current research interests include the development of biomaterial scaffolds for in vitro cancer models and interaction and intracellular trafficking of colloids, polymeric micelles, and antibody–drug conjugates.

Molly Shoichet holds the Tier 1 Canada Research Chair in Tissue Engineering and is a professor in three departments at the University of Toronto: Chemical Engineering and Applied Chemistry, Chemistry, and Biomaterials and Biomedical Engineering. An expert in the study of polymers for drug delivery and regeneration, she has published over 450 papers, patents, and abstracts and has given over 275 lectures worldwide. She leads a laboratory of 25 researchers and has graduated 115 researchers over the past 18 years. She founded two spin-off companies from research in her laboratory and is actively engaged in translational research.

She has received numerous prestigious awards.

CRS Foundation CRS Foundation fellowships are designed to identify and acknowledge the next leaders of CRS. By providing a catalytic amount of funding from generous individual and corporate contributions, as well as recognition from the CRS Foundation, the goal is to accelerate those candidates in their careers in delivery science and to create a long-term home for them within CRS. Created to honor individuals who have made notable contributions to CRS by supporting the scientific training of future leadership, the awards are given to individuals who demonstrate scientific excellence, scholarship, motivation, and leadership potential.

Sung Wan Kim Postdoctoral Fellowship 2012: A Year in Review The CRS Foundation welcomes back 2012 fellowship awardee Tram Dang to highlight her work over the past year, made possible by the Sung Wan Kim Postdoctoral Fellowship. Dang will provide a brief summary presentation regarding her fellowship year as part of the Monday afternoon plenary session.

Presentation: Plenary Session, Monday, July 22 Engineering Inflammation – Responsive Materials for Drug Delivery in Wound Dressing 13:30 – 14:45 • 315 Tram Dang received her Ph.D. in chemical engineering in the laboratories of Prof.

Robert Langer and Prof. Daniel G. Anderson at the Massachusetts Institute of Technology, with a minor in business management. Dr. Dang developed new noninvasive imaging techniques to assess and understand the effects of controlled release anti-inflammatory drugs on the immunological response to biomaterials in rodent models and pioneered the development of new glucose-responsive biomaterials as well as innovative microfabrication methods for tissue engineering and controlled drug delivery. In her postdoctoral appointment in the laboratory of Professor Ali Khademhosseini at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Dang works in collaboration with teams from Tufts and Purdue universities. Her role focuses on the development of an intelligent anti-inflammatory drug delivery approach for integration into a smart wound-dressing platform embedded with microelectronics and an array of physical, chemical, and biological modules capable of sensing and active intervention in the wound microenvironment.

FOUNDATION

The CRS Foundation thanks individual and corporate donors for making the postdoctoral fellowship program possible.

Jorge Heller Journal of Controlled Release Outstanding Paper Award Cosponsored by Elsevier This award recognizes an outstanding regular paper related to the science of controlled release (not an invited, review, or special meeting paper) that was published during 2012 in the Journal of Controlled Release.

Presentation: Plenary Session, Tuesday, July 23 08:00 – 09:30 • 315 Sungho Jin received his Ph.D. in materials science from the University of California, Berkeley, U.S.A., in 1974. After a career at Bell Labs, he joined UC San Diego in 2002. A distinguished professor, he serves as director of the Materials Science and Engineering Program. His research activities include biomaterials, nanomaterials, energy materials, and magnetic and electronic materials. He has around 350 publications and 200 patents and is a member of the U.S. National Academy of Engineering.

Magnetic Targeting of Nanoparticles Across the Intact Blood-brain Barrier Journal of Controlled Release 164(1): 49-57 (2012) Seong Deok Kong, Jisook Lee, Srinivasan Ramachandran, Brian P. Eliceiri, Veronica I. Shubayev, Ratnesh Lal, and Sungho Jin

Drug Delivery and Translational Research Outstanding Paper Award Cosponsored by Springer This award recognizes outstanding research in the field of drug delivery and translational research that was published during 2012 in Drug Delivery and Translational Research.

Presentation: Plenary Session, Tuesday, July 23 08:00 – 09:30 • 315 Xiao Yu (Shirley) Wu received her Ph.D. in chemical engineering from McMaster University, Canada. After a postdoctoral fellowship at the University of Toronto, she joined the Faculty of Pharmacy. Her research interests include novel nanomedicine for enhanced therapy of multidrug-resistant and metastatic cancer, multifunctional polymers and nanocomposites for theranostics and CNS drug delivery, closed-loop insulin delivery, mechanism of controlled drug release and excipient–drug interactions, and mathematical modeling and computer-aided design of controlled release dosage forms. Dr. Wu and coworkers have published over 300 papers, book chapters, proceedings, and abstracts and hold 16 issued or pending patents.

Evaluation of New Bi-functional Terpolymeric Nanoparticles for Simultaneous In Vivo Optical Imaging and Chemotherapy of Breast Cancer Drug Delivery and Translational Research 6: 437-453 (2012) Alireza Shalviri, Ping Cai, Andrew M. Rauth, Jeffery T. Henderson, and Xiao Yu Wu 65

Outstanding Chapter of the Year Award

Outstanding Pharmaceutical Paper Award

The CRS Chapter of the Year Award recognizes a local chapter that has provided exceptional service to its members and to the Controlled Release Society. The award will be presented during the Tuesday morning plenary session to the chapter that has best met these criteria.

Cosponsored by PharmaCircle

Presentation: Plenary Session, Tuesday, July 23 08:00 – 09:30 • 315 2013 CRS Outstanding Local Chapter of the Year: United Kingdom-Ireland Local Chapter This chapter was chosen for its balanced, comprehensive events providing exceptional value to its members, as well as for its consistent commitment to sharing information with the CRS membership. Congratulations to this outstanding chapter.

Outstanding Annual Meeting Abstract Paper Awards Presentation: Plenary Session, Wednesday, July 24 09:45 – 11:00 • 315

Outstanding Oral Drug Delivery Paper Award Cosponsored by Patheon This award recognizes a CRS member whose winning abstract relates specifically to oral drug delivery.

Comparison of Alkyl Ester Versus Triglyceride Mimetic Lipid Prodrug Strategies to Target a Model Immunomodulator to the Lymphatic System Presenting author: Sifei Han, Monash University, Australia.

Coauthors: Tim Quach, Luojuan Hu, Anisa Wahab, William Charman, Valentino Stella, Natalie Trevaskis, Jamie Simpson, and Christopher Porter.

Author present: Poster Session 2, #166 Sifei Han, after completing his undergraduate study at Nanjing University (2006) and master’s study at the Chinese Academy of Sciences (2009), relocated to Australia in 2010 for Ph.D. training at Monash Institute of Pharmaceutical Sciences in Melbourne. His current research focuses on using lipid-mimetic prodrug strategies to enhance (up to 100-fold) targeted delivery of immunomodulatory drugs to their target site, the lymphatics, in an attempt to improve treatment of conditions such as autoimmune diseases in which the lymphatic system is closely involved. Mechanistic studies from his project have confirmed sequential prodrug metabolic pathways, providing informative insights for lymphotropic drug design.

66

This award recognizes a CRS member whose winning abstract relates specifically to pharmaceutical research.

Camouflaged and Thrombin-triggered Delivery of Tissue Plasminogen Activator for Targeted Thrombolysis Presenting author: Shahriar Absar, Texas Technical University, U.S.A. Coauthor: Fakhrul Ahsan.

Author present: Poster Session 2, #587 Shahriar Absar is a Ph.D. candidate in pharmaceutical sciences in Dr. Fakhrul Ahsan’s lab at Texas Tech University Health Sciences Center (TTUHSC), U.S.A. He obtained his bachelor and master of pharmacy degrees from the University of Dhaka, Bangladesh. Since joining TTUHSC in 2009, he has been working on the development of triggered-release drug delivery systems.

He also received training in pulmonary drug delivery and in pharmacokinetic and pharmacodynamic modeling. His doctoral research has been published in the Journal of Controlled Release, Pharmaceutical Research, and Thrombosis Research. He has been recognized as a dean’s scholar at TTUHSC School of Pharmacy.

Outstanding Preclinical Sciences & Animal Health Paper Award Cosponsored by Akina Inc., PolySciTech Division This award recognizes a CRS member whose winning abstract relates specifically to preclinical sciences and animal health research.

In Vitro Drug Release and In Vivo Tumor Delivery of NearInfrared Emissive Biodegradable Polymersomes Containing Poly(ethylene glycol) and Randomized Poly(trimethylene carbonateco-caprolactone) Presenting author: Christina Hofmann, Duke University, U.S.A. Coauthors: W. Qi, C. D. Landon, M. J. Therien, M. W. Dewhirst, and G. M. Palmer.

Author present: Poster Session 1, #227 Christina Lehmkuhl Hofmann received her B.S. (2006) and M.S. (2007) from Case Western Reserve University, U.S.A., in biomedical engineering, focusing on polymer biomaterials. After graduation, she worked as a scientist at Ferro Corporation, engineering drug delivery formulations.

Christina then joined the Cleveland Clinic as a research engineer in the Renal Nanotechnology Laboratory. She returned to school in 2009 to pursue her Ph.D. in biomedical engineering from Duke University, where she received a fellowship from the Center for Biomolecular and Tissue Engineering. She currently works under Drs. Mark Dewhirst and Greg Palmer, studying near-infrared imaging and delivery of therapeutics for cancer theranostics.

Outstanding Transdermal Drug Delivery Paper Award Cosponsored by 3M Drug Delivery Systems This award recognizes a CRS member whose winning abstract relates specifically to transdermal drug delivery research.

Honoring CRS Leaders Past, Present, and Future

Rapidly-Dissolvable Microneedles for Transdermal Delivery via a Highly Reproducible Soft Lithography Approach

“The Sung Wan Kim Postdoctoral Fellowship has given me the wonderful opportunity to freely explore different aspects of a new field of study.”

Presenting author: Katherine A. Moga, University of North Carolina, U.S.A. Coauthors: Lissett Bickford, Robert Geil, Stuart Dunn, Ashish Pandya, Yapei Wang, John Fain, Christine Archuleta, Adrian O’Neill, and Joseph DeSimone.

Author present: Poster Session 1, #919 Katherine A. Moga received a B.S. in chemistry and a B.S.Ed. in secondary education from Ashland University in Ashland, Ohio, U.S.A. She currently attends the University of North Carolina at Chapel Hill and is a third-year doctoral student pursuing a Ph.D. in analytical chemistry.

Katherine works in the laboratory of Joseph M. DeSimone, a chemist and entrepreneur responsible for inventing the Particle Replication In Non-wetting Templates (PRINT®) technology. Her work focuses on the development of microneedle devices for the transdermal delivery of therapeutics via the PRINT process.

Tram Dang

You’re Invited Join us Monday, July 22, in Honolulu, Hawaii, prior to the CRS Annual Meeting Plenary Session to hear Sung Wan Kim Postdoctoral Fellowship 2012 awardee Tram Dang discuss her postdoctoral appointment in the laboratory of Prof. Ali Khademhosseini at the Brigham and Women’s Hospital and the Harvard Medical School. The fellowship honors Professor Kim for his CRS leadership and pioneering research in delivery science.

Sung Wan Kim Postdoctoral Fellowship 2012: A Year in Review Engineering Inflammation – Responsive Materials for Drug Delivery in Wound Dressing Monday, July 22 13:30 – 13:45 • Room 315

Give It Forward You can help support excellence in delivery science through your support of the CRS Foundation.

Donations can be made online at controlledreleasesociety.org/about/foundation

In 2007 CRS established the CRS Foundation, a 501(c)(3) educational endowment, to honor individuals who have made notable contributions to the society and its technologies and to support the scientific training of its future leadership.

FOUNDATION

67

Acknowledgements Volunteers Make It Happen

From annual meeting program planning to specialized committees providing leadership and oversight on everything from awards to webinars, CRS volunteers are the engines that drive our society forward. In return, they gain valuable experiences, professional connections, and the knowledge that they have made a real difference in their careers and in their profession. Thank you to the many volunteers listed here who have served CRS during the past year.

CRS Board of Directors

Board of Scientific Advisors Director-at-Large: Christine J. Allen University of Toronto, Canada

President: Kazunori Kataoka University of Tokyo, Japan President-Elect: Ian G. Tucker University of Otago, New Zealand

Director-at-Large: Marcus E. Brewster Johnson & Johnson, Belguim

Immediate Past President: Martyn C. Davies University of Nottingham, United Kingdom

Director-at-Large: Andrew L. Lewis Ipsen, France

Treasurer: Tom E. Redelmeier Northern Lipids Inc., Canada

Director-at-Large: Tamara Minko Rutgers University, U.S.A. Director-at-Large: Yvonne Perrie Aston University, United Kingdom

Secretary: Ruth B. Schmid SINTEF, Norway

2013 Annual Meeting Program Committee Chair: W. Mark Saltzman.

Deputy Chair: Ick Chan Kwon. Members: Marcel B. Bally, Marcus E. Brewster, Sarah J. Eccleston, Charles R. Frey, Justin S. Hanes, Hideyoshi Harashima, Nicole Papen-Botterhuis, Joshua J. Reineke, Christian Seiler.

2014 Annual Meeting Program Committee Chair: Ick Chan Kwon.

Deputy Chair: Justin S. Hanes. Members: You Han Bae, Donald Barbieri, Ben J. Boyd, Peter Cheifetz, Samir Mitragotri, Ruth B. Schmid, Hardik Shah, Ronald L. Smith, Geert Verreck, Fanwen Zeng.

68

Director-at-Large: Michael J. Rathbone International Medical University, Malaysia Chapter Committee Chair: Paolo Caliceti. Deputy Chair: Claudio Ortiz.

Australia President: Ben J. Boyd. Canada President: Michael Doschak. China President: Zhirong Zhang.

Taiwan President: MingThau Sheu. Germany President: Martin Bultmann.

Greece President: Panos Macheras. India President: Amarjit Singh. Israel President: Ronit SatchiFainaro. Italy President: Paolo Caliceti. New Zealand President: Arlene McDowell.

Nordic President: Ingunn Tho. Spain-Portugal President: Maria J. Vicent.

Turkey President: Yildiz Ozsoy-Erginer. United Kingdom-Ireland President: Woei Ping Cheng.

Connecticut Student President: Keshia Ashe. The Hebrew Univ. of Jerusalem Chair: Gadi Cohen. Illinois Student President: Mary Tang. New Jersey Student President: Tannaz Ramezanli.

Chair: Kenneth A. Howard Deputy Chair: Ben J. Boyd Members: Theresa M. Allen, Maria Jose Alonso, Mansoor M. Amiji, Aron B. Anderson, Padma V. Devarajan, Dennis Discher, Justin S. Hanes, Leaf Huang, Edith Mathiowitz, Christopher J. H. Porter, Pavla Simerska, Gert Storm, Ernst Wagner, Roderick B. Walker.

Ex-officio: Christine J. Allen

College of Fellows Selection Committee Chair: Gary W. Cleary.

Members: Susan M. Cady, Alexander T. Florence, Lisbeth Illum, Jindrich Kopecek, Teruo Okano, Vladimir P. Torchilin.

Consumer and Diversified Products Division Committee Chair: Nicole PapenBotterhuis. Deputy Chair: Christopher W. McDaniel.

Secretary: Jei C. McKinney.

Members: Ahmad Akashe, Christophe J. Barbe, Igor Bodnar, Craig R. Bunt, Kenneth H. Carson, Douglas A. Dale, Jiten O. Dihora, Howard Epstein, Charles R. Frey, Irwin C. Jacobs, Jamileh M. Lakkis, Jean-Antoine Meiners, Claudio Ortiz, James D. Oxley, James S. Paik, Bhaumik T. Patel, Rufino Perez, Omathanu P. Perumal, Paul H. Richardson, Ruth B. Schmid, Robert Hans Tromp, Ronald J. Versic, Teresa

Virgallito, Michael Yan, Fanwen Zeng.

CRS Foundation Chair: Randall J. Mrsny.

Members: Susan M. Cady, Richard H. Guy, Robert Langer, Tsuneji Nagai, Kinam Park, Arthur J. Tipton. Exofficio: Yvonne Perrie.

CRS Founders Award Chair: Yechezkel Barenholz.

Members: Diane J. Burgess, Vladimir P. Torchilin.

CRS Journal of Controlled Release Best Paper Award Chair: Juergen Siepmann.

Deputy Chair: Thomas Rades. Members: Theresa M. Allen, Carmen AlvarezLorenzo, Abdul W. Basit, Smadar Cohen, Paolo Colombo, Elias Fattal, Ram I. Mahato, Ravi Kumar N. V. Majeti, Daniel W. Pack, Yvonne Perrie, Veronique Preat, David A. Putnam, Garnpimol C. Ritthidej.

CRS Outstanding Oral Drug Delivery Best Paper Award Members: Carla M. Caramella, Woei Ping Cheng, Xiu Xiu Cheng, Sonke Svenson, Peter Timmins.

CRS Outstanding Pharmaceutical Paper Award Members: Vasily V. Belov, Glen S. Kwon, Patrick J. Sinko.

CRS Outstanding Preclinical Sciences & Animal Health Best Paper Award Chair: Michael J. Rathbone.

Members: David J. Brayden, Peter Cheifetz, Mark G. Papich, Sevda Senel.

CRS Outstanding Transdermal Drug Delivery Paper Award Chair: Vinod D. Labhasetwar.

Members: Ajay K. Banga, Richard H. Guy, Jared C. Hahn, Kentaro Kogure.

CRS T. Nagai Postdoctoral Research Achievement Award Chair: Stefaan De Smedt.

Members: Camilla Foged, Hideyoshi Harashima, Ick Chan Kwon, Ernst Wagner.

CRS Women in Delivery Science Task Force Chair: Diane J. Burgess.

Members: Theresa M. Allen, Debra J. Bingham, Susan M. Cady, Shivani Chilampalli, Padma V. Devarajan, Jamileh M. Lakkis, Weiyue Lu, Barbara Lueckel, Marilyn N. Martinez, Ndidi C. Ngwuluka, Jun Pan, Nicole PapenBotterhuis, Julia E. RashbaStep, Louise RosenmayrTempleton, Jie Shen, MingThau Sheu, Kailas Thakker, Ae-June Wang, Elizabeth Wen. Ex-officio: Christine J. Allen, Tamara Minko, Yvonne Perrie, Ruth B. Schmid.

CRS Young Investigator Award Chair: Steven P. Schwendeman. Members: Joke A. Bouwstra, Alexander V. Kabanov, Claus-Michael Lehr, Kam W. Leong, JeanChristophe Leroux, Samir Mitragotri, Kinam Park, Mark R. Prausnitz, Molly M. Stevens.

DDTR Outstanding Research Paper Selection Committee Chair: Vinod D. Labhasetwar.

Members: Franco Alhaique, Sing Yian Chew, Padma V. Devarajan, David R. Friend, Natalie Medlicott, V. Prasad R. Shastri, Elka Touitou.

Drug Delivery and Translational Research Editorial Board Editor-in-Chief: Vinod D. Labhasetwar. Associate Editors: Martyn C. Davies, Kensuke Egashira, Justin S. Hanes. Editors: Aron B. Anderson, Rinti Banerjee, Raymond T. Bartus, Jayesh Bellare, Diane J. Burgess, Perry Calias, Sing Yian Chew, Mark Davis, Kenneth A. Dawson, Farid A. Dorkoosh, Elazer R. Edelman, Pierandrea Esposito, David R. Friend, Rogerio S. Gaspar, Kenneth A. Howard, Jeffrey A. Hubbell, Lisbeth Illum, Mansoor A. Khan, Robert Levy, Weiyue Lu, David M. Lynn, Natalie Medlicott, Tamara Minko, Samir Mitragotri, Tetsuya Ohtaki, Kinam Park, Mark R. Prausnitz, Suzie Pun, Michael J. Rathbone, Lonnie D. Shea, Patrick J. Sinko, Thomas R. Tice, Elka Touitou, Ijeoma Uchegbu, Xiao Yu Wu, Qiang Zhang.

Finance Committee Chair: Tom E. Redelmeier.

Members: Debra J. Bingham, Marcus E. Brewster, Christopher W. McDaniel, Martha Sloboda, Patrick A. Walters.

Marketing Committee Chair: Sarah L. Reiver.

Members: Robert Bloder, Joseph A. Fix, Izabela Galeska, Jei C. McKinney. Ex-officio: Andrew L. Lewis, Tom E. Redelmeier.

Membership & Development Committee Chair: Teresa Virgallito.

Deputy Chair: Kenneth J. Miller. Members: Prajakta Dandekar-Jain, Ratnesh Jain, Bhaumik T. Patel.

Nanomedicine Focus Group Chair: Christine J. Allen.

Deputy Chair: Marcel B. Bally. Member: Dusica Maysinger.

Newsletter Committee Chair: Yvonne Perrie.

Members: Charles R. Frey, Steven A. Giannos, Arlene McDowell, Bozena B. Michniak-Kohn, Roderick B. Walker.

Nominating Committee Chair: Martyn C. Davies.

Members: Theresa M. Allen, David J. Brayden, Irwin C. Jacobs, Marilyn N. Martinez, Julia E. Rashba-Step, Ronald A. Siegel, Ian G. Tucker.

Ocular Drug Delivery Focus Group Chair: Ruiwen Shi. Deputy Chair: Clive G. Wilson.

Oral Drug Delivery Focus Group Chair: Ali Rajabi-Siahboomi.

Deputy Chair: Sarah J. Eccleston.

Preclinical Sciences & Animal Health Division Committee Cochairs: Marilyn N. Martinez, Michael J. Rathbone. Deputy Chair: Peter Cheifetz. Members: Terry L. Bowersock, David J. Brayden, Cyril Desevaux, Praveen S. Hiremath, Sarah M. Hook, Tim McCaffery,

Barry D. Moore, Anette Müllertz, Sevda Senel, Thierry Vandamme.

Satellite Meeting Committee Chair: James D. Oxley.

Members: Marcus E. Brewster, Martyn C. Davies, Christopher W. McDaniel.

Website Committee Chair: Biana Godin Vilentchouk. Deputy Chair: Hardik Shah. Members: Jake E. Barralet, Diana Samuel, Xiaoming Xu. Ex-officio: Tamara Minko.

Young Scientist Committee Chair: Ron Ortiz. Deputy Chair: Joshua J. Reineke. Past Chair: Louise RosenmayrTempleton. Members: Raid G. Alany, Ranjith Kumar Averineni, Adam Bohr, David Chen, Tram Dang, Kaushalkumar Dave, Padma V. Devarajan, Farid A. Dorkoosh, Jeff James, Sunny Kumar, Patrick Lim Soo, Amrita Mehta, Rafi Mohammad, Giorgia Pastorin, Michael J. Rathbone, Dody L. Reimer, Hardik Shah, Pirthi Pal Singh, Soren H. Welling, Zimei Wu, Sara Yazdi. Exofficio: Ruth B. Schmid.

AMPC Liaison: Sarah J. Eccleston.

Young Scientist Mentorship/Protégé Subcommittee Chair: Pirthi Pal Singh.

Deputy Chair: Patrick Lim Soo. Past Chair: Padma V. Devarajan. Members: Adam Bohr, Amrita Mehta, Michael J. Rathbone, Soren H. Welling.

69

2013 CRS Presenting Author Index Abstract authors named as the presenting author for a particular abstract can be found in the index below. To search all authors of an abstract, please use the CRS Mobile App, CRS website, or abstract printing station.

Abdelbary, A.......................... 481 Abedin. Dorkoosh, F.............152, 274 Abhari, R................................. 39 Absar, S.................................. 587 Acharya, S............................. 181 Agarwal, R............................. 398 Agato, Y................................. 129 Ahrens, L............................... 611 Akagi, T..........................269, 625 Akala, E................................. 407 Akao, C................................. 789 Akhter, A............................... 265 Akita, H................................. 712 Akiyoshi, K............................ 174 Albekairi, N........................... 540 Albertini, B............................ 507 Alhaider, I.............................. 404 Al-Kinani, A........... 195, 366, 699 Allen, C................................... 32 Alm, M.................................. 568 Altintas, I............................... 360 Amidi, M..........................31, 272 Anastasiadis, P....................... 257 Andersson, H........................... 87 Ando, H................................. 733 Anraku, Y.............................. 598 Aoyama, M............................ 333 Arima, H............................... 384 Aryal, S.................................. 348 Asayama, S............................ 775 Atwe, S.................................. 615 Baek, J.............................299, 888 Bahnsen, J.............................. 590 Barata, T................................ 646 Barnes, T............................... 477 Bar-Shalom, D........................ 56 Becker, D............................... 105 Bell, R.................................... 179 Bergstrรถm, C..................141, 824 Bernardi, D............................ 927 Beyer, S.................................. 383 Bhatia, G............................... 895 Bhujbal, P.............................. 600 Bi, V...................................... 823 Boegh, M............................... 508 Bohr, A.................................. 379 Bolko, K................................. 842 Boone, C.................................. 75 Borgheti-Cardoso, L............. 768 Bork, O.................................... 81 Boyd, B.............................66, 844 Bradbury, M............................ 98 Brewster, M....................450, 484 Bunt, C.............................82, 431 Burgess, D............................. 298 Burmester, M......................... 704 Burnett, D.............. 672, 689, 846 Caffarel-Salvador, E.......889, 907 Cai, B..................................... 214 Cai, F..................................... 684

70

Caldwell, W........................... 501 Campos, P............................. 874 Capece, M............................... 85 Carmali, S.............................. 628 Carvalho, E............................ 663 Chang, C............................... 722 Chang, L............................... 860 Chapman, A...................184, 933 Chaubal, M............................ 533 Chen, C................................... 53 Chen, K................................. 509 Chen, X................................. 403 Chen, Y................................. 610 Cheng, W.............................. 368 Chiang, C.............................. 344 Chiang, W............................. 254 Chirra Dinakar, H................. 457 Chiu, H................................. 243 Chiu, J................................... 322 Cho, C..............................84, 801 Cho, H................................... 206 Cho, H................................... 246 Cho, H................................... 744 Cho, J..................................... 552 Choi, D...........................103, 463 Choi, J................................... 916 Choi, S................................... 572 Choi, Y.................................. 661 Chokshi, R......................438, 459 Chu, D............................131, 599 Chu, M.................................. 635 Chuanoi, S............................. 786 Clark, A................................. 652 Clark, J..................................... 44 Coleman, J............................. 848 Corbett, D............................. 180 Cornejo-Bravo, J.................... 413 Cui, L.................................... 212 Dadparvar, M........................ 258 Dall, O................................... 470 Darkwa, J................................. 57 Darville, N............................. 551 Das, M................................... 165 Dave, K.................................. 914 Decuzzi, P............................. 236 Desai, D................................. 295 Di Maio, S............................. 517 Dickerson, M......................... 294 Dihora, J................................ 106 Ding, J................................... 399 Do, D..................................... 451 Dodapaneni, B....................... 528 Dohmeier, D............................ 63 Dorkoosh, F........... 146, 157, 387, 522 Draheim, C............................ 673 Du Plessis, J........................... 926 Duan, S.................................... 17 Dufes, C................................ 818 Dumbauld, D........................ 563 Duvall, C........................626, 820

Dyrli, A................................... 59 Ebara, M............................... 123 Eetezadi, S............................. 235 Eloy, J.................................... 300 Engels, S................................ 432 Enlow, E................................ 696 Eom, H.................................. 644 Es Sabar, K................................ 6 Evangelopoulos, M.........278, 428 Evenbratt, H.......................... 910 Fahmy, T.................................. 60 Fang, J.................................... 711 Fang, Z.................................. 251 Farah, S.................................. 188 Feeney, O............................... 836 Ferber, S................................. 573 Ferrati, S................................ 543 Fetherston, S............................ 48 Fischer, K............................... 583 Florinas, S.............................. 800 Forte, A................................. 108 Frey , C.................................. 934 Freyman, T.............................. 91 Fu, L...................................... 882 Fujita, R................................. 317 Gรฅrdebjer, S........................... 125 Ge, X..................................... 808 Gerber, M.............................. 880 Gill, H..................................... 97 Giorgio, T.............................. 313 Goharzadeh, M..................... 489 Gokhale, A............. 434, 465, 466 Goto, A.................................. 304 Grapentin, C......................... 268 Grattoni, A............................ 544 Green, J................................. 100 Greene, M............................. 400 Greish, K............................... 292 Griffin, P................................... 8 Griffiths, D............................ 253 Gu, Z..................................... 202 Gugulothu, D........................ 142 Guillot, A.............................. 352 Gujrati, M............................. 742 Gunatillake, P........................ 793 Gupta, S................................ 679 Gupta, U................................ 776 Hahn, S................................... 74 Hama, S................................. 305 Hammarlund-Udenaes, M...... 24 Hampp, N................................ 96 Han, H.................................. 396 Han, M.................................. 905 Han, S................................... 166 Harada-Shiba, M.................. 694 Harsha, S............................... 404 Hasegawa, U.......................... 421 Hashimoto, Y........................ 397 Hass, M................................. 923 Hatakeyama, H...................... 736 Hathi, D................................ 922

Hayashi, Y............................. 735 Hazekawa, M........................ 574 He, C..................................... 549 He, Q..................................... 287 Higashi, T.............................. 245 Higuchi, Y............................. 222 Hikima, T.............................. 915 Hill, B...................................... 88 Hirobe, S............................... 134 Ho, Y..................................... 335 Hofbauer, A........................... 453 Hofmann, C.......................... 227 Hong, C................................. 726 Hook, S..........................614, 617 Horvat, M............................. 518 Hossain, S.............................. 783 Hossen, M............................. 315 Hsieh, H................................ 885 Hu, A.................................... 499 Hu, J...................................... 695 Hu, X..................................... 350 Hu, Z..................................... 638 Huang, C............................... 338 Huang, Y............................... 340 Huang, Y............................... 378 Husseini, G............................ 207 Hye, J..................................... 805 Ichikawa, H........................... 354 Ickowicz, D........................... 562 Ikeda, Y................................. 579 Ishizuka, N............................ 822 Itaka, K.................................. 817 Itakura, S............................... 753 Itoh, K................................... 471 Jaganathan, H........................ 194 Jain, A.................................... 782 Jain, R...................................... 80 Jain, R.................................... 728 Jain, S...................................... 18 Jalaal, M................................. 117 Janรกt-Amsbury, M.........139, 164, 172 Jang, S.................................... 485 Jang, Y............................435, 436 Jang, Y................................... 653 Jeannin, L.............................. 570 Jin, T...............................602, 616 Jo, J........................................ 791 Johnson, D............................. 178 Jonker, H................................. 37 Joshi, R.................................. 137 Ju, E....................................... 261 Jung, E................................... 929 Kakumanu, S..................674, 850 Kamberi, M........................... 872 Kanazawa, H......................... 283 Kanazawa, T.......................... 771 Kane, R.................................... 38 Kanei, T................................. 582 Kang, D................................. 647 Kao, C................................... 487

Karn, P.................................... 90 Kastellorizios, M.................... 539 Katayama, Y........................... 784 Katsumi, H............................ 306 Kawamura, E......................... 767 Kawasaki, R........................... 829 Kazazi Hyseni, F................... 375 Keck, C...........238, 409, 669, 827, 899, 900, 925 Keller, S................................. 458 Kendall, M............................... 50 Keskin, D............................... 425 Key, J...................................... 394 Khaja, F................................. 714 Kikuchi, I............................... 346 Kim, C................................... 493 Kim, C................................... 802 Kim, D................................... 196 Kim, D................................... 564 Kim, D................................... 749 Kim, E................................... 804 Kim, H.................................... 13 Kim, H.................................. 189 Kim, H...........................193, 656 Kim, H.................................. 223 Kim, H.................................. 657 Kim, H.................................. 748 Kim, H.................................. 920 Kim, J.................................... 200 Kim, J.................................... 536 Kim, K..................................... 34 Kim, K................................... 248 Kim, S.................................... 761 Kim, S.................................... 858 Kim, W.................................. 794 Kim, Y................................... 623 Kim, Y................................... 710 Kim, Y............................716, 729 Kishimura, A......................... 369 Klebl, B...................................... 7 Klein, S.................................. 101 Klostergaard, J......................... 70 Klukkert, M......................92, 687 Ko, E..................................... 389 Kogure, K................................ 23 Kong, W.................................. 22 Krick, K................................. 631 Kristan, K.............................. 514 Krogstad, E............................ 151 Kuo, J..................................... 658 Kuo, Y.................................... 260 Kurosaki, T............................ 738 Kussmann, M............................ 1 Labouta, H............................ 289 Lai, P....................................... 15 Lamb, S.......... 154, 441, 504, 862 Lambert, A............................ 446 Lambert, W........................... 585 Lee, B.................................... 199 Lee, D.............................273, 715 Lee, E.................................... 884 Lee, H................................... 357 Lee, H................................... 747 Lee, J..................................... 147 Lee, J..................................... 586 Lee, J..................................... 894 Lee, K.................................... 309

Lee, S..................................... 730 Lee, Y.................................... 859 Lehr, C...........................676, 707 Leleux, J................................. 558 Leonard, F............................... 33 Li, J........................................ 750 Li, S....................................... 171 Li, S....................................... 408 Li, X...................................... 418 Li, Y......................................... 99 Lian, Z..................................... 86 Liaw, J.................................... 691 Lim, L............................284, 353 Lim, S.................................... 640 Lin, T.................................... 204 Lin, W................................... 411 Liu, D.................................... 104 Liu, H.............................525, 556 Liu, J...................................... 821 Liu, S..................................... 765 Liu, T..................................... 367 Liu, T..................................... 654 Liu, W................................... 140 Liu, X.................................... 659 Lo, Y...................................... 546 Loebmann, K..................826, 852 Love, D.................................. 575 Lowry, D............................... 690 Lu, W.............................130, 329 Luo, D..................................... 93 Luz, P.................................... 845 M.M.Sadeghi, A................... 645 Ma, G.................................... 651 Ma, X.................................... 840 Ma, X.................................... 869 Macchi, E............... 468, 472, 486 Machluf, M....................266, 803 Mäder, K.................................. 52 Maeda, H.............................. 219 Maeda, H.............................. 928 Maeda, K............................... 388 Makwana, H.......................... 392 Maltesen, M.......................... 548 Mande, P............................... 144 Marizza, P............................... 68 Martin, F............................... 559 Mathiowitz, E................110, 326 Matsukami, Y........................ 416 Matsumoto, Y........................ 209 Matsumoto, Y........................ 605 Matsuura, M.......................... 215 Matsuyama, T........................ 402 May, J..................................... 422 May, S.................................... 705 Mayer, L.................................. 76 McConnell, K........................ 772 McConville, J......................... 591 Meenach, S............................ 213 Meeus, J................................. 535 Mi, F...................................... 203 Mi, P..................................... 220 Miller, K................................ 576 Mima, Y................................ 267 Mittal, A...........................45, 918 Miyamoto, N......................... 732 Mo, J...................................... 374 Mochizuki, S......................... 737

Moga, K................................. 919 Mole, J.................... 861, 867, 870 Monteiro-Riviere, N.............. 342 Mori, T.................................... 62 Mu, H.................................... 613 Mukerjee, A....................228, 256 Müller, R.......... 42, 675, 833, 902 Müllertz, A.....................218, 515 Munjal, M............................. 890 Murata, M............................. 619 Murata, M............................. 743 Na, H..................................... 603 Na, K..................................... 604 Nadithe, V............................. 780 Nafee, N......... 276, 702, 708, 904 Nagano, K.............................. 606 Nagano, T.............................. 334 Nagasaki, Y................. 14, 26, 567 Nagase, S............................... 136 Nagata, K............................... 764 Nahar, K................................ 377 Nakamura, H......................... 310 Nakamura, T.......................... 420 Nakayama, M........................ 121 Nam, K.................................. 758 Nan, Y................................... 145 Nehoff, H.............................. 419 Nguyen, T.............................. 831 Nielsen, E.............................. 589 Nielson, K.............................. 433 Nigam, S................................ 288 Niidome, T............................ 427 Nishida, H............................. 718 Nishida, K.............................. 588 Nishio, M.............................. 376 Novikova, A........................... 447 Novo, L.................................. 770 Nukolova, N............................ 27 Oda, Y................................... 725 Ofek, P.................................. 812 Oh, N.................................... 401 Ohyama, A............................ 790 Okamoto, A........................... 810 Omata, D............................... 811 Oni, Y.............................249, 503 Ortiz, C................................. 667 Osada, K................................ 813 Oxley, J.................................... 58 Özer, A.................................. 210 Palakurthi, S.......................... 282 Pan, X.................................... 177 Pandey, M.............................. 838 Pang, Z.................................. 216 Papen-Botterhuis, N................ 40 Park, H...................................... 3 Park, H.................................. 903 Park, J.................................... 186 Park, J.................................... 264 Park, J.............................727, 917 Park, J.................................... 745 Park, K................................... 231 Park, K..................................... 55 Park, M.................................. 385 Patel, A.................................. 240 Patel, B...........................115, 255 Patel, R.................................. 187 Patel, S................................... 111

Pathak, Y.................. 51, 648, 853 Patil, R................................... 237 Pereira, T............................... 906 Perrie, Y.......... 474, 500, 594, 677 Persson, L.............................. 839 Perumal, O............................ 911 Phan, S.................................. 863 Pornputtapitak, W................. 698 Powell, D................................. 78 Prestidge, C........................... 871 Prow, T.................................. 892 Qi, R...................................... 815 Qin, G................................... 363 Qureshi, F.......................639, 649 Rajabi-Siahboomi, A.............439, 443, 456, 492 Ramanathan, R...................... 135 Raphael, A............................. 756 Ravula, R............................... 883 Rege, K................... 410, 746, 754 Reineke, J................................. 71 Remenar, J............................. 553 Repka, M.................. 69, 864, 866 Ribeiro, A.............................. 356 Rice, K................................... 781 Riviere, J................................ 875 Rogers, T........................478, 498 Rosenberger, I........................ 430 Rossi, A................................. 473 Ruiz-Hernández, E............... 391 Rupenthal, I........................... 113 Ruvinov, E............................. 584 Ryan, G............................10, 112 Sahoo, S................................. 239 Sahota, T............................... 150 Sajomsang, W.......................... 16 Sakai, K................................. 837 Sakuma, S.............................. 351 Sakurai, K.............................. 122 Salzano, G........................25, 787 Samadi, N.............................. 417 Samant, T.............................. 532 Saraf, P.................................. 293 Satchi-Fainaro, R................... 429 Sato, T................................... 596 Sawant, S............................... 153 Schaefer, S............................. 161 Schmid, R.............................. 336 Schoellhammer, C................... 46 Schwarz, A............................ 534 Schweizer, D............................ 72 Schwendeman, S........................ 9 Scomparin, A......................... 555 Scott, C...........................312, 908 Senel, S.................................. 454 Sengupta, A........................... 185 Seo, B.................................... 550 Serda, R................................. 772 Serrano-Medina, A................ 291 Sestak, J................................. 190 Seyfoddin, A.......................... 114 Shamsudeen, S....................... 234 Shanker, R............................... 65 Shen, H................................. 757 Shen, J................................... 630 Shen, S..................................... 67 Sherje, A................................ 856

71

Sheu, M................................. 682 Shi, J...................................... 541 Shi, J...............................719, 773 Shi, P..................................... 311 Shi, S..................................... 405 Shi, Y..................................... 854 Shigeno, A............................. 740 Shima, F................................ 412 Shimizu, J.............................. 502 Shimizu, T............................... 64 Shin, D.................................. 841 Shin, J.................................... 592 Shiraishi, K............................ 343 Shirakura, T........................... 290 Shukla, P............................... 671 Si, X....................................... 133 Silva, C.................................. 526 Silva, J.................................... 597 Simerska, P............................ 634 Singh, A................................ 241 Sinko, P................................. 380 Somiya, M............................. 321 Son, T.................................... 901 Son, Y.............................182, 226 Song, I................................... 857 Song, Y.................................. 452 Speaker, T.............................. 230 Stapleton, S........................... 217 Staufenbiel, S..................271, 281 Steffensen, S.......................... 632 Stephenson, R........................ 655 Sterner, B................................. 11 Stocke, N............................... 330 Suemitsu, E........................... 713 Sugisawa, K............ 437, 461, 462 Sun, F.................................... 913 Sun, X.................................... 893 Suzuki, R............................... 739 Svirskis, D......................331, 855 Syu, W................................... 318 Szekely, Z.............................. 364 Szeto, K..........................513, 519 Tabata, Y................................ 627 Takafuji, Y............................. 143 Takami, T.............................. 701 Takamoto, R.......................... 280 Takeuchi, H............................. 36 Tamura, A.............................. 752 Tan, S.................................... 371 Tanaka, A.............................. 891 Tanaka, H.............................. 760 Tang, M................................. 557 Tang, S................................... 386 Tangso, K............................... 183 Taratula, O............................ 777 Tasciotti, E.....................270, 763 Taurin, S................................ 393 Teixeira, H............................. 807 Tekade, R............................... 609 Teng, L.................................. 263 Tewari, D............................... 469 Thambi, T.............................. 279 Thiele, C................................ 723 Thomsen, P............................ 159 Tian, H.................................. 390 Tian, Z...................................... 2

72

Timmins, P.............................. 83 Tobinaga, Y........................... 873 Togashi, R.............................. 814 Toh, K.................................... 232 Toledano Furman, N............... 94 Torrisi, B................................ 886 Tripathi, P............................. 531 Tsai, S.................................... 327 Uchida, S............................... 795 Uchida, Y............................... 521 Udupa, N............................... 247 Uhrich, K..........................95, 665 Ukawa, M.............................. 779 Unga, J................................... 415 van der Heijden, I.................. 762 Van der Vlies, A..................... 119 van Herk, A........................... 361 Vandana, M........................... 560 Venkatraman, S...................... 697 Viegas, T.........................561, 569 Vinogradov, S.......................... 28 Virgallito, T............................. 41 Vueba, M............................... 494 Wacker, M............................. 325 Wada, T................................. 796 Wagner, E................................ 20 Walker, R........................505, 678 Wallbrecher, R......................... 61 Walsh, C.................................. 89 Wan, F................................... 681 Wang, A................................ 878 Wang, C.........................127, 688 Wang, J.................................. 847 Wang, L................................. 529 Wang, Q................................ 341 Wang, X..................................... 4 Warren, D.............................. 868 Washiyama, M....................... 601 Watanabe, S........................... 755 Water, J.................................. 620 Webster, C............................. 339 Wei, G................................... 633 Wei, H................................... 314 Wei, W.................................. 641 Weitschies, W......... 233, 510, 516 Weitz, D.................................. 29 Weitz, X................................... 73 Wen, J...........................5, 43, 424 Wertz, C................................ 506 Wild, W................................ 302 Won, Y.................................... 21 Woodrow, K............................. 47 Wu, C..................... 495, 816, 912 Wu, C.................................... 816 Wu, F...................... 580, 636, 662 Wu, J...................................... 538 Wu, L.................................... 155 Wu, P.................................... 924 Wu, X.................................... 102 Wu, X.................................... 201 Wu, Z.................................... 547 Wulff, R................................. 475 Xia, D.................................... 835 Xia, H.................................... 488 Xiang, x.................................. 806 Xu, J....................................... 876

Xu, X..................................... 323 Xu, Y..................................... 797 Yamada, Y.............................. 717 Yamamoto, A......................... 612 Yamaoka, T............................ 160 Yamashita, M........................... 49 Yang, J.................................... 395 Yang, J.................................... 664 Yellepeddi, V.......................... 303 Yin, Q.................................... 724 Yin, Z.................................... 545 Yoon, S.................................. 530 Yoshida, C............................. 523 Yoshida, M............................. 511 Yoshida, N............................. 683 Youngren, S........................... 741 Yousefi, A............................... 769 Yu, S...................................... 359

Yuan, H................................. 666 Yuan, W................................. 621 Yukawa, H............................. 324 Yun, C..................................... 19 Zeleznik, J............................. 482 Zhang, H............................... 149 Zhang, J................................. 809 Zhang, L.................................. 77 Zhang, R................................ 275 Zhang, X................................ 345 Zhang, X................................ 426 Zhang, Y................................ 721 Zhang, Z............................... 262 Zheng, J................................... 54 Zheng, Y................................ 308 Zhong, Z................................. 35 Zhu, Y................................... 799 Ziemys, A.........................12, 372

CRS Headquarters & Staff 3340 Pilot Knob Road, St. Paul, MN 55121 U.S.A. Telephone +1.651.454.7250 • Facsimile +1.651.454.0766 controlledreleasesociety.org Amy Hope Executive Vice President +1.651.994.3827 ahope@scisoc.org Barbara Mock Vice President of Finance +1.651.994.3829 bmock@scisoc.org Susan Kohn Executive Director +1.651.994.3812 skohn@scisoc.org Megan Pagel Program Manager • News Capsules • Webcasts Chapter Coordinator +1.651.994.3854 mpagel@scisoc.org Leah Barna Meeting Manager +1.651.994.3867 lbarna@scisoc.org Linda Schmitt, Program Supervisor • Awards +1.651.994.3828 lschmitt@scisoc.org Sue Casey Registration and Abstracts Meeting Coordinator +1.651.994.3846 scasey@scisoc.org

Debby Woodard Director of Development • Exhibits, Sponsorship • Advertising Sales • Foundation +1.651.994.3817 dwoodard@scisoc.org Cheryl Kruchten Member Relations Specialist +1.651.994.3801 ckruchten@scisoc.org Kayleen Larson Marketing Manager +1.651.994.3840 klarson@scisoc.org Brian Simdars Webmaster +1.651.994.3849 bsimdars@scisoc.org Greg Grahek Publications Director +1.651.994.3841 ggrahek@scisoc.org Carol Duling CRS Newsletter Technical Editor +1.651.994.3869 cduling@scisoc.org

Choose Choice.

Sustained-Release

Immediate-Release

Taste Masking

Lyophilization Aseptic Filling

Multi-Therapy

Solubilization

No other partner gives you more formulation options – royalty free.

Get access to the industry’s widest range of complex formulation technologies for small molecules and biologics, and benefit from expertise forged over thousands of projects.

At Patheon, we’re not tied to any technology. That means science alone drives the development of an optimal formulation, and you’ll never pay us a royalty. Our commitment is to your success.

Choose choice – choose Patheon.

Visit www.patheon.com Call +1 866-PATHEON Email doingbusiness@patheon.com ©Patheon Inc. All rights reserved. Published 11/12 PATH0214R6

Visit us at Booth #207 at CRS in Hawaii